Tumor-specific payload delivery and immune activation using human antibody targeting highly specific tumor cell surface antigen

JP2024110988A5Inactive Publication Date: 2024-12-03RGT UNIV OF CALIFORNIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024090709
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-11-30
Filing Date
2024-06-04
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cancer therapies, such as antibody drug conjugates (ADCs) and immunotherapy, face challenges in achieving sustained responses due to inefficiencies in drug delivery, particularly in solid tumors, and there is a need to identify highly specific tumor antigens to minimize toxicity and expand applicability to a broader range of cancer types.

Method used

Development of antibodies that specifically bind to ALPP and/or ALPPL2 expressed in human placenta but not extraplacentally, with high affinity, to target cancer cells, and conjugation of these antibodies to cytotoxic agents for targeted delivery.

Benefits of technology

The antibodies effectively bind to cancer cells with high specificity and affinity, enabling targeted delivery of cytotoxic agents to reduce tumor cell proliferation and migration, potentially expanding therapeutic efficacy to a broader range of cancer types.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide antibodies against a highly specific, previously unrecognized marker for cancerous cells.SOLUTION: The present invention relates to an isolated antibody or a fragment thereof that specifically binds to human placentally expressed ALPPL2, but not ALPL and ALPI.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 261,112, filed November 30, 2015, which is incorporated herein by reference in its entirety for all purposes.

[0002] Statement of government support This invention was made with government support under grants R01 CA129491, R01 CA118919, and R01 CA171315 awarded by the National Institutes of Health. The government has certain rights in this invention. [Background technology]

[0003] Cancer therapy is progressing along several promising platforms, including antibody-drug conjugates (ADCs) and immunotherapy. Achieving durable responses remains a challenge in the ADC field. While responses are sustainable in immunotherapy, only a small proportion of treated patients respond, and this approach only works on a minority of cancer types (Rizvi et al., (2015) Lancet Oncol., 16:257-265; Topalian et al., (2012) NEJM, 366:2443-2454). In addition to developing biomarkers to predict responders versus non-responders, a major challenge in the immunotherapy field is increasing response rates and expanding applicability to a broader range of indications.

[0004] To achieve durable responses with ADCs, the field is trending toward arming antibodies with ultratoxic drugs (e.g., PBDs and other DNA chelators) that kill both dividing and dormant tumor cells and are orders of magnitude more potent than microtubule inhibitors such as auristatin derivatives (Jeffrey et al., (2013) Bioconjug. Chem., 24:1256-1263; Kung et al., (2013) Blood, 122:1455-1463; Saunders et al., (2015) Sci. Transl. Med., 7:302ra136). This approach may be necessary to compensate for the relative inefficiency of drug delivery by antibody conjugation, particularly in solid tumors. Promising clinical trial results with durable responses have been reported using these supertoxin-armed ADCs in both hematological malignancies (CD33-PBD in AML) (Stein et al., (2014) Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML). 56th ASH annual meeting Session 616) and solid tumors (DLL3-PBD in neuroendocrine small cell lung cancer) (Pietanza et al., (2015) Eur. J. Canc. Vol. 51(3): S712). A prerequisite for successfully adapting this approach to other tumors is the identification of highly specific, highly expressed tumor antigens, so that targeted toxicity is kept to a minimum.

[0005] There are many ways to improve current immunotherapies, including a better understanding of responders versus non-responders, analysis of T cell repertoire diversification or clonal development in relation to response and toxicity, and combination therapies such as checkpoint inhibitor combo (CTLA-4+PD1), checkpoint inhibitor+chemo, and vaccine+checkpoint inhibitor. Yet another approach to harness the capabilities of the host immune system against cancer is based on the site-specific recruitment and activation of T cells. For example, bispecific antibodies can be constructed by combining anti-tumor and anti-T cell (e.g., CD3) antibody fragments using either BiTE (bispecific T cell engager) (Harrington et al., (2015) PloS One 10: e0135945; Klinger et al., (2012) Blood 119: 6226-6233; Molhoj et al., (2007) Mol. Immunol. 44: 1935-1943) or DART (dual affinity retargeting) platforms (Chichili et al., (2015) Sci. Transl. Med. 7: 289ra282; Moore et al., (2011) Blood 117: 4542-4551). Although promising, application of this approach requires the identification of highly specific tumor cell surface antigens to minimize targeted toxicity and expand the therapeutic window. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] WO99 / 55720 [Patent Document 2] U.S. Patent No. 6,670,188 [Patent Document 3] U.S. Patent No. 6,642,051 [Patent Document 4] U.S. Patent No. 6,669,936 [Patent Document 5] WO1994 / 011026(PCT / US1993 / 010953) [Patent Document 6] European Patent Application No. 188,256 [Patent Document 7] U.S. Patent No. 4,671,958 [Patent Document 8] U.S. Patent No. 4,659,839 [Patent Document 9] U.S. Patent No. 4,414,148 [Patent Document 10] U.S. Patent No. 4,699,784 [Patent Document 11] U.S. Patent No. 4,680,338 [Patent Document 12] U.S. Patent No. 4,569,789 [Patent Document 13] U.S. Patent No. 4,589,071 [Patent Document 14] U.S. Patent No. 4,545,985 [Patent Document 15] U.S. Patent No. 4,894,443 [Patent Document 16] U.S. Patent No. 4,618,492 [Patent Document 17] U.S. Patent No. 4,542,225 [Patent Document 18] U.S. Patent No. 4,625,014 [Patent Document 19] U.S. Patent No. 5,773,001 [Patent Document 20] U.S. Patent No. 4,957,735 [Patent Document 21] U.S. Patent No. 6,190,923 [Patent Document 22] U.S. Patent No. 6,187,285 [Patent Document 23] U.S. Patent No. 6,183,721 [Patent Document 24] U.S. Patent No. 6,177,562 [Patent Document 25] U.S. Patent No. 6,159,445 [Patent Document 26] U.S. Patent No. 6,153,775 [Patent Document 27] U.S. Patent No. 6,149,890 [Patent Document 28] U.S. Patent No. 6,143,276 [Patent Document 29] U.S. Patent No. 6,143,274 [Patent Document 30] U.S. Patent No. 6,139,819 [Patent Document 31] U.S. Patent No. 6,132,764 [Patent Document 32] U.S. Patent No. 6,123,923 [Patent Document 33] U.S. Patent No. 6,123,921 [Patent Document 34] U.S. Patent No. 6,120,768 [Patent Document 35] U.S. Patent No. 6,120,751 [Patent Document 36] U.S. Patent No. 6,117,412 [Patent Document 37] U.S. Patent No. 6,106,866 [Patent Document 38] U.S. Patent No. 6,096,290 [Patent Document 39] U.S. Patent No. 6,093,382 [Patent Document 40] U.S. Patent No. 6,090,800 [Patent Document 41] U.S. Patent No. 6,090,408 [Patent Document 42] U.S. Patent No. 6,088,613 [Patent Document 43] U.S. Patent No. 6,077,499 [Patent Document 44] U.S. Patent No. 6,075,010 [Patent Document 45] U.S. Patent No. 6,071,494 [Patent Document 46] U.S. Patent No. 6,071,490 [Patent Document 47] U.S. Patent No. 6,060,040 [Patent Document 48] U.S. Patent No. 6,056,939 [Patent Document 49] U.S. Patent No. 6,051,207 [Patent Document 50] U.S. Patent No. 6,048,979 [Patent Document 51] U.S. Patent No. 6,045,821 [Patent Document 52] U.S. Patent No. 6,045,775 [Patent Document 53] U.S. Patent No. 6,030,840 [Patent Document 54] U.S. Patent No. 6,028,066 [Patent Document 55] U.S. Patent No. 6,022,966 [Patent Document 56] U.S. Patent No. 6,022,523 [Patent Document 57] U.S. Patent No. 6,022,522 [Patent Document 58] U.S. Patent No. 6,017,522 [Patent Document 59] U.S. Patent No. 6,015,897 [Patent Document 60] U.S. Patent No. 6,010,682 [Patent Document 61] U.S. Patent No. 6,010,681 [Patent Document 62] U.S. Patent No. 6,004,533 [Patent Document 63] U.S. Patent No. 6,001,329 [Patent Document 64] U.S. Patent No. 6,024,938 [Patent Document 65] U.S. Patent No. 4,458,066 [Patent Document 66] U.S. Patent No. 5,399,163 [Patent Document 67] U.S. Patent No. 5,383,851 [Patent Document 68] U.S. Patent No. 5,312,335 [Patent Document 69] U.S. Patent No. 5,064,413 [Patent Document 70] U.S. Patent No. 4,941,880 [Patent Document 71] U.S. Patent No. 4,790,824 [Patent Document 72] U.S. Patent No. 4,596,556 [Patent Document 73] U.S. Patent No. 4,487,603 [Patent Document 74] U.S. Patent No. 4,486,194 [Patent Document 75] U.S. Patent No. 4,447,233 [Patent Document 76] U.S. Patent No. 4,447,224 [Patent Document 77] U.S. Patent No. 4,439,196 [Patent Document 78] U.S. Patent No. 4,475,196 [Patent Document 79] U.S. Patent No. 4,522,811 [Patent Document 80] U.S. Patent No. 5,374,548 [Patent Document 81] U.S. Patent No. 5,399,331 [Patent Document 82] U.S. Patent No. 5,416,016 [Patent Document 83] U.S. Patent No. 5,399,346 [Patent Document 84] U.S. Patent No. 5,580,859 [Patent Document 85] U.S. Patent No. 5,589,466 [Patent Document 86] WO01 / 96584 [Patent Document 87] WO01 / 29058 [Patent Document 88] U.S. Patent No. 6,326,193 [Patent Document 89] U.S. Patent No. 5,350,674 [Patent Document 90] U.S. Patent No. 5,585,362 [Patent Document 91] U.S. Patent No. 6,352,694 [Patent Document 92] U.S. Patent No. 6,534,055 [Patent Document 93] U.S. Patent No. 6,905,680 [Patent Document 94] U.S. Patent No. 6,692,964 [Patent Document 95] U.S. Patent No. 5,858,358 [Patent Document 96] U.S. Patent No. 6,887,466 [Patent Document 97] U.S. Patent No. 6,905,681 [Patent Document 98] U.S. Patent No. 7,144,575 [Patent Document 99] U.S. Patent No. 7,067,318 [Patent Document 100] U.S. Patent No. 7,172,869 [Patent Document 101] U.S. Patent No. 7,232,566 [Patent Document 102] U.S. Patent No. 7,175,843 [Patent Document 103] U.S. Patent No. 5,883,223 [Patent Document 104] U.S. Patent No. 6,905,874 [Patent Document 105] U.S. Patent No. 6,797,514 [Patent Document 106] U.S. Patent No. 6,867,041 [Patent Document 107] U.S. Patent Publication No. 2006 / 0121005 [Patent Document 108] U.S. Patent Publication No. 2004 / 0101519 [Patent Document 109] U.S. Patent Publication No. 2006 / 0034810 [Patent Document 110] U.S. Patent No. 5,199,942

Non-licensed literature

[0007]

Non-patent document 1

Non-patent document 2

Non-patent document 3

Non-patent document 4

Non-patented document 5

Non-patent document 6

Non-patent document 7

Non-patent document 8

Non-patent document 9

Non-patent document 10

Non-patent document 11

Non-patent document 12

Non-patent document 13

Non-patent document 14

Non-patent document 15

Non-patent document 16

Non-patent document 17

Non-patent document 18

Non-patent document 19

Non-patent document 20

Non-patent document 21

Non-patent document 22

Non-patent document 23

Non-patent document 24

Non-patented document 25

Non-patent document 26

Non-patent document 27

Non-patent document 28

Non-patent document 29

Non-patent document 30

Non-patent document 31

Non-patent document 32

Non-patent document 33

Non-patent document 34

Non-patented document 35

Non-patent document 36

Non-patent document 37

Non-patent document 38

Non-patent document 39

Non-patent document 40

Non-patent document 41

Non-patent document 42

Non-patent document 43

Non-patent document 44

Non-patented document 45

Non-patent document 46

Non-patent document 47

Non-patent document 48

Non-patent document 49

Non-patented Document 50

Non-patent document 51

Non-patented document 52

Non-patent document 53

Non-patented document 54

Non-patented document 55

Non-patented document 56

Non-patented document 57

Non-patent document 58

Non-patent document 59

Non-patented document 60

Non-patent document 61

Non-patented document 62

Non-patent document 63

Non-patented document 64

[0008] Various embodiments contemplated herein may include, but are not limited to, one or more of the following.

[0009] Embodiment 1: An isolated antibody or fragment thereof that specifically binds to ALPP and / or ALPPL2 expressed in the human placenta but not to ALPL and ALPI expressed outside the placenta.

[0010] Embodiment 2: The antibody specifically binds to cells expressing ALPPL2 and / or ALPP, and the antibody is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25 2. The antibody of embodiment 1, which specifically binds to an epitope bound by one or more antibodies selected from the group consisting of GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

[0011] Embodiment 3: The antibody of any one of embodiments 1-2, wherein said antibody preferentially binds to the cell surface form of ALPPL2 compared to the released / solution form of ALPPL2.

[0012] Embodiment 4: The antibody of any one of embodiments 1 to 3, wherein the antibody binds to cells expressing ALPPL2 with an affinity of about 5 nM or better, or about 3 nM or better, or about 2 nM or better.

[0013] Embodiment 5: The antibody of any one of embodiments 1 to 3, wherein the antibody, in its IgG1 form, binds to cells expressing ALPPL2 with an affinity better than about 50 pM, or better than about 40 pM, or better than about 30 pM, or with an apparent affinity of about 28 pM.

[0014] Embodiment 6: The antibody of any one of embodiments 2 to 5, wherein the cells expressing ALPP and / or ALPPL2 are cancer cells.

[0015] Embodiment 7: The antibody of any one of embodiments 2 to 6, wherein the expressing or overexpressing cells are cells of a cancer selected from the group consisting of mesothelioma, testicular cancer, endometrial cancer, and a subset of ovarian, pancreatic, and non-small cell lung cancer.

[0016] Embodiment 8: The antibody of embodiment 7, wherein the antibody binds to cells of a cell line selected from the group consisting of M28, VAMT-1, CAPAN-1, and H1651 cells.

[0017] Embodiment 9: The antibody comprises at least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein the heavy chain variable region is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25AD 9. The antibody of any one of embodiments 1 to 8, comprising VH CDR1, and / or VH CDR2, and / or VH CDR3 of an antibody selected from the group consisting of Y93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

[0018] Embodiment 10: The antibody comprises at least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein the light chain variable region is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25A 9. The antibody of any one of embodiments 1 to 8, comprising VL CDR1, and / or VL CDR2, and / or VL CDR3 of an antibody selected from the group consisting of DY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

[0019] Embodiment 11: The antibody comprises at least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein the heavy chain variable region is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSR 9. The antibody of any one of embodiments 1 to 8, wherein the heavy chain variable region is an antibody heavy chain variable region selected from the group consisting of M25ALF, ...

[0020] Embodiment 12: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADLF antibody.

[0021] Embodiment 13: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADLFEG antibody.

[0022] Embodiment 14: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADLFDS antibody.

[0023] Embodiment 15: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25FYIA antibody.

[0024] Embodiment 16: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25FYIAEG antibody.

[0025] Embodiment 17: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25FYIADS antibody.

[0026] Embodiment 18: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25 antibody.

[0027] Embodiment 19: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25EG antibody.

[0028] Embodiment 20: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25DS antibody.

[0029] Embodiment 21: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25AELF antibody.

[0030] Embodiment 22: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25AELFEG antibody.

[0031] Embodiment 23: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25AELFDS antibody.

[0032] Embodiment 24: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADL99P antibody.

[0033] Embodiment 25: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADL99G antibody.

[0034] Embodiment 26: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADS95R antibody.

[0035] Embodiment 27: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADD28G antibody.

[0036] Embodiment 28: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADS91G antibody.

[0037] Embodiment 29: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADY93H antibody.

[0038] Embodiment 30: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADYHSRLF antibody.

[0039] Embodiment 31: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25GRITSGFYGDwtLC antibody.

[0040] Embodiment 32: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25FSITSGFYGDwtLC antibody.

[0041] Embodiment 33: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M253018IA antibody.

[0042] Embodiment 34: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M253018LF antibody.

[0043] Embodiment 35: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25AD antibody.

[0044] Embodiment 36: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ADX antibody.

[0045] Embodiment 37: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the ALPPL2rd3_1 antibody.

[0046] Embodiment 38: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the ALPPL2rd3_2 antibody.

[0047] Embodiment 39: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25AGIA antibody.

[0048] Embodiment 40: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25AGLF antibody.

[0049] Embodiment 41: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ASIA antibody.

[0050] Embodiment 42: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ASLF antibody.

[0051] Embodiment 43: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ASwt antibody.

[0052] Embodiment 44: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25AVIA antibody.

[0053] Embodiment 45: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25AVLF antibody.

[0054] Embodiment 46: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ALIA antibody.

[0055] Embodiment 47: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25ALLF antibody.

[0056] Embodiment 48: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25wtIA antibody.

[0057] Embodiment 49: The antibody of embodiment 11, wherein the antibody contains at least one heavy chain variable region of the M25wtLF antibody.

[0058] Embodiment 50: The antibody comprises at least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein the light chain variable region is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSR 9. The antibody of any one of embodiments 1 to 8, wherein the antibody light chain variable region is selected from the group consisting of: M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

[0059] Embodiment 51: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADLF antibody.

[0060] Embodiment 52: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADLFEG antibody.

[0061] Embodiment 53: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADLFDS antibody.

[0062] Embodiment 54: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25FYIA antibody.

[0063] Embodiment 55: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25FYIAEG antibody.

[0064] Embodiment 56: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25FYIADS antibody.

[0065] Embodiment 57: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25 antibody.

[0066] Embodiment 58: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25EG antibody.

[0067] Embodiment 59: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25DS antibody.

[0068] Embodiment 60: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25AELF antibody.

[0069] Embodiment 61: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25AELFEG antibody.

[0070] Embodiment 62: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25AELFDS antibody.

[0071] Embodiment 63: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADL99P antibody.

[0072] Embodiment 64: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADL99G antibody.

[0073] Embodiment 65: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADS95R antibody.

[0074] Embodiment 66: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADD28G antibody.

[0075] Embodiment 67: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADS91G antibody.

[0076] Embodiment 68: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADY93H antibody.

[0077] Embodiment 69: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADYHSRLF antibody.

[0078] Embodiment 70: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25GRITSGFYGDwtLC antibody.

[0079] Embodiment 71: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25FSITSGFYGDwtLC antibody.

[0080] Embodiment 72: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M253018IA antibody.

[0081] Embodiment 73: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M253018LF antibody.

[0082] Embodiment 74: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25AD antibody.

[0083] Embodiment 75: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ADX antibody.

[0084] Embodiment 76: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the ALPPL2rd3_1 antibody.

[0085] Embodiment 77: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the ALPPL2rd3_2 antibody.

[0086] Embodiment 78: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25AGIA antibody.

[0087] Embodiment 79: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25AGLF antibody.

[0088] Embodiment 80: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ASIA antibody.

[0089] Embodiment 81: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ASLF antibody.

[0090] Embodiment 82: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ASwt antibody.

[0091] Embodiment 83: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25AVIA antibody.

[0092] Embodiment 84: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25AVLF antibody.

[0093] Embodiment 85: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ALIA antibody.

[0094] Embodiment 86: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25ALLF antibody.

[0095] Embodiment 87: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25wtIA antibody.

[0096] Embodiment 88: The antibody of embodiment 50, wherein the antibody contains at least one light chain variable region of the M25wtLF antibody.

[0097] Embodiment 89: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ADLF antibody and the light chain variable region (VL) of the M25ADLF antibody.

[0098] Embodiment 90: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ADLFEG antibody and the light chain variable region (VL) of the M25ADLFEG antibody.

[0099] Embodiment 91: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ADLFDS antibody and the light chain variable region (VL) of the M25ADLFDS antibody.

[0100] Embodiment 92: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25FYIA antibody and the light chain variable region (VL) of the M25FYIA antibody.

[0101] Embodiment 93: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25FYIAEG antibody and the light chain variable region (VL) of the M25FYIAEG antibody.

[0102] Embodiment 94: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25FYIADS antibody and the light chain variable region (VL) of the M25FYIADS antibody.

[0103] Embodiment 95: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25 antibody and the light chain variable region (VL) of the M25 antibody.

[0104] Embodiment 96: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25EG antibody and the light chain variable region (VL) of the M25EG antibody.

[0105] Embodiment 97: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25DS antibody and the light chain variable region (VL) of the M25DS antibody.

[0106] Embodiment 98: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25AELF antibody and the light chain variable region (VL) of the M25AELF antibody.

[0107] Embodiment 99: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25AELFEG antibody and the light chain variable region (VL) of the M25AELFEG antibody.

[0108] Embodiment 100: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25AELFDS antibody and the light chain variable region (VL) of the M25AELFDS antibody.

[0109] Embodiment 101: The antibody of any one of embodiments 1 to 8, wherein said antibody comprises the heavy chain variable region (VH) of the M25ADL99P antibody and the light chain variable region (VL) of the M25ADL99P antibody.

[0110] Embodiment 102: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ADL99G antibody and the light chain variable region (VL) of the M25ADL99G antibody.

[0111] Embodiment 103: The antibody of any one of embodiments 1 to 8, wherein said antibody comprises the heavy chain variable region (VH) of the M25ADS95R antibody and the light chain variable region (VL) of the M25ADS95R antibody.

[0112] Embodiment 104: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ADD28G antibody and the light chain variable region (VL) of the M25ADD28G antibody.

[0113] Embodiment 105: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ADS91G antibody and the light chain variable region (VL) of the M25ADS91G antibody.

[0114] Embodiment 106: The antibody of any one of embodiments 1 to 8, wherein said antibody comprises the heavy chain variable region (VH) of the M25ADY93H antibody and the light chain variable region (VL) of the M25ADY93H antibody.

[0115] Embodiment 107: The antibody of any one of embodiments 1 to 8, wherein said antibody comprises the heavy chain variable region (VH) of the M25ADYHSRLF antibody and the light chain variable region (VL) of the M25ADYHSRLF antibody.

[0116] Embodiment 108: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25GRITSGFYGDwtLC antibody and the light chain variable region (VL) of the M25GRITSGFYGDwtLC antibody.

[0117] Embodiment 109: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25FSITSGFYGDwtLC antibody and the light chain variable region (VL) of the M25FSITSGFYGDwtLC antibody.

[0118] Embodiment 110: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M253018IA antibody and the light chain variable region (VL) of the M253018IA antibody.

[0119] Embodiment 111: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M253018LF antibody and the light chain variable region (VL) of the M253018LF antibody.

[0120] Embodiment 112: The antibody of any one of embodiments 1 to 8, wherein said antibody comprises the heavy chain variable region (VH) of the M25AD antibody and the light chain variable region (VL) of the M25AD antibody.

[0121] Embodiment 113: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ADX antibody and the light chain variable region (VL) of the M25ADX antibody.

[0122] Embodiment 114: The antibody according to any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the ALPPL2rd3_1 antibody and the light chain variable region (VL) of the ALPPL2rd3_1 antibody.

[0123] Embodiment 115: The antibody according to any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the ALPPL2rd3_2 antibody and the light chain variable region (VL) of the ALPPL2rd3_2 antibody.

[0124] Embodiment 116: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25AGIA antibody and the light chain variable region (VL) of the M25AGIA antibody.

[0125] Embodiment 117: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25AGLF antibody and the light chain variable region (VL) of the M25AGLF antibody.

[0126] Embodiment 118: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ASIA antibody and the light chain variable region (VL) of the M25ASIA antibody.

[0127] Embodiment 119: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ASLF antibody and the light chain variable region (VL) of the M25ASLF antibody.

[0128] Embodiment 120: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ASwt antibody and the light chain variable region (VL) of the M25ASwt antibody.

[0129] Embodiment 121: The antibody of any one of embodiments 1 to 8, wherein said antibody comprises the heavy chain variable region (VH) of the M25AVIA antibody and the light chain variable region (VL) of the M25AVIA antibody.

[0130] Embodiment 122: The antibody of any one of embodiments 1 to 8, wherein said antibody comprises the heavy chain variable region (VH) of the M25AVLF antibody and the light chain variable region (VL) of the M25AVLF antibody.

[0131] Embodiment 123: The antibody of any one of embodiments 1 to 8, wherein the antibody comprises the heavy chain variable region (VH) of the M25ALIA antibody and the light chain variable region (VL) of the M25ALIA antibody.

[0132] Embodiment 124: The antibody of any one of embodiments 1 to 8, wherein said antibody comprises the heavy chain variable region (VH) of the M25ALLF antibody and the light chain variable region (VL) of the M25ALLF antibody.

[0133] Embodiment 125: The antibody of any one of embodiments 1 to 8, wherein said antibody comprises the heavy chain variable region (VH) of the M25wtIA antibody and the light chain variable region (VL) of the M25wtIA antibody.

[0134] Embodiment 126: The antibody of any one of embodiments 1 to 8, wherein said antibody comprises the heavy chain variable region (VH) of the M25wtLF antibody and the light chain variable region (VL) of the M25wtLF antibody.

[0135] Embodiment 127: The antibody of any one of embodiments 1 to 126, wherein said antibody is a substantially intact immunoglobulin.

[0136] Embodiment 128: The antibody of embodiment 127, wherein the antibody comprises IgA, IgE, or IgG.

[0137] Embodiment 129: The antibody of embodiment 127, wherein the antibody comprises an IgG.

[0138] Embodiment 130: The antibody of embodiment 127, wherein the antibody comprises an IgG1.

[0139] Embodiment 131: The antibody of any one of embodiments 1 to 126, wherein the antibody is an antibody fragment that specifically binds to cells expressing ALPP and / or ALPPL2.

[0140] Embodiment 132: The antibody of embodiment 131, wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, (Fab')2, (Fab')3, IgGΔCH2, and minibody.

[0141] Embodiment 133: The antibody of any one of embodiments 1 to 126, wherein said antibody is a single-chain antibody.

[0142] Embodiment 134: The antibody of embodiment 133, wherein the antibody is a human scFv.

[0143] Embodiment 135: The antibody of embodiment 134, wherein the heavy chain variable region is connected to the light chain variable region by a linker comprising or consisting of the amino acid sequence (Gly4Ser)3 (SEQ ID NO: 82).

[0144] Embodiment 136: An immunoconjugate comprising the antibody of any one of embodiments 1 to 135 linked to an effector, wherein the effector is selected from the group consisting of a second antibody, a detectable label, a cytotoxic or cytostatic agent, a liposome containing a drug, a radionuclide, a drug, a prodrug, an immunomodulatory agent, a viral particle, a cytokine, a second antibody, and a chelate.

[0145] Embodiment 137: The immunoconjugate of embodiment 136, wherein the antibody is conjugated to a cytotoxic and / or cytostatic agent.

[0146] Embodiment 138: The immunoconjugate of embodiment 136, wherein the antibody is bound, directly or via a linker, to one or more of the following: the drug; a lipid or liposome containing the drug; a polymeric drug carrier containing the drug; and a nanoparticle drug carrier containing the drug.

[0147] Embodiment 139: The immunoconjugate of any one of embodiments 137 to 138, wherein the drug is an anticancer drug.

[0148] Embodiment 140: The immunoconjugate of any one of embodiments 137 to 138, wherein the drug is selected from the group consisting of microtubule inhibitors, DNA damaging agents, and polymerase inhibitors.

[0149] Embodiment 141: The immunoconjugate of embodiment 140, wherein the drug comprises a tubulin inhibitor.

[0150] Embodiment 142: The immunoconjugate of embodiment 141, wherein the drug comprises a drug selected from the group consisting of auristatin, dolstatin-10, synthetic derivatives of the natural product dolstatin-10, and maytansine or a maytansine derivative.

[0151] Embodiment 143: The immunoconjugate of embodiment 141, wherein the drug comprises a drug selected from the group consisting of monomethyl auristatin F (MMAF), auristatin E (AE), monomethyl auristatin E (MMAE), vcMMAE, and vcMMAF.

[0152] Embodiment 144: The immunoconjugate of embodiment 141, wherein the drug comprises a maytansine selected from the group consisting of mertansine (DM1), DM3, and DM4.

[0153] Embodiment 145: The immunoconjugate of embodiment 140, wherein the drug comprises a DNA damaging agent.

[0154] Embodiment 146: The immunoconjugate of embodiment 145, wherein the drug comprises a drug selected from the group consisting of a calicheamicin, a duocarmycin, and a pyrrolobenzodiazepine.

[0155] Embodiment 147: The immunoconjugate of embodiment 146, wherein the drug comprises a calicheamicin or a calicheamicin analog.

[0156] Embodiment 148: The immunoconjugate of embodiment 146, wherein the drug comprises a duocarmycin.

[0157] Embodiment 149: The immunoconjugate of embodiment 148, wherein the drug comprises a duocarmycin selected from the group consisting of duocarmycin A, duocarmycin B1, duocarmycin B2, duocarmycin C1, duocarmycin C2, duocarmycin D, duocarmycin SA, cyclopropylbenzoindole duocarmycin (CC-1065), and centanamycin, rachelmycin, adozelesin, bizeresin, and carzelesin.

[0158] Embodiment 150: The immunoconjugate of embodiment 146, wherein the drug comprises a pyrrolobenzodiazepine or a pyrrolobenzodiazepine dimer.

[0159] Embodiment 151: The immunoconjugate of embodiment 150, wherein the drug comprises a drug selected from the group consisting of anthramycin (and its dimer), mazethramycin (and its dimer), tomaymycin (and its dimer), prothracarcin (and its dimer), ticamycin (and their dimers), neothramycin A (and its dimer), neothramycin B (and its dimer), DC-81 (and its dimer), sibiromycin (and its dimer), polothramycin A (and its dimer), polothramycin B (and its dimer), sivanomycin (and its dimer), abveymycin (and its dimer), SG2000, and SG2285.

[0160] Embodiment 152: The immunoconjugate of any one of embodiments 137 to 138, wherein the drug is selected from the group consisting of auristatins, dolastatins, colchicine, combretastatins, and mTOR / PI3K inhibitors.

[0161] Embodiment 153: The drug is fluorouracil (5-FU), capecitabine, 5-trifluoromethyl-2'-deoxyuridine, methotrexate sodium, raltitrexed, pemetrexed, cytosine arabinoside, 6-mercaptopurine, azathioprine, 6-thioguanine (6-TG), pentostatin, fludarabine phosphate, cladribine, floxuridine (5-fluoro-2), ribonucleotide reductase inhibitors (RNR), cyclophosphamide, neosal, ifosfamide, thiotepa , 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, methyl (CCNU), hexamethylmelamine, busulfan, procarbazine HCl, dacarbazine (DTIC), chlorambucil, melphalan, cisplatin, carboplatin, oxaliplatin, bendamustine, carmustine, chloromethine, fotemustine, lomustine, mannosulfan, nedaplatin, nimustine, prednimustine, ranimustine, Satraplatin, semustine, streptozocin, temozolomide, treosulfan, triaziquone, triethylenemelamine, thioTEPA, triplatin tetranitrate, trofosfamide, uramustine, doxorubicin, daunorubicin citrate, mitoxantrone, actinomycin D, etoposide, topotecan HCl, teniposide (VM-26), irinotecan HCl (CPT-11), camptothecin, belotecan, rubitecan, vincristine, vinblastine sulfate, vinorelbine tartrate, vindesine sulfate 139. The immunoconjugate of any one of embodiments 137-138, wherein the immunoconjugate is selected from the group consisting of vinflunine, paclitaxel, docetaxel, nanoparticulate paclitaxel, abraxane, ixabepilone, larotaxel, ortataxel, tesetaxel, vinflunine, retinoic acid, retinoic acid derivatives, doxorubicin, vinblastine, vincristine, cyclophosphamide, ifosfamide, cisplatin, 5-fluorouracil, camptothecin derivatives, interferon, tamoxifen, and taxol.In certain embodiments, the anti-cancer compound is selected from the group consisting of Abraxane, doxorubicin, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, toremifene, letrozole, trastuzumab, megestrol tamoxifen, paclitaxel, docetaxel, capecitabine, goserelin acetate, and zoledronic acid.

[0162] Embodiment 154: The immunoconjugate of embodiment 136, wherein the antibody is conjugated to a cytotoxin.

[0163] Embodiment 155: The immunoconjugate of embodiment 154, wherein the antibody is conjugated to a cytotoxin selected from the group consisting of diphtheria toxin, Pseudomonas exotoxin, ricin, abrin, saporin, and thymidine kinase.

[0164] Embodiment 156: The immunoconjugate of embodiment 136, wherein the antibody is conjugated to an immunomodulatory agent.

[0165] Embodiment 157: The immunoconjugate of embodiment 156, wherein said immunomodulator comprises a second antibody.

[0166] Embodiment 158: The immunoconjugate of embodiment 157, wherein the second antibody comprises an anti-CD3 antibody.

[0167] Embodiment 159: The immunoconjugate of embodiment 156, wherein the immunomodulatory agent blocks an immune checkpoint.

[0168] Embodiment 160: The immunoconjugate of embodiment 159, wherein said immunomodulatory effector is an antibody selected from the group consisting of an anti-CTLA4 antibody, an anti-PDL1 antibody, an anti-PDL2 antibody, an anti-ICOS antibody, and an anti-BTLA antibody.

[0169] Embodiment 161: The immunoconjugate of embodiment 160, wherein said antibody is an antibody comprising the VH and VL domains of an antibody selected from the group consisting of ipilimumab, nivolumab, and pembrolizumab.

[0170] Embodiment 162: The immunoconjugate of embodiment 160, wherein the antibody is an antibody selected from the group consisting of ipilimumab, nivolumab, and pembrolizumab.

[0171] Embodiment 163: The antibody as defined above, 99 Tc, 99 Tc, 97 Ru, 95 Ru, 94 Tc, 90 Y, 90 Y, 89 Zr, 86 Y, 77 Br, 77 As, 76 Br, 75 Se, 72 As, 68 Ga, 68 Ga, 67 Ga, 67 Ga, 67 Cu, 67 Cu, 64 Cu, 62 Cu, 62 Cu, 59 Fe, 58 Co, 57 Co, 52 Mn, 52 Fe, 51 Cr, 47 Sc, 3 H, 35 S, 33 P, 32 P, 225 Ac, 224 Ac, 223 Ra, 213 Bi, 212 Pb, 212 Bi, 211 At, 203 Pb, 203 Hg, 201 Tl, 199 Au, 198 Au,198 Au, 197 Pt, 18 F, 189 Re, 188 Re, 188 Re, 186 Re, 186 Re, 177 Lu, 177 Lu, 175 Yb, 172 Tm, 169 Yb, 169 Yb, 169 Er, 168 Tm, 167 Tm, 166 Ho, 166 Dy, 165 Tm, 165 Dy, 161 Tb, 15 O. 15 N, 159 Gd, 157 Gd, 153 Sm, 153 Pb, 151 Pm, 14 C. 149 Pm, 143 Pr, 142 Pr, 13 N, 133 I, 131 In, 131 I, 127 Te, 126 I, 125 Te, 125 I, 124 I, 123 I, 122 Te, 121 Te, 121 Sn, 11 C. 113 In, 111 In, 111 In, 111 Ag, 111 Ag, 109 Pd, 109 Pd, 107 Hg, 105 Ru, 105 Rh, 105 Rh, and 103 137. The immunoconjugate of embodiment 136, wherein the immunoconjugate is bound to a chelate comprising an isotope selected from the group consisting of Ru.

[0172] Embodiment 164: The immunoconjugate of embodiment 136, wherein the antibody is complexed with an anti-cancer drug or bound to a lipid or liposome containing an anti-cancer drug.

[0173] Embodiment 165: The immunoconjugate of embodiment 136, wherein the antibody is linked to a detectable label.

[0174] Embodiment 166: A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and an antibody according to any one of embodiments 1 to 135; and / or a pharmaceutically acceptable carrier and an immunoconjugate according to any one of embodiments 136 to 165.

[0175] Embodiment 167: The pharmaceutical formulation of embodiment 166, wherein the formulation is a unit dose formulation.

[0176] Embodiment 168: The formulation of any one of embodiments 166 to 167, wherein the formulation is formulated for administration via a route selected from the group consisting of oral administration, nasal administration, rectal administration, intraperitoneal injection, intravascular injection, subcutaneous injection, transdermal administration, and intramuscular injection.

[0177] Embodiment 169: A method for reducing tumor-initiating cells in a cell population, comprising contacting a cell population comprising tumor-initiating cells expressing ALPPL2 and cells other than tumor-initiating cells with an anti-ALPPL2 immunoconjugate described in any one of embodiments 136 to 164, wherein the effector comprising the immunoconjugate has cytostatic and / or cytotoxic and / or immunomodulatory activity, thereby reducing the frequency of tumor-initiating cells in the tumor cell population.

[0178] Embodiment 170: The method of embodiment 169, wherein the contacting step is performed in vivo.

[0179] Embodiment 171: The method of embodiment 169, wherein the contacting step is carried out in vitro.

[0180] Embodiment 172: A method for inhibiting the growth and / or proliferation of cells expressing ALPPL2, comprising contacting the cells with an antibody described in any one of embodiments 1 to 135; and / or contacting the cells with an anti-ALPPL2 immunoconjugate described in any one of embodiments 136 to 164, wherein the effector comprising the immunoconjugate has cytostatic and / or cytotoxic and / or immunomodulatory activity.

[0181] Embodiment 173: The method of claim 172, wherein the cell is a cancer cell.

[0182] Embodiment 174: The method of embodiment 173, wherein the cancer cells are selected from the group consisting of mesothelioma, testicular cancer, endometrial cancer, and a subset of ovarian cancer, pancreatic cancer, and non-small cell lung cancer.

[0183] Embodiment 175: The method of any one of embodiments 173 to 174, wherein the cell is a metastatic cell.

[0184] Embodiment 176: The method of any one of embodiments 173 to 175, wherein the cells are solid tumor cells.

[0185] Embodiment 177: The method of any one of claims 172 to 176, wherein the effector comprises a radionuclide and / or a cytostatic agent.

[0186] Embodiment 178: The method of embodiment 177, wherein the effector comprises one or more of the following: a cytotoxic and / or cytostatic agent; a lipid or liposome containing a cytotoxic and / or cytostatic agent; a polymeric drug carrier comprising a cytotoxic and / or cytostatic agent; and a nanoparticle drug carrier comprising a cytotoxic and / or cytostatic agent.

[0187] Embodiment 179: The method of embodiment 178, wherein the drug is an anticancer drug.

[0188] Embodiment 180: The method of embodiment 179, wherein the drug is selected from the group consisting of an auristatin, a dolastatin, a colchicine, a combretastatin, and an mTOR / PI3K inhibitor.

[0189] Embodiment 181: The method of embodiment 179, wherein the drug is monomethyl auristatin F.

[0190] Embodiment 182: The drug is fluorouracil (5-FU), capecitabine, 5-trifluoromethyl-2'-deoxyuridine, methotrexate sodium, raltitrexed, pemetrexed, cytosine arabinoside, 6-mercaptopurine, azathioprine, 6-thioguanine (6-TG), pentostatin, fludarabine phosphate, cladribine, floxuridine (5-fluoro-2), ribonucleotide reductase inhibitors (RNR), cyclophosphamide, neosal, ifosfamide. , thiotepa, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, methyl (CCNU), hexamethylmelamine, busulfan, procarbazine HCl, dacarbazine (DTIC), chlorambucil, melphalan, cisplatin, carboplatin, oxaliplatin, bendamustine, carmustine, chloromethine, fotemustine, lomustine, mannosulfan, nedaplatin, nimustine, prednisone , ranimustine, satraplatin, semustine, streptozocin, temozolomide, treosulfan, triaziquone, triethylenemelamine, thioTEPA, triplatin tetranitrate, trophosfamide, uramustine, doxorubicin, daunorubicin citrate, mitoxantrone, actinomycin D, etoposide, topotecan HCl, teniposide (VM-26), irinotecan HCl (CPT-11), camptothecin, belotecan, rubitecan, vincristine, vinblastine sulfate, tartar 180. The method of embodiment 179, wherein the medicament is selected from the group consisting of vinorelbine acid, vindesine sulfate, paclitaxel, docetaxel, nanoparticulate paclitaxel, abraxane, ixabepilone, larotaxel, ortataxel, tesetaxel, vinflunine, retinoic acid, retinoic acid derivatives, doxorubicin, vinblastine, vincristine, cyclophosphamide, ifosfamide, cisplatin, 5-fluorouracil, camptothecin derivatives, interferon, tamoxifen, and taxol.In certain embodiments, the anti-cancer compound is selected from the group consisting of Abraxane, doxorubicin, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, toremifene, letrozole, trastuzumab, megestrol tamoxifen, paclitaxel, docetaxel, capecitabine, goserelin acetate, and zoledronic acid.

[0191] Embodiment 183: The method of any one of embodiments 178 to 182, wherein the drug is directly conjugated to the antibody; or the drug is contained in a lipid or liposome bound to the antibody; or the drug is contained in a polymeric carrier and / or nanoparticle carrier bound to the antibody.

[0192] Embodiment 184: The method of any one of embodiments 172 to 176, wherein the effector comprises a cytotoxin.

[0193] Embodiment 185: The method of embodiment 172, wherein the effector comprises a radionuclide.

[0194] Embodiment 186: The method of any one of embodiments 172 to 185, wherein the immunoconjugate or antibody is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

[0195] Embodiment 187: The method of any one of embodiments 172 to 186, wherein said administering comprises administering to a human or non-human mammal.

[0196] Embodiment 188: The method of any one of embodiments 172 to 187, wherein said administering comprises administering parenterally; and / or administering to a tumor or surgical site.

[0197] Embodiment 189: The method of any one of embodiments 172 to 188, wherein the antibody and / or immunoconjugate is administered as an adjuvant therapy to surgery and / or radiation therapy.

[0198] Embodiment 190: The method of any one of embodiments 172 to 189, wherein the antibody and / or immunoconjugate is administered in combination with another anti-cancer agent and / or hormone.

[0199] Embodiment 191: A method for detecting cancer cells of a cancer expressing ALPPL2, comprising the steps of contacting said cancer cells with an immunoconjugate comprising the antibody of any one of embodiments 1 to 135 linked to a detectable label; and detecting the presence and / or location of said detectable label, wherein the presence and / or location is indicative of the location and / or presence of cancer cells. A method comprising:

[0200] Embodiment 192: The method of embodiment 191, wherein the label comprises a label selected from the group consisting of a radioactive label, a radiopaque label, an MRI label, a PET label, and a SPECT label.

[0201] Embodiment 193: The method of any one of embodiments 191 to 192, wherein the cancer cells are selected from the group consisting of mesothelioma, testicular cancer, endometrial cancer, and a subset of ovarian cancer, pancreatic cancer, and non-small cell lung cancer.

[0202] Embodiment 194: The method of any one of embodiments 191 to 193, wherein the contacting step comprises administering the immunoconjugate to a non-human mammal or a human.

[0203] Embodiment 195: The method of any one of embodiments 191 to 194, wherein said detecting comprises detecting said label in vivo.

[0204] Embodiment 196: The method of embodiment 195, wherein said detecting step comprises using a detection method selected from the group consisting of X-ray, PET, SPECT, MRI, and CAT.

[0205] Embodiment 197: The method of any one of embodiments 191 to 194, wherein said detecting step comprises detecting said label ex vivo in a biopsy or a biopsy-derived sample.

[0206] Embodiment 198: A nucleic acid encoding an antibody or a fragment of an antibody according to any of embodiments 1 to 135.

[0207] Embodiment 199: An expression vector comprising the nucleic acid of embodiment 198.

[0208] Embodiment 200: A cell comprising an expression vector according to embodiment 199.

[0209] Embodiment 201: A chimeric antigen receptor (CAR) comprising an antibody according to any one of embodiments 1 to 135.

[0210] Embodiment 202: The chimeric antigen receptor of embodiment 201, wherein said receptor comprises the antibody; a transmembrane domain; at least one costimulatory signaling region; and a CD3 zeta signaling domain.

[0211] Embodiment 203: The chimeric antigen receptor of embodiment 202, wherein the costimulatory signaling region comprises the intracellular domain of a costimulatory molecule selected from the group consisting of CD27, CD2S, 4-IBB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, and any combination thereof.

[0212] Embodiment 204: The chimeric antigen receptor of embodiment 202, wherein the costimulatory signaling region comprises 4-1BB.

[0213] Embodiment 205: The chimeric antigen receptor of any one of embodiments 202 to 204, wherein the transmembrane domain comprises a CD8 hinge domain or a fragment thereof.

[0214] Embodiment 206: An isolated nucleic acid sequence encoding the chimeric antigen receptor (CAR) of any one of embodiments 201 to 205.

[0215] Embodiment 207: A cell comprising a nucleic acid sequence encoding the chimeric antigen receptor (CAR) of any one of embodiments 201 to 205.

[0216] Embodiment 208: The cell of embodiment 207, wherein the cell is selected from the group consisting of a T cell, a natural killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.

[0217] Embodiment 209: The cell of any one of embodiments 207 to 208, wherein the cell exhibits an anti-cancer immune response when the antigen-binding domain binds to a cell expressing ALPP and / or ALPPL2.

[0218] Embodiment 210: A pharmaceutical composition for treating cancer in a mammal, wherein the formulation comprises the genetically engineered cells (CAR-T cells) of any one of embodiments 207 to 209, and a pharmaceutically acceptable carrier.

[0219] Embodiment 211: The formulation comprises an antitumor effective amount of cells, wherein the antitumor effective amount of cells is about 10 per kg of body weight of a mammal in need of such cells. 4 ~Up to about 10 7 211. The composition of embodiment 210, which is a range of cells.

[0220] Embodiment 212: A vector comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR) according to any one of embodiments 201 to 205.

[0221] Embodiment 213: A method of stimulating a T cell-mediated immune response against a target cell population or tissue in a mammal, said target cell population and / or tissue expressing ALPP and / or ALPPL2, or a region of ALPP and / or ALPPL2 bound by antibodies M25AD, M25ADX and / or M25, comprising administering to the mammal an effective amount of cells genetically modified to express a chimeric antigen receptor (CAR) according to any one of embodiments 201 to 205.

[0222] Embodiment 214: A method of conferring anti-tumor immunity in a mammal against tumors expressing ALPP and / or ALPPL2, and / or regions of ALPP and / or ALPPL2 bound by antibodies M25AD, M25ADX and / or M25, comprising administering to the mammal an effective amount of a chimeric antigen receptor (CAR) genetically modified to express the chimeric antigen receptor (CAR) of any one of embodiments 201 to 205, thereby conferring anti-tumor immunity in the mammal.

[0223] Embodiment 215: A method of treating a mammal having cancer comprising cells expressing ALPP and / or ALPPL2, or a region of ALPP and / or ALPPL2 bound by antibodies M25AD, M25ADX and / or M25, comprising administering to the mammal an effective amount of cells genetically modified to express a chimeric antigen receptor (CAR) according to any one of embodiments 201 to 205.

[0224] Embodiment 216: A method of generating a persistent population of genetically engineered T cells in a mammal diagnosed with cancer, comprising administering to the mammal T cells genetically modified to express a chimeric antigen receptor (CAR) of any one of embodiments 201 to 205, wherein the persistent population of genetically engineered T cells persists in the human for at least one month after administration.

[0225] Embodiment 217: The method of embodiment 216, wherein the persistent population of engineered T cells comprises memory T cells.

[0226] Embodiment 218: The method of any one of embodiments 216 to 217, wherein the persistent population of engineered T cells persists in the human for at least 3 months, or at least 4 months, or at least 5 months, or at least 6 months, or at least 7 months, or at least 8 months, or at least 9 months, or at least 10 months, or at least 11 months, or at least 12 months, or at least 2 years, or at least 3 years after administration.

[0227] Embodiment 219: The method of any one of embodiments 213 to 215, wherein the cell is a T cell.

[0228] Embodiment 220: The method of any one of embodiments 213 to 215, wherein said cells are autologous T cells.

[0229] Embodiment 221: The method of any one of embodiments 213 to 215, wherein the cells are allogeneic T cells.

[0230] Embodiment 222: A method of expanding a population of genetically engineered T cells in a mammal diagnosed with cancer, comprising administering to said mammal genetically modified T cells that express a chimeric antigen receptor (CAR) according to any one of embodiments 201 to 215, wherein the administered genetically engineered T cells produce a population of progeny T cells in the human.

[0231] Embodiment 223: The method of any one of embodiments 213 to 222, wherein the mammal is a human.

[0232] Embodiment 224: The method of any one of embodiments 213 to 222, wherein said mammal is a non-human mammal.

[0233] Embodiment 225: The method of any one of embodiments 213 to 224, wherein the cancer comprises cells of a cancer selected from the group consisting of mesothelioma, testicular cancer, endometrial cancer, and ovarian cancer, pancreatic cancer, and non-small cell lung cancer, which express ALPP and / or ALPPL2.

[0234] Embodiment 226: The method of any one of embodiments 213 to 225, wherein the administered cells are T cells.

[0235] Embodiment 227: The method of any one of embodiments 213 to 226, wherein the administered cells are autologous T cells.

[0236] Embodiment 228: A method for treating cancer, comprising contacting a genetically engineered T cell (CAR-T cell) described in any one of embodiments 201 to 205 with a mammalian cancer cell to induce apoptosis of the cancer cell.

[0237] definition The term "patient" includes human and other mammalian subjects receiving either prophylactic or therapeutic treatment.

[0238] As used herein, the term "subject" includes any human or non-human animal. For example, the methods and compositions of the present invention can be used to treat a subject with cancer. In an exemplary embodiment, the subject is a human. The term "non-human animal" includes all vertebrates, including mammals and non-mammals, such as non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, etc.

[0239] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The term applies to amino acid polymers in which one or more amino acid residues are artificial chemical analogues of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The term also includes variations on the traditional peptide linkages connecting the amino acids that make up a polypeptide.

[0240] The term "nucleic acid" or "oligonucleotide" or grammatical equivalents herein refers to at least two nucleotides covalently linked to each other. Nucleic acids of the present invention are preferably single- or double-stranded and generally contain phosphodiester bonds, although in some cases include nucleic acid analogs which may have alternative backbones as outlined below, e.g., phosphoramide linkages (Beaucage et al. (1993) Tetrahedron 49(10):1925) and references therein; Letsinger (1970) J. Org. Chem. 35:3800; Sprinzl et al. (1977) Eur. J. Biochem. 81:579; Letsinger et al. (1986) Nucl. Acids Res. 14:3487; Sawai et al. (1984) Chem. Lett. 805, Letsinger et al. (1988) J. Am. Chem. Soc. 110:4470; Pauwels et al. (1986) Chemica Scripta 26: 1419), phosphorothioate linkages (Mag et al. (1991) Nucleic Acids Res. 19:1437; U.S. Pat. No. 5,644,048), phosphorodithioate linkages (Briu et al. (1989) J. Am. Chem. Soc. 111:2321), O-methyl phosphoramidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm (1992) J. Am. Chem. Soc. 114:1895; Meier et al. (1992) Chem. Int. Ed. Engl. 31:1008; Nielsen (1993) Nature, 365:566; Carlsson et al. (1996) Nature 380:207).Other similar nucleic acids include those with normal backbones (Denpcy et al., (1995) Proc. Natl. Acad. Sci. USA 92:6097); non-ionic backbones (U.S. Pat. Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141, and 4,469,863; Angew. (1991) Chem. Intl. Ed. English 30:423; Letsinger et al., (1988) J. Am. Chem. Soc. 110:4470; Letsinger et al., (1994) Nucleoside & Nucleotide 13:1597; Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research," Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al. (1994), Bioorganic & Medicinal Chem. Lett. 4:395; Jeffs et al. (1994) J. Biomolecular NMR 34:17; Tetrahedron Lett. 37:743 (1996)) and those with non-ribose backbones, such as those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research," Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within the definition of nucleic acid (see Jenkins et al. (1995), Chem. Soc. Rev. 169-176). Some nucleic acid analogs are described in Rawls, C & E News, June 2, 1997, page 35. These modifications of the ribose-phosphate backbone can be made to facilitate the addition of additional moieties, such as labels, or to increase the stability and half-life of such molecules in physiological environments.

[0241] The term "residue" as used herein refers to a natural, synthetic, or modified amino acid.

[0242] As used herein, "antibody" refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. Recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively.

[0243] A typical immunoglobulin (antibody) structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" chain (approximately 25 kD) and one "heavy" chain (approximately 50-70 kD). The N-terminus of each chain defines a variable region of approximately 100-110 or more amino acids that is primarily responsible for antigen recognition. The variable light chain (VLC) L ) and variable heavy chain (V H ) refer to these light and heavy chains respectively.

[0244] Antibodies exist as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests antibodies at the disulfide linkages in the hinge region, itself splitting the V H -C HThe resulting antibody fragments are F(ab)'2, a dimer of Fab, a light chain connected to a target nucleotide. The F(ab)'2 can be reduced under mild conditions to disrupt the disulfide linkage in the hinge region, thereby converting the (Fab')2 dimer into a Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology, W.E. Paul, ed., Raven Press, NY (1993) for a more detailed description of other antibody fragments). While various antibody fragments have been defined in terms of the digestion of intact antibodies, those skilled in the art will understand that such Fab' fragments can be synthesized chemically or de novo using recombinant DNA methodologies. Thus, the term "antibody," as used herein, also includes antibody fragments produced by the modification of whole antibodies or synthesized de novo using recombinant DNA methodologies. Certain preferred antibodies include single-chain antibodies (antibodies present as a single polypeptide chain) in which the variable heavy chain and variable light chain are connected (either directly or via a peptide linker) to form a contiguous polypeptide, more preferably single-chain Fv antibodies (sFv or scFv). Single-chain Fv antibodies are antibodies in which the V chains are connected directly or by a peptide-encoding linker. H and V L a covalently linked V that can be expressed from a nucleic acid comprising a sequence encoding H -V L It is a heterodimer. Huston et al. (1988) Proc. Nat. Acad. Sci. USA, Vol. 85: 5879-5883. V H and V L are linked together as a single polypeptide chain, while V H and V LThe domains are noncovalently linked. The first functional antibody molecules expressed on the surface of filamentous phage were single-chain Fvs (scFvs), although other expression strategies have also been successful. For example, Fab molecules can be displayed on phage when one of the chains (heavy or light) is fused to the g3 capsid protein and the complementary chain is released as a soluble molecule into the periplasm. The two chains can be encoded on the same or different replicons; the key is that the two antibody chains in each Fab molecule assemble post-translationally, and the dimer is incorporated into the phage particle via linkage of one of the chains, for example, to g3p (see, e.g., U.S. Pat. No. 5,733,743). scFv antibodies and numerous other structures that convert naturally aggregated but chemically separated light and heavy polypeptide chains from antibody V regions into molecules that fold into three-dimensional structures substantially similar to the structure of an antigen-binding site are known to those of skill in the art (see, e.g., U.S. Pat. Nos. 5,091,513, 5,132,405, and 4,956,778). Particularly preferred antibodies should include all those displayed on phage, such as scFv, Fv, Fab, and disulfide-linked Fv (see, e.g., Reiter et al. (1995) Protein Eng. 8:1323-1331).

[0245] The term "specifically bind," as used herein, when referring to a biomolecule (e.g., protein, nucleic acid, antibody, etc.), refers to a binding reaction that is determinative of the presence of the biomolecule (e.g., protein and other biologic) in a heterogeneous population of molecules. Thus, under specified conditions (e.g., immunoassay conditions in the case of antibodies or stringent hybridization conditions in the case of nucleic acids), a particular ligand or antibody will bind to its particular "target" molecule and not to other molecules present in significant amounts in the sample.

[0246] The phrase "inhibition of proliferation of cells expressing ALPP and / or ALPPL2," as used herein, refers to the ability of an anti-ALPP / ALPPL2 antibody or immunoconjugate described herein to reduce, preferably statistically significantly reduce, the proliferation of cells expressing ALPP and / or ALPPL2 or a fragment thereof, compared to proliferation in the absence of the antibody or immunoconjugate. In one embodiment, the proliferation of cells expressing ALPP / ALPPL2 or a fragment thereof (e.g., cancer cells) can be reduced by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100%, when the cells are contacted with an antibody or antigen-binding portion thereof or immunoconjugate described herein, compared to proliferation measured in the absence of the antibody or antigen-binding portion thereof or immunoconjugate (control). Cell proliferation can be assayed using art-recognized techniques that measure the rate of cell division, the fraction of cells within a cell population undergoing cell division, and / or the rate of cell loss from a cell population due to terminal differentiation or cell death (e.g., using a cell titer glow assay or thymidine incorporation).

[0247] The phrase "inhibition of migration of cells expressing ALPP / ALPPL2," as used herein, refers to the ability of an anti-ALPP / ALPPL2 antibody or antigen-binding portion thereof, or immunoconjugate thereof described herein, to inhibit the migration of cells expressing ALPP and / or ALPPL2 or a fragment thereof (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95) compared to the migration of cells in the absence of the antibody. M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or a fragment to which M25wtLF binds). In one embodiment, the migration of cells expressing ALPP / ALPPL2 (e.g., cancer cells) may be reduced by at least 10%, or at least 20%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or 100% when the cells are contacted with the antibody or antigen-binding portion thereof, or immunoconjugate thereof, compared to cell migration measured in the absence of the antibody or antigen-binding portion thereof, or immunoconjugate thereof (control). Cell migration can be assayed using conventionally recognized techniques.In various embodiments, the antibodies and / or immunoconjugates described herein are selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25ADYHSRLF ... It is contemplated that 53018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF can inhibit the migration of cells (e.g., cancer cells described herein) that express or overexpress ALPP and / or ALPPL2, and domains of ALPP and / or ALPPL2 to which they bind.

[0248] The term "antigen-binding portion" of an antibody (or simply "antibody portion"), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., ALPP and / or ALPPL2). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed by the term "antigen-binding portion" of an antibody include: (i) V L , V H (ii) a Fab fragment, which is a monovalent fragment consisting of the CL and CH1 domains; (iii) a F(ab')2 fragment, which is a bivalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region; H and a Fd fragment consisting of the CH1 domain; (iv) a V of a single arm of an antibody. L and V H Fv fragment consisting of domains; (v) V H and V L (vi) V domain-containing dAb; H(vii) dAb fragments consisting of the V domain (see, e.g., Ward et al. (1989) Nature 341:544-546); H or V L and (viii) an isolated complementarity determining region (CDR), or (ix) a combination of two or more isolated CDRs, optionally connected by a synthetic linker. L and V H The two domains may be encoded by separate genes, but using recombinant methods, they can be combined into a V domain to form a monovalent molecule. L The V and V regions can be connected by a synthetic linker, which can be produced as a paired single protein chain (known as a single-chain Fv (scFv); see, e.g., Bird et al. (1988) Science 242:423-426; Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single-chain antibodies are also intended to be encompassed by the term "antigen-binding portion" of an antibody. These antibody fragments are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. Antigen-binding portions can be produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact immunoglobulins.

[0249] The term "monoclonal antibody," as used herein, refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprise a population which are identical except for possible naturally occurring mutations which may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. Monoclonal antibodies can be prepared using any art-recognized technique, such as the hybridoma method described, for example, in Kohler et al. (1975) Nature 256:495, transgenic animals as described, for example, in Lonberg et al. (1994) Nature 368(6474):856-859, recombinant DNA methods (see, for example, U.S. Pat. No. 4,816,567), or the use of phage antibody libraries using, for example, the techniques described in Clackson et al. (1991) Nature 352:624-628, Marks et al. (1991) J. Mol. Biol. 222:581-597, and the techniques described herein. Monoclonal antibodies include chimeric, human, and humanized antibodies, and can be naturally occurring or recombinantly produced.

[0250] The term "recombinant antibody" refers to antibodies prepared, expressed, generated, or isolated by recombinant means, such as (a) antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for immunoglobulin genes (e.g., human immunoglobulin genes) or hybridomas prepared therefrom; (b) antibodies isolated from a host cell that has been transformed to express the antibody, e.g., from a transfectoma; (c) antibodies isolated from a recombinant, combinatorial antibody library (e.g., containing human antibody sequences) using phage display; and (d) antibodies prepared, expressed, generated, or isolated by any other means involving splicing immunoglobulin gene sequences (e.g., human immunoglobulin genes) to other DNA sequences. Such recombinant antibodies may have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies may be subjected to in vitro mutagenesis, thus modifying the V and constant regions of the recombinant antibody. H and V L The amino acid sequences of the regions are similar to those of the human germline V- and V L While derived from and related to the sequence, it may not naturally occur within the human antibody germline repertoire in vivo.

[0251] The term "chimeric immunoglobulin" or antibody refers to an immunoglobulin or antibody whose variable regions derive from a first species and whose constant regions derive from a second species. Chimeric immunoglobulins or antibodies can be constructed, for example, by genetic engineering, from immunoglobulin gene segments belonging to different species.

[0252] The term "human antibody," as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences, for example, as described by Kabat et al. (See Kabat et al., (1991) Sequences of proteins of Immunological Interest, 5th ed., U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Furthermore, if the antibody contains a constant region, the constant region also is derived from human germline immunoglobulin sequences. Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody," as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0253] A human antibody can have at least one or more amino acids substituted with an amino acid residue, e.g., an activity-enhancing amino acid residue not encoded by the human germline immunoglobulin sequence. Typically, a human antibody can have up to 20 positions substituted with an amino acid residue that is not part of the human germline immunoglobulin sequence. In certain embodiments, such substitutions are in the CDR regions, as described in more detail below.

[0254] The term "humanized immunoglobulin" or "humanized antibody" refers to an immunoglobulin or antibody comprising at least one humanized immunoglobulin or antibody chain (i.e., at least one humanized light or heavy chain). The term "humanized immunoglobulin chain" or "humanized antibody chain" (i.e., "humanized immunoglobulin light chain" or "humanized immunoglobulin heavy chain") refers to an immunoglobulin or antibody chain (i.e., light or heavy chain, respectively) having a variable region comprising substantially a variable framework region from a human immunoglobulin or antibody and substantially a complementarity-determining region (CDR) (e.g., at least one CDR, preferably two CDRs, more preferably three CDRs) from a non-human immunoglobulin or antibody, and further comprising a constant region (e.g., at least one constant region or portion thereof in the case of a light chain, and preferably three constant regions in the case of a heavy chain). The term "humanized variable region" (e.g., "humanized light chain variable region" or "humanized heavy chain variable region") refers to a variable region that substantially comprises a variable framework region from a human immunoglobulin or antibody and complementarity-determining regions (CDRs) from a non-human immunoglobulin or antibody.

[0255] As used herein, a "heterologous antibody" is defined in relation to the transgenic non-human organism or plant that produces such an antibody.

[0256] An "isolated antibody," as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigen specificities (e.g., an isolated antibody that specifically binds to ALPP and / or ALPL2 is substantially free of antibodies that specifically bind to antigens other than ALPP and / or ALPL2). In addition, an isolated antibody is typically substantially free of other cellular material and / or chemicals. In one embodiment, a combination of "isolated" monoclonal antibodies with different ALPP / ALPPL2 binding specificities are combined in a well-defined composition.

[0257] As used herein, "isotype" refers to the antibody class (e.g., IgM or IgG1) encoded by the heavy chain constant region genes. In one embodiment, the antibody, or antigen-binding portion thereof, is of an isotype selected from the following antibody isotypes: IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, or IgE. In some embodiments, the monoclonal antibodies of the invention are of the IgG1 isotype. In other embodiments, the monoclonal antibodies of the invention are of the IgG2 isotype.

[0258] An "antigen" is an entity (e.g., a proteinaceous entity or peptide) to which an antibody, or antigen-binding portion thereof, binds. In various embodiments of the invention, the antigen is, for example, ALPP and / or ALPPL2 displayed on a cell (e.g., an ALPPL2-positive cancer cell), and / or M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H , M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

[0259] The term "epitope" or "antigenic determinant" refers to a site on an antigen to which an immunoglobulin or antibody specifically binds. Epitopes can be formed from both contiguous and non-contiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids typically remain after exposure to denaturing solvents, while epitopes formed by tertiary folding typically disappear after treatment with denaturing solvents. Epitopes typically contain at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in a unique spatial conformation. Methods for determining the spatial conformation of epitopes include techniques in the art and described herein, such as x-ray crystallography and two-dimensional nuclear magnetic resonance (see, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996)).

[0260] Also included herein are M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, and M25GRITSGF, which are described herein. YGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies. Antibodies that recognize the same epitope can be identified using routine techniques such as immunoassays, i.e., competitive binding assays, for example, by demonstrating the ability of one antibody to prevent the binding of another antibody to a target antigen. Competitive binding is determined in an assay in which the immunoglobulin under test inhibits specific binding of a reference antibody to a common antigen, such as ALPP and / or ALPPL2. For example, numerous types of competitive binding assays are known, including, for example, solid-phase direct or indirect radioimmunoassays (RIAs), solid-phase direct or indirect enzyme immunoassays (EIAs), sandwich competition assays (see, e.g., Stahl et al. (1983) Meth. Enzymol. 9:242); solid-phase direct biotin-avidin EIA (see, e.g., Kirkland et al. (1986) J. Immunol. 137:3614); solid-phase direct labeling assays, solid-phase direct labeling sandwich assays (see, e.g., Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Press); 125Solid-phase direct-labeling RIA using I-label (see, e.g., Morel et al. (1988) Mol. Immunol. 25(1):7); solid-phase direct biotin-avidin EIA (Cheung et al. (1990) Virology 176:546); and direct-labeling RIA (Moldenhauer et al. (1990) Scand J. Immunol. 32:77). Typically, such assays involve the use of purified antigen (e.g., APPL and / or APPL2) bound to a solid surface or cells bearing either an unlabeled test immunoglobulin or a labeled reference immunoglobulin. Competitive inhibition can be measured by determining the amount of label bound to the solid surface or cells in the presence of the test immunoglobulin. The test immunoglobulin is usually present in excess. Typically, a competing antibody, when present in excess, inhibits specific binding of a reference antibody to a common antigen by at least 50-55%, 55-60%, 60-65%, 65-70%, 70-75% or more.

[0261] As used herein, the terms "specific binding," "binds specifically," "selective binding," and "selectively binds" mean that an antibody, or antigen-binding portion thereof, exhibits significant affinity for a particular antigen or epitope, but typically does not exhibit significant cross-reactivity with other antigens and epitopes. "Significant" or preferred binding is at least 10 (equal to or less than the KD). -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M or 10 -11 Binding with an affinity of M. 10 -9 Larger than M, preferably 10 -10 Affinities greater than M are more preferred. Values ​​intermediate between those specified herein are also intended to be within the scope of the invention, with preferred binding affinities being, for example, 10 -6 M to 10 -11 M, preferably 10 -7 M or 10 -8 M to 10-10 The affinity of an antibody may be expressed as an affinity in the range of M, ...

[0262] The term “K D " as used herein is intended to refer to the dissociation equilibrium constant of a particular antibody-antigen interaction, or the affinity of an antibody for an antigen. In one embodiment, an antibody or antigen-binding portion thereof according to the invention binds to an antigen (e.g., ALPP and / or ALPPL2) with an affinity (K) of 5 nM or better (i.e., less than 5 nM) as measured using a surface plasmon resonance assay or a cell binding assay. D ) (e.g., 40 nM, 30 nM, 20 nM, or 10 nM or less). In certain embodiments, antibodies or antigen-binding portions thereof of the invention bind to cells expressing the antigen with an affinity (K) of 5 nM or better as measured using a surface plasmon resonance assay or a cell binding assay. D) (e.g., 4 nM, 2 nM, 1.5 nM, 1.4 nM, 1.3 nM, 1 nM or less) to inhibit ALPP and / or ALPPL2, and / or M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M In another embodiment, the antibody or antigen-binding portion thereof binds to a domain of ALPP and / or ALPPL2 bound by 25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtL. -10 M, or 100 x 10 -11 M or 10 x 10 -11 Affinity (K D ) binds to the antigen (e.g., ALPP and / or ALPPL2).

[0263] The term “K off ", as used herein, is intended to refer to the off-rate constant for dissociation of an antibody from the antibody / antigen complex.

[0264] The term "EC50," as used herein, refers to the concentration of an antibody or antigen-binding portion thereof, or immunoconjugate described herein, that induces a response in an in vitro or in vivo assay that is 50% of the maximal response, i.e., midway between the maximal response and the baseline.

[0265] The term "naturally-occurring," as used herein, as applied to an object refers to the fact that the object can be found in nature. For example, a polypeptide or polynucleotide sequence present in an organism (including a virus) that can be isolated from a natural source and has not been intentionally modified by humans in the laboratory is naturally-occurring.

[0266] The terms "modifying" or "modification," as used herein, are intended to refer to changing one or more amino acids in an antibody or antigen-binding portion thereof. The changes can be made by adding, substituting, or deleting amino acids at one or more positions. The changes can be made using known techniques, such as PCR mutagenesis. For example, in some embodiments, an antibody or antigen-binding portion thereof identified using the methods of the invention can be modified to thereby modify the binding affinity of the antibody or antigen-binding portion thereof to ALPP / ALPPL2.

[0267] In certain embodiments, "conservative amino acid substitutions" in the sequences of the anti-ALPP / ALPPL2 antibodies described herein are contemplated, i.e., modifications to the nucleotide and amino acid sequences that do not abrogate the binding of the antibody encoded by the nucleotide sequence or containing the amino acid sequence to an antigen, e.g., ALPP / ALPPL2. Conservative amino acid substitutions include the substitution of an amino acid in one class with an amino acid in the same class, where classes are defined by common physicochemical amino acid side chain properties and high substitution frequencies in homologous proteins found in nature, as determined, for example, by standard Dayhoff frequency exchange matrices or BLOSUM matrices. Amino acid side chains are generally classified into six classes, including: Class I (Cys); Class II (Ser, Thr, Pro, Ala, Gly); Class III (Asn, Asp, Gln, Glu); Class IV (His, Arg, Lys); Class V (Ile, Leu, Val, Met); and Class VI (Phe, Tyr, Trp). For example, substitution of Asp for another class III residue, such as Asn, Gln, or Glu, is a conservative substitution. Thus, a predicted non-essential amino acid residue in an anti-ALPP / ALPPL2 antibody is preferably replaced with another amino acid residue from the same class. Methods for identifying conservative nucleotide and amino acid substitutions that do not eliminate antigen binding are well known in the art (see, e.g., Brummell et al. (1993) Biochem. 32:1180-1187; Kobayashi et al. (1999) Protein Eng. 12(10):879-884; Burks et al. (1997) Proc. Natl. Acad. Sci. USA 94:412-417).

[0268] The term "non-conservative amino acid substitution" refers to the substitution of an amino acid in one class with an amino acid from another class; for example, the substitution of a class II residue, Ala, with a class III residue such as Asp, Asn, Glu, or Gln.

[0269] In another embodiment, mutations (conservative or non-conservative) can be introduced randomly along all or part of an anti-ALPP / ALPPL2 antibody coding sequence, such as by saturation mutagenesis, and the resulting modified antibodies can be screened for binding activity.

[0270] A "consensus sequence" is a sequence formed from the amino acids (or nucleotides) that occur most frequently in a family of related sequences (see, e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987)). In a family of proteins, each position in the consensus sequence is occupied by the amino acid that occurs most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. A "consensus framework" of an immunoglobulin refers to the framework region in the consensus immunoglobulin sequence.

[0271] Similarly, consensus sequences for the CDRs can be derived by optimal alignment of the CDR amino acid sequences of the anti-ALPP / ALPPL2 antibodies described herein.

[0272] With respect to nucleic acids, the term "substantial homology" means that two nucleic acids, or designated sequences thereof, when optimally aligned and compared, are identical in at least about 80% of the nucleotides, usually at least about 90% to 95% of the nucleotides, and more preferably at least about 98% to 99.5% of the nucleotides, with appropriate nucleotide insertions or deletions. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions to the complement of the strand.

[0273] The percent identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences (i.e., % homology = number of identical positions / total number of positions x 100). The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.

[0274] The percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software, using the NWSgapdna.CMP matrix, a gap weight of 40, 50, 60, 70, or 80, and a length weight of 1, 2, 3, 4, 5, or 6. The percent identity between two nucleotide or amino acid sequences can also be determined using the algorithm of Meyers and Miller (1989) CABIOS, 4:11-17, which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. Additionally, the percent identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:444-453, which is incorporated into programs in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6.

[0275] The nucleic acid and protein sequences contemplated herein can also be used as "query sequences" to search public databases, for example, to identify related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12, to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3, to obtain amino acid sequences homologous to the protein molecules of the invention. To obtain spaced alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (eg, XBLAST and NBLAST) can be used.

[0276] While frequently present in naturally occurring sequences (excluding modified restriction sites, etc.), the nucleic acid compositions described herein (e.g., nucleic acids encoding all or a portion of an anti-ALPP / ALPPL2 antibody or immunoconjugate), whether derived from cDNA, genomic, or a mixture thereof, can be mutated according to standard techniques to result in different sequences. For coding sequences, such mutations can affect the amino acid sequence as desired. In particular, DNA sequences that are substantially homologous to or derived from naturally occurring V, D, J, constant, switch, and other such sequences described herein are contemplated ("derived" indicates that the sequence is identical to or modified from another sequence).

[0277] The term "operably linked" refers to a nucleic acid sequence that is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to promote translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, both contiguous and in reading phase. Enhancers, however, need not be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adapters or linkers are used in accordance with conventional practice. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. With respect to transcriptional regulatory sequences, operably linked means that the DNA sequences being linked are contiguous and, where necessary to join two protein-coding regions, contiguous in reading frame. With respect to switch sequences, operably linked indicates that the sequences are capable of effecting recombination by the switch.

[0278] The term "vector," as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. The terms "plasmid" and "vector" may be used interchangeably. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (eg, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0279] The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which an expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur subsequently, either due to mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

[0280] The terms "treat," "treating," and "treatment," as used herein, refer to therapeutic or prophylactic measures described herein. Methods of "treatment" employ administration to a subject (e.g., a subject in need thereof) of an anti-ALPP / ALPPL2 antibody or antigen-binding portion, or an immunoconjugate comprising an antibody or antigen-binding portion described herein. In certain embodiments, the subject is one who has been diagnosed with and / or is undergoing treatment for an ALPPL2-positive cancer (e.g., mesothelioma) to prevent, cure, delay, reduce the severity of, or ameliorate one or more symptoms of, or the recurrence of, a disease or disorder, or to significantly extend the subject's expected survival in the absence of such treatment.

[0281] The terms "cancer" and "cancerous" refer to or describe a physiological disease in mammals that is typically characterized by uncontrolled cell growth. ALPP- or ALPPL2-positive cancers include, but are not limited to, M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, and M25F "ALPPL2-positive cancer" refers to a cancer characterized by cells expressing or overexpressing ALPP and / or ALPPL2 or fragments thereof that are bound by the SITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies. Exemplary ALPPL2-positive cancers include, but are not limited to, mesothelioma, testicular cancer, endometrial cancer, and subsets of pancreatic cancer, ovarian cancer, and non-small cell lung cancer.

[0282] The term "effective amount," as used herein, refers to the amount of an anti-ALPP / ALPPL2 antibody or antigen-binding portion thereof and / or immunoconjugate thereof that, upon administration to a subject, is sufficient to achieve treatment, prognosis, or diagnosis of a disease associated with the growth and / or proliferation of ALPP / ALPPL2-positive cells (e.g., an ALPP / ALPPL2-positive cancer) as described herein. The therapeutically effective amount varies depending on the subject and the disease state being treated, the subject's weight and age, the severity of the disease state, the method of administration, etc., and can be readily determined by one of ordinary skill in the art.Dosages for administration may range from, for example, about 1 ng to about 10,000 mg, about 5 ng to about 9,500 mg, about 10 ng to about 9,000 mg, about 20 ng to about 8,500 mg, about 30 ng to about 7,500 mg, about 40 ng to about 7,000 mg, about 50 ng to about 6,500 mg, about 1 ng to about 10,0 ... 00ng to about 6,000mg, about 200ng to about 5,500mg, about 300ng to about 5,000mg, about 400ng to about 4,500mg, about 500ng to about 4,000mg, about 1μg to about 3,500mg, about 5μg to about 3,000mg, about 10μg to about 2,600mg, about 20μg to about 2,575mg, about 30μg to about 2,550mg, about 40μg to about 2,500mg, about 50μg to about 2,475mg, about 100μg to about 2,4 50 mg, about 200 μg to about 2,425 mg, about 300 μg to about 2,000 mg, about 400 μg to about 1,175 mg, about 500 μg to about 1,150 mg, about 0.5 mg to about 1,125 mg, about 1 mg to about 1,100 mg, about 1.25 mg to about 1,075 mg, about 1.5 mg to about 1,050 mg, about 2.0 mg to about 1,025 mg, about 2.5 mg to about 1,000 mg, about 3.0 mg to about 975 mg, about 3.5 mg to about 950 mg, The effective dose may range from about 4.0 mg to about 925 mg, about 4.5 mg to about 900 mg, about 5 mg to about 875 mg, about 10 mg to about 850 mg, about 20 mg to about 825 mg, about 30 mg to about 800 mg, about 40 mg to about 775 mg, about 50 mg to about 750 mg, about 100 mg to about 725 mg, about 200 mg to about 700 mg, about 300 mg to about 675 mg, about 400 mg to about 650 mg, about 500 mg, or about 525 mg to about 625 mg. Dosage regimens may be adjusted to provide the optimal therapeutic response. An effective amount is also one in which any toxic or detrimental effects (i.e., side effects) of the antibody or antigen-binding portion thereof are minimized and / or outweighed by the beneficial effects.

[0283] "Effector" refers to any molecule or combination of molecules whose activity is desired to be delivered to and / or localized in a cell. Effectors include, but are not limited to, labels, cytotoxins, enzymes, growth factors, transcription factors, antibodies, drugs, etc.

[0284] For example, the phrase "inhibiting the growth and / or proliferation" of cancer cells includes, among other things, inducing apoptosis or other cell death mechanisms in the cells, reducing cell invasion, arresting cells at a particular point in the cell cycle, etc.

[0285] The term "immunoconjugate" refers to an antibody bound to one or more effectors, or to multiple antibodies bound to one or more effectors. The term "immunoconjugate" is intended to include effectors that are chemically conjugated to antibodies, as well as antibodies expressed as fusion proteins in which an antibody (or a portion thereof) is bound directly or via a linker to a peptide or peptide-containing effector.

[0286] The term "anti-tumor effect," as used herein, refers to a biological effect that may be manifested by a reduction in tumor volume, a reduction in tumor cell number, a reduction in the number of metastases, an increase in life expectancy, or an improvement in various physiological symptoms associated with a cancerous condition. An "anti-tumor effect" may also be manifested by the ability of the antibodies, immunoconjugates, and CAR-cells described herein to prevent tumor development in the first place.

[0287] The term "autologous" is meant to refer to any material originating from the same individual that is later reintroduced into the individual.

[0288] The term "allogeneic" refers to cells or grafts derived from a different animal of the same species.

[0289] The term "xenogeneic" refers to cells or grafts derived from an animal of a different species.

[0290] The term "costimulatory ligand," as used herein, includes molecules on antigen-presenting cells (e.g., APCs, dendritic cells, B cells, etc.) that specifically bind to a cognate costimulatory molecule on a T cell, thereby mediating T cell responses, including, but not limited to, proliferation, activation, differentiation, etc., in addition to the primary signal provided by the binding of the TCR / CD3 complex to a peptide-loaded MHC molecule. Costimulatory ligands can include, but are not limited to, CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM, lymphotoxin beta receptor, TR6, IL-1 T3, IL-1 T4, agonists or antibodies that bind to the Toll ligand receptor, and ligands that specifically bind B7-H3. Costimulatory ligands also include, inter alia, antibodies that specifically bind to costimulatory molecules present on T cells, such as, but not limited to, ligands that specifically bind to CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and CD83.

[0291] A "costimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules include, but are not limited to, MHC class I molecules, BTLA, and Toll-like receptors.

[0292] A "costimulatory signal," as used herein, refers to a signal that, in combination with a primary signal, such as TCR / CD3 ligation, leads to T cell proliferation and / or upregulation or downregulation of key molecules.

[0293] The term "stimulation" refers to a primary response induced by the binding of a stimulatory molecule (e.g., a TCR / CD3 complex) to its cognate ligand, thereby mediating a signal transduction event, such as, but not limited to, signal transduction through the TCR / CD3 complex. Stimulation can mediate changes in the expression of specific molecules, such as downregulation of TGF-β and / or rearrangement of cytoskeletal structure.

[0294] "Stimulatory molecule," as the term is used herein, means a molecule on a T cell that specifically binds to a cognate stimulatory ligand present on an antigen-presenting cell.

[0295] "Stimulatory ligand," as used herein, means a ligand that, when present on an antigen-presenting cell (e.g., APC, dendritic cell, B cell, etc.), can specifically bind to a T cell's cognate binding partner (also referred to herein as a "stimulatory molecule"), thereby mediating a primary response by the T cell, including, but not limited to, activation, initiation of an immune response, proliferation, etc. Stimulatory ligands are well known in the art and include, inter alia, peptide-loaded MHC class I molecules, anti-CD3 antibodies, superagonist anti-CD28 antibodies, and superagonist anti-CD2 antibodies. [Brief explanation of the drawings]

[0296] [Figure 1] FIG. 1 illustrates the amino acid sequences of ALPP (SEQ ID NO: 1) and ALPPL2 (SEQ ID NO: 2). [Figure 2] Figure 2 illustrates the potent and specific tumor cell killing in vitro. MMAF was conjugated to M25 IgG1 via the mc-vc-pab linker, purified, and incubated with the mesothelioma cell line M28 and control cells (HS775Li, a primary human liver cell line, and HS27, a foreskin fibroblast cell line). There was a >1,000-fold difference in EC50 between the tumor cells and the control non-tumorigenic cells (0.54 nM vs. >1 μM), demonstrating potent and selective tumor killing by our new ADC. [Figure 3]Figures 3A and 3B show that anti-ALLP / ALLPL2 ADCs potently inhibit tumor xenograft growth in vivo. Figure 3A shows a plot of the geometric mean of tumor volume. Injections began on day 7 and were given every 5 days at 5 mg / kg per mouse for 5 doses. M25mcvcpabMMAF: Test ADC (MMAF conjugated to M25 IgG1). IgG: Naked M25 IgG1 control. Figure 3B: Animal weights were monitored and plotted. No overt signs of toxicity were observed. Note: The experiments shown in A and B did not include a control ADC (ctr IgG1-mcvcpab-MMAF), but we tested the control ADC in other experiments, which behaved similarly to the vehicle or naked IgG control. [Figure 4] Figure 4 shows the evaluation of an MMAE-based ADC in a mesothelioma xenograft model. M25AD-mcvcpab-MMAE was injected at 3 mg / kg every 3–4 days for five doses. Unconjugated IgG1-mcvcpab-MMAE was used as a control. [Figure 5] FIG. 5 shows FACS of the inventors' anti-ALPPL2 antibody M25 against mesothelioma, pancreatic, and non-small cell lung cancer lines. [Figure 6] Figure 6 shows the killing curves of M25AD-MMAF and M25AD-MMAE against pancreatic (Capan-1, panels A and B) and non-small cell lung cancer (H1651, panels C and D) lines. All conjugates are IgG1-mcvcpab-MMAF (panels A and C) or IgG1-mcvcpab-MMAE (panels B and D). [Figure 7]Figure 7 shows FACS analysis of M25ADLF IgG1 binding to live HEK293 cells transfected with an ALPPL2 expression plasmid along with a plasmid expressing green fluorescent protein (GFP). Cells were incubated with the antibody in PBS / 0.2% fetal bovine serum for 1 hour at room temperature, washed three times, and further incubated with ALEXAFLOU®-647-conjugated anti-human secondary antibody. GFP+ cells were gated and analyzed for mean fluorescence intensity (MFI). Normalized MFI was used for curve fitting using Prism (GraphPad) to obtain an apparent KD value of 17.04 + / - 6.18 pM. Similar binding results were obtained for ALPP-transfected cells. There was no binding to ALPL-transfected cells. Binding to APLI-transfected cells has an apparent KD value of >5 μM. [Figure 8] Figure 8 shows FACS analysis of M25FYIA IgG1 binding to live HEK293 cells transfected with an ALPPL2 expression plasmid along with a plasmid expressing green fluorescent protein (GFP). Cells were incubated with the antibody in PBS / 0.2% fetal bovine serum for 1 hour at room temperature, washed three times, and further incubated with ALEXAFLOU®-647-conjugated anti-human secondary antibody. GFP+ cells were gated and analyzed for mean fluorescence intensity (MFI). Normalized MFI was used for curve fitting using Prism (GraphPad) to obtain an apparent KD value of 20.36 + / - 7.85 pM. Similar binding results were obtained for cells transfected with ALPP. There was no binding to cells transfected with ALPL. Binding to cells transfected with ALPI has an apparent KD value of >3.3 μM. [Figure 9]Figure 9 shows FACS analysis of M25 IgG1 binding to live HEK293 cells transfected with an ALPPL2 expression plasmid along with a plasmid expressing green fluorescent protein (GFP). Cells were incubated with the antibody in PBS / 0.2% fetal bovine serum for 1 hour at room temperature, washed three times, and further incubated with ALEXAFLOU®-647-conjugated anti-human secondary antibody. GFP+ cells were gated and analyzed for mean fluorescence intensity (MFI). Normalized MFI was used for curve fitting using Prism (GraphPad) to obtain an apparent KD value of 506.1 + / - 55.95 pM. Similar binding results were obtained for cells transfected with ALPP. There was no binding to cells transfected with either ALPL or ALPI. DETAILED DESCRIPTION OF THE INVENTION

[0297] In various embodiments, antibodies are provided that bind to cell surface antigens that are overexpressed by tumor cells that have no or minimal expression on normal human tissues. The antibodies can be used alone in the treatment of cancer, or in various embodiments, uses of the antibodies include, but are not limited to, the following: 1) Use for payload delivery (e.g., drugs, siRNA, mRNA, cytokines, radionuclides) to tumor cells; 2) as components of bispecific or oligospecific antibodies that selectively activate the immune system at the site of the tumor; 3) Use in constructing chimeric antigen receptors (CAR-T) for cell-based therapy; 4) Use in constructing bispecific antibodies; and 5) Use as a diagnostic / staging tool for tumor detection / quantification and patient stratification and outcome analysis.

[0298] By screening a phage antibody display library on viable tumor cells and cancer specimens, the present inventors identified a novel anti-ALPPL2 antibody. ALPPL2 is specifically expressed by several types of incurable cancers but is not expressed in normal human tissues, except for placental trophoblasts. The exquisite tissue specificity of ALPPL2 should facilitate the preparation of highly specific targeted therapies and immunotherapies against cancers that overexpress this antigen. Such cancers include, but are not limited to, mesothelioma, testicular cancer, endometrial cancer, and subsets of pancreatic, ovarian, and non-small cell lung cancer. As shown in the Examples herein, the targetability of the antigen has been demonstrated in vitro and in vivo using antibody-drug conjugates (ADCs) with auristatin derivatives.

[0299] Thus, in various embodiments, provided are isolated anti-ALPP / ALPPL2 antibodies, as well as chimeric moieties comprising an anti-ALPP / ALPPL2 antibody linked to an effector. In certain embodiments, provided are antibody-drug conjugates (ADCs) comprising an anti-ALPP / ALPPL2 antibody linked to a cytotoxic / cytostatic agent, e.g., a drug with activity against both dividing and quiescent tumor cells, such as a DNA chelator.

[0300] Additionally, chimeric constructs are provided that expand beyond targeted chemotherapy into immunotherapy, for example, by incorporating the provision of bispecific antibodies comprising an anti-ALPP / ALPPL2 antibody conjugated to a moiety that is a checkpoint inhibitor (e.g., anti-CTLA4 (e.g., comprising the ipilimumab variable region), and / or an antibody directed against PD-L1 (e.g., comprising the nivolumab or pembrolizumab variable region), and / or an antibody directed against PD-L2). In certain embodiments, anti-ALPP / ALPPL2 antibodies are used in other platforms, including, but not limited to, platforms such as chimeric antigen receptor-engineered T cells (CAR-T) and immunocytokines.

[0301] Antibodies that bind to ALPP / ALPPL2 The antibodies have been found to specifically bind to ALPP and / or ALPPL2 in vitro and in situ, for example, when ALPPL2-expressing cancer cells are present in a tissue microenvironment. As noted above, such antibodies are useful for targeting cancer when used alone or when linked to an effector to form a "targeted effector."

[0302] Thus, in certain embodiments, isolated antibodies are provided that specifically bind to ALPP and / or ALPPL2 and specifically bind to cells that express or overexpress ALPPL / ALPPL2 (e.g., mesothelioma cells, testicular cancer cells, endometrial cancer cells, and certain pancreatic, ovarian, and non-small cell lung cancer cells).

[0303] M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M 25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFY Antibodies designated herein as GDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF (see, e.g., Table 1) are exemplary prototypic antibodies. In certain embodiments, antibodies comprising one or more VL CDR1 and / or VL CDR2, and / or VL CDR3, and / or VH CDR1 and / or VH CDR2, and / or VH CDR3 of these antibodies are contemplated. In certain embodiments, antibodies comprising one or more VH and / or VL domains of these antibodies are contemplated, as are antibodies that compete with one or more of M25AD, MD25ADX, and / or M25 for binding to ALPPL and / or ALPPL2, particularly when expressed and displayed on the cell surface.

[0304] M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AE LFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, The amino acid sequences of the VH and VL domains of the M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and M25wtLF antibodies are shown in Table 1.

[0305] [Table 1A]

[0306] [Table 1B]

[0307] [Table 1C]

[0308] [Table 1D]

[0309] [Table 1E]

[0310] [Table 1F]

[0311] M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M 25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGD Using the amino acid sequences provided for the wtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and M25wtLF antibodies, numerous antibody forms can be prepared, for example, as described below. Such forms include, but are not limited to, substantially intact (e.g., full-length) immunoglobulins (e.g., IgA, IgE, IgG, etc.), antibody fragments (e.g., Fv, Fab, (Fab')2, (Fab')3, IgGΔCH2, minibodies, etc.), single chain antibodies (e.g., scFv), diabodies, unibodies, affibodies, etc.

[0312] It will be appreciated that in certain embodiments, for example when the antibody is a single chain antibody, the VH and VL domains comprising such an antibody can be joined directly together or connected by a peptide linker. Exemplary peptide linkers include, but are not limited to, GGGGS GGGGS GGGGS (SEQ ID NO:41), GGGGS GGGGS (SEQ ID NO:42), GGGGS (SEQ ID NO:43), GS GGGGS GGGGS GGS GGGGS (SEQ ID NO:44), SGGGGS (SEQ ID NO:45), GGGS (SEQ ID NO:46), VPGV (SEQ ID NO:47), VPGVG (SEQ ID NO:48), GVPGVG (SEQ ID NO:49), GVG VP GVG (SEQ ID NO:50), VP GVG VP GVG (SEQ ID NO:51), GGSSRSS (SEQ ID NO:52), and GGSSRSSSSGGGGSGGGG (SEQ ID NO:53), etc.

[0313] As noted above, in various embodiments, the antibodies bind (e.g., specifically bind) ALPP and / or ALPPL2 (see, e.g., Figure 1 for ALPP and ALPPL2 sequences). Typically, antibodies contemplated herein include those of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC ... Specifically binds to cancer cells expressing ALPPL2 or a domain thereof bound by M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies. In certain embodiments, the antibody has a K of less than about 5 nM (as measured on live cells by FACS). D ) or with an affinity of less than about 4 nM, or less than about 3 nM, or less than about 2 nM D In certain embodiments, the antibody binds to cells expressing ALPPL2 with a K of less than about 50 pM as measured on live cells by FACS. D ) or with an affinity of less than about 40 pM, or less than about 30 pM D and binds to cells expressing ALPPL2.

[0314] Using the sequence information provided herein, antibodies comprising one or more CDRs, such as M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M25ADYHSRLF, M25GR ... Antibodies comprising 253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF, or the VH and / or VL domains of these antibodies, can be readily prepared using standard methods well known to those of skill in the art (e.g., chemical synthesis and / or recombinant expression), for example, as described below.

[0315] Additionally, other "related" anti-ALPP / ALPPL2 antibodies may be used to bind to the same epitope (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91R, M25ADD28G, M25ADLF1R, M25ADLF ... M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies), and / or M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, The M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies can be modified to generate a library of modified antibodies, which can then be identified by rescreening the antibodies in the library for improved binding to cells expressing or overexpressing ALPP and / or ALPPL2 or a domain thereof.

[0316] Identification of other antibodies that bind to the same ALPP and / or ALPPL2 epitopes as M25AD, MD25ADX and / or M25 Useful antibody target(s) include ALPP and / or ALPP2, and useful prototypic antibodies include M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYG Upon identification of DwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies, other "related" antibodies that bind ALPP and / or ALPPL2 may be identified, e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYI A, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93 H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M2 epitopes bound by 5ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF, including M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H,M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M For antibodies that cross-react with one or more of M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF, and / or for binding to mesothelioma cells (e.g., M28 cell line), M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AE M25AF, M25AF, M25AFEG, M25AFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

[0317] Monoclonal antibodies Binds to ALPP and / or ALPPL2, preferably M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGD Monoclonal antibodies that bind to epitopes bound by one or more of wtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF can be generated using a variety of known techniques, such as standard somatic cell hybridization techniques as reported by Kohler and Milstein (1975) Nature 256: 495, viral or oncogenic transformation of B lymphocytes, or phage display techniques using libraries of human antibody genes. In certain embodiments, the antibodies are fully human monoclonal antibodies.

[0318] Thus, in one embodiment, a hybridoma method is used to generate antibodies that bind to ALPP and / or ALPPL2. In this method, mice or other suitable host animals can be immunized with an appropriate antigen to elicit lymphocytes that produce or are capable of producing antibodies that specifically bind to the antigen used for immunization. Alternatively, lymphocytes can be immunized in vitro. The lymphocytes can then be fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form hybridoma cells (Goding (1986) Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press)). The culture medium in which the hybridoma cells are growing is analyzed for the production of monoclonal antibodies directed against the antigen. After identifying hybridoma cells that produce antibodies with the desired specificity, affinity, and / or activity, the clones can be subcloned by limiting dilution procedures and grown by standard methods (ibid.). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal. The monoclonal antibodies secreted by the subclones can be separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[0319] In another embodiment, antibodies and antibody portions that bind to ALPP and / or ALPPL2 are described, for example, in McCafferty et al. (1990) Nature 348:552-554, Clackson et al. (1991) Nature 352:624-628, Marks et al. (1991) J. Mol. Biol. 222:581-597; Hoet et al. (2005) Nature Biotechnol. 23:344-348; U.S. Patent Nos. 5,223,409; 5,403,484; and 5,571,698 to Ladner et al.; U.S. Patent Nos. 5,427,908 and 5,580,717 to Dower et al.; U.S. Patent Nos. 5,969,108 and 6,172,197 to McCafferty et al.; Antibody phage libraries can be isolated from antibodies generated using the techniques described in U.S. Patent Nos. 5,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915, and 6,593,081 by Griffiths et al. In addition, chain shuffling (Marks et al., (1992) Bio / Technology, 10:779-783) and combinatorial infection and in vivo recombination (Waterhouse et al., (1993) Nucl. Acids. Res., 21:2265-2266) as strategies for constructing very large phage libraries can also be used to generate high-affinity (nM range) humanized antibodies.

[0320] In certain embodiments, the antibodies bind to ALPP and / or ALPPL2, preferably M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGD Monoclonal antibodies, or antigen-binding portions thereof, that bind to the epitope bound by one or more of wtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF are generated using the phage display technology described by Hoet et al., supra. This technology involves generating human Fab libraries containing unique combinations of immunoglobulin sequences isolated from human donors and containing synthetic diversity in the heavy chain CDRs. The library then contains the following antibodies that bind to ALPP and / or ALPPL2, preferably M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GR The antibody is screened for Fabs that compete for binding with one or more of ITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

[0321] In yet another embodiment, the agonist is directed against ALPP and / or ALPPL2, preferably M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M25 Human monoclonal antibodies comprising an epitope bound by one or more of 53018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF can be generated using transgenic or transchromosomic mice carrying parts of the human immune system rather than the mouse immune system (see, e.g., Lonberg et al.). (1994) Nature 368(6474): 856-859; Lonberg and Huszar, (1995) Intern. Rev. Immunol. 13: 65-93, Harding and Lonberg (1995) Ann. NY. Acad. Sci. 764: 536-546, all from Lonberg and Nos. 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,789,650; 5,877,397; 5,661,016; 5,814,318; 5,874,299; and 5,770,429 to Kay; U.S. Pat. No. 5,545,807 to Surani et al.; PCT Publication Nos. WO 92 / 03918, WO 93 / 12227, WO 94 / 25585, WO 97 / 13852, WO 98 / 24884, and WO 99 / 45962, all to Lonberg and Kay; PCT Publication No. WO 01 / 14424 to Korman et al.).

[0322] In another embodiment, the compound is directed against ALPP and / or ALPPL2, preferably M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, AL Human antibodies that bind to an epitope bound by one or more of PPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF can be raised using mice carrying human immunoglobulin sequences on a transgene and transchromosome, such as mice carrying a human heavy chain transgene and a human light chain transchromosome (see, e.g., PCT Publication WO 02 / 43478 by Ishida et al.).

[0323] Alternative transgenic animal systems expressing human immunoglobulin genes are available in the art and can be used to raise anti-ALPP / ALPPL2 antibodies of the invention. For example, an alternative transgenic system called Xenomouse (Abgenix, Inc.) can be used; such mice are described, for example, in U.S. Patent Nos. 5,939,598; 6,075,181; 6,114,598; 6,150,584; and 6,162,963 by Kucherlapati et al.

[0324] Alternative transchromosomal animal systems expressing human immunoglobulin genes are available in the art and can be used to raise anti-ALPP / ALPPL2 antibodies as contemplated herein. For example, mice carrying both a human heavy chain transchromosome and a human light chain transchromosome can be used as described in Tomizuka et al. (2000) Proc. Natl. Acad. Sci. USA 97:722-727. Additionally, cattle carrying human heavy and light chain transchromosomes have been described in the art (e.g., Kuroiwa et al. (2002) Nature Biotechnology 20:889-894) and can be used to raise anti-ALPP / ALPPL2 antibodies.

[0325] In yet another embodiment, the compound specifically binds to ALPP and / or ALPPL2, preferably M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwt Antibodies that bind to epitopes bound by one or more of LC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF can be prepared using transgenic plants and / or cultured plant cells (e.g., tobacco, corn, and duckweed) that produce such antibodies. For example, transgenic tobacco leaves expressing an antibody or an antigen-binding portion thereof can be used to produce such antibodies, for example, by using an inducible promoter (see, e.g., Cramer et al. (1999) Curr. Top. Microbol. Immunol. 240:95-118). Transgenic corn can also be used to express such antibodies and antigen-binding portions thereof (see, e.g., Hood et al. (1999) Adv. Exp. Med. Biol. 464:127-147). Antibodies can also be produced in large quantities from transgenic plant seeds containing antibody portions, such as single-chain antibodies (scFvs), using, for example, tobacco seeds and potato tubers (see, e.g., Conrad et al. (1998) Plant Mol. Biol. 38:101-109).Methods for producing antibodies or antigen-binding portions in plants can also be found, for example, in Fischer et al. (1999) Biotechnol. ALPP. Biochem. 30:99-108, Ma et al. (1995) Trends Biotechnol. 13:522-527, Ma et al. (1995) Plant Physiol. 109:341-346; Whitelam et al. (1994) Biochem. Soc. Trans. 22:940-944, U.S. Pat. No. 6,040,498, and U.S. Pat. No. 6,815,184.

[0326] M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwt which bind to ALPP and / or ALPPL2 and which may preferably be prepared using any technique, including those disclosed herein. The binding specificity of monoclonal antibodies or portions thereof that bind to the epitope bound by one or more of LC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF can be determined by immunoprecipitation or by in vitro binding assays such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). The binding affinity of monoclonal antibodies or portions thereof can be determined by the Scatchard analysis of Munson et al. (1980) Anal. Biochem., 107:220.

[0327] Cross-reactivity with M25AD, MD25ADX, M25, ALPPL2rd3 1, ALPPL2rd3 2, M25AG, M25AS, M25AV, and / or M25AL In another approach, the antibody that binds to ALPP and / or ALPPL2 is a "prototypical" antibody described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25 Such antibodies may be identified by the fact that they bind to the same epitope as ALPP / ALPP2 (e.g., M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF). Identifying such antibodies does not require isolation of the epitope of interest. In certain embodiments, for example, antibody libraries can be screened for antibodies that compete with the original antibodies of the invention for binding by and / or to ALPP / ALPPL2-expressing cells (e.g., mesothelioma cells such as M28).

[0328] Methods for screening libraries for epitope binding and / or cell binding and / or internalization are well known to those of skill in the art. In certain embodiments, the cross-reactive ALPP and / or ALPPL2 antibodies are selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25AD ... M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies, with at least 60%, preferably 80%, more preferably 90%, and most preferably at least 95% or at least 99% cross-reactivity.

[0329] Phage display methods for selecting other "related" anti-ALPP / ALPPL2 antibodies M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25A DL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M Using the known sequences for antibodies 253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF, various phage display (or yeast display) methods can be used to generate antibodies specific for ALPP / ALPPL2. M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDw The antibodies may be used to generate other antibodies that bind to the epitope bound by tLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

[0330] Chain Shuffling Method One approach to generating antibody variants is to use the original V to generate new partners (chain shuffling) in phage display or yeast display libraries (Clackson et al. (1991) Nature. 352:624-628). H or V L The goal was to replace the gene into a V gene repertoire. Using chain shuffling and phage display, the affinity of a human scFv antibody fragment for binding to the hapten phenyloxazolone (phOx) was increased from 300 nM to 1 nM (300-fold) (Marks et al. (1992) Bio / Technology 10:779-783).

[0331] Thus, for example, to alter the affinity of the anti-ALPP / ALPPL2 antibodies described herein, mutant scFv gene repertoires can be constructed using mutant scFvs such as the original M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS 91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies and human V L V of gene repertoire (light chain shuffling) H The scFv gene repertoire can be cloned into a phage display vector, such as pHEN-1 (Hoogenboom et al., (1991) Nucleic Acids Res., 19:4133-4137), or other vectors, and after transformation, a library of transformants is obtained.

[0332] Similarly, for heavy chain shuffling, the mutant scFv gene repertoire consisted of the original M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADY94H, M25ADY95G ... 5ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies and human V H V of gene repertoire (heavy chain shuffling) L The scFv gene repertoire can be cloned into a phage display vector, such as pHEN-1 (Hoogenboom et al., (1991) Nucleic Acids Res., 19:4133-4137), or other vectors, and after transformation, a library of transformants is obtained.

[0333] The resulting libraries can be directed against relevant targets (e.g., ALPP / ALPPL2, cells expressing ALPP / ALPPL2), and / or against M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY 93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

[0334] Site-directed mutagenesis to improve binding affinity Many antigen contacting amino acid side chains are typically located in the complementarity determining regions (CDRs) and V H Three (CDR1, CDR2, and CDR3) and V LThese residues are located in three of the CDRs (CDR1, CDR2, and CDR3) (Chothia et al., (1987) J. Mol. Biol., 196:901-917; Chothia et al., (1986) Science, 233:755-8; Nhan et al., (1991) J. Mol. Biol., 217:133-151). These residues contribute a large amount of the binding energy that accounts for antibody affinity for the antigen. In other molecules, mutation of amino acids that contact the ligand has been shown to be an effective means of increasing the affinity of a protein molecule for its binding partner (Lowman et al., (1993) J. Mol. Biol., 234:564-578; Wells (1990) Biochemistry, 29:8509-8516). For example, as described herein, site-directed mutagenesis of the CDRs and screening against cells / cell lines expressing ALPP / ALPPL2 can generate antibodies with improved binding affinity.

[0335] CDR randomization to generate higher affinity human scFv In an extension of simple site-directed mutagenesis, mutant antibody libraries can be created in which partial or entire CDRs are randomized (V L CDR1, CDR2 and / or CDR3 and / or V HIn one embodiment, each CDR is selected from the group consisting of CDR1, CDR2, and / or CDR3 of a known antibody (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25G The CDR sequences of the highest affinity mutants from each CDR library are combined to obtain an additive increase in affinity. A similar method is used to randomize 3.4 x 10 CDRs. -10 to 9.0 x 10 -13 It has been used to increase the affinity of human growth hormone (hGH) for the growth hormone receptor by more than 1500-fold to M (Lowman et al., (1993) J. Mol. Biol., 234:564-578).

[0336] V H CDR3 often occupies the center of the binding pocket, and therefore mutations in this region may result in increased affinity (Clackson et al. (1995) Science 267:383-386). In one embodiment, V HThe CDR3 residues are randomized (see, e.g., Schier et al. (1996) Gene 169:147-155; Schier and Marks (1996) Human Antibodies and Hybridomas. 7:97-105, 1996; Schier et al. (1996) J. Mol. Biol. 263:551-567).

[0337] Other antibody modifications In one embodiment, M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSIT Partial antibody sequences derived from the SGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies can be used to generate structurally and functionally related antibodies. For example, antibodies interact with target antigens predominantly through amino acid residues located in the six heavy and light chain complementarity-determining regions (CDRs). For this reason, the amino acid sequences within the CDRs are more diverse between individual antibodies than sequences outside the CDRs. Because CDR sequences are responsible for most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties of a particular naturally occurring antibody by constructing an expression vector containing CDR sequences from that particular naturally occurring antibody grafted onto framework sequences from a different antibody with different properties (see, e.g., Riechmann et al. (1998) Nature 332:323-327; Jones et al. (1986) Nature 321:522-525; Queen et al. (1989) Proc. Natl. Acad. Sci. USA 86:10029-10033). Such framework sequences can be obtained from public DNA databases containing germline antibody gene sequences.

[0338] Thus, one or more structural features of an anti-ALPP / ALPPL2 antibody, such as a CDR, may be selected from the group consisting of, for example, M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITS These antibodies may be used to generate structurally related anti-ALPP / ALPPL2 antibodies that retain at least one functional property of the GFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies, e.g., binding to ALPPL2-expressing tumor cells.

[0339] In certain embodiments, one or more of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25G The CDR regions (e.g., VH CDR1, and / or CDR2, and / or CDR3, and / or VL CDR1, and / or CDR2, and / or CDR3) of RITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF are recombinantly combined with known human framework regions and CDRs to generate additional recombinantly engineered anti-ALPP / ALPPL2 antibodies. The variable framework regions of the heavy and light chains can be derived from the same or different antibody sequences.

[0340] It is well known in the art that the CDR3 domains of the heavy and light chains of an antibody play a particularly important role in the binding specificity / affinity of an antibody for an antigen (see, for example, Hall et al., (1992) J. Immunol., 149:1605-1612; Polymenis et al., (1994) J. Immunol., 152:5318-5329; Jahn et al., (1995) Immunobiol., 193:400-419; Klimka et al., (2000) Brit. J. Cancer, 83:252-260; Beiboer et al., (2000) J. Mol. Biol, 296:833-849; Rader et al., (1998) Proc. Natl. Acad. Sci. USA, 95: (See, e.g., pp. 8910-8915; Barbas et al. (1994) J. Am. Chem. Soc., vol. 116: pp. 2161-2162; Ditzel et al. (1996) J. Immunol., vol. 157: pp. 739-749). Thus, in certain embodiments, certain antibodies described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF,

[0039] Antibodies may be generated that contain the heavy and / or light chain CDR3s of any of the following antibodies: M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.Thus, in certain embodiments, certain antibodies described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF,

[0039] Antibodies may be generated that contain the heavy and / or light chain CDR1s of any of the following antibodies: M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF. Further, the antibody may be any of the antibodies of the present invention (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITS The CDRs may comprise other heavy chain and / or light chain CDRs of any of the following: M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF).

[0341] In certain embodiments, the CDR1, 2, and / or 3 regions of the engineered antibodies described above are those disclosed herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25 The antibody may comprise the exact amino acid sequence(s) of ALPPL2 (e.g., ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF). However, one of skill in the art will recognize that some deviations from the exact CDR sequences are possible while still retaining the ability of the antibody to effectively bind ALPP and / or ALPPL2 (e.g., conservative amino acid substitutions). Thus, in another embodiment, the engineered antibody is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSIT It may be composed of one or more CDRs that are, for example, 90%, 95%, 98%, 99%, or 99.5% identical to one or more of the CDRs of the SGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF antibodies.

[0342] In another embodiment, one or more residues of the CDRs can be altered to modify binding to achieve a more favorable on-rate binding. Using this strategy, e.g., 10 M -1 Antibodies with extremely high binding affinities, or higher, can be achieved. Affinity maturation techniques, well known in the art and described herein, can be used to alter the CDR region(s) and then screen the resulting binding molecules for the desired changes in binding. Thus, as the CDR(s) are altered, changes in binding affinity and immunogenicity can be monitored and scored to achieve an antibody optimized for best combinatorial binding and low immunogenicity.

[0343] In addition to or instead of modifications within the CDRs, modifications can also be made in one or more of the framework regions FR1, FR2, FR3, and FR4 of the antibody heavy and / or light chain variable regions, so long as these modifications do not eliminate the binding affinity of the antibody.

[0344] In another embodiment, the antibody is further modified with respect to effector function, e.g., to enhance the efficacy of the antibody in treating cancer. For example, cysteine ​​residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC) (see, e.g., Caron et al. (1992) J. Exp Med. 176:1191-1195; Shopes (1992) J. Immunol. 148:2918-2922). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional crosslinkers (see, e.g., Wolff et al. (1993) Cancer Res. 53:2560-2565). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities (see, e.g., Stevenson et al. (1989) Anti-Cancer Drug Design 3:219-230).

[0345] In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. In certain embodiments, the antibodies can comprise residues not found in the human or non-human frameworks, but included to further refine and optimize antibody performance. In certain embodiments, the antibodies can have a modified Fc region as described in PCT Publication WO 99 / 58572.

[0346] Antibody generation In various embodiments, the antibodies described herein can be produced by chemical synthesis or can be recombinantly expressed.

[0347] chemical synthesis Using the sequence information provided herein, the anti-ALPPL2 specific antibodies described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF ...

[00130] A single-chain antibody (e.g., 5GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF), or variants thereof, can be chemically synthesized using well-known methods of peptide synthesis. Solid-phase synthesis, in which the C-terminal amino acid of the sequence is attached to an insoluble support, followed by sequential addition of the remaining amino acids in the sequence, is one preferred method for chemically synthesizing single-chain antibodies. Techniques for solid phase synthesis are described in Barany and Merrifield, Solid Phase Peptide Synthesis; pp. 3-284 in The Peptides: Analysis, Synthesis, Biology. Vol. 2: Special Methods in Peptide Synthesis, Part A., Merrifield et al. (1963) J. Am. Chem. Soc., Vol. 85: pp. 2149-2156, Stewart et al. (1984) Solid Phase Peptide Synthesis, 2nd ed. Pierce Chem. Co., Rockford, Ill.

[0348] Recombinant expression of anti-ALPPL2 / ALPPL antibodies In certain embodiments, the anti-ALPPL2 / ALPPL specific antibodies described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF), or variants thereof, are recombinantly expressed using methods well known to those of skill in the art. For example, M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSIT ... Using the sequence information of SGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF, nucleic acids encoding the desired antibodies can be prepared according to any number of standard methods known to those of skill in the art. The nucleic acids are then transfected into host cells that express the desired antibody or chain.

[0349] Molecular cloning techniques to achieve these goals are known in the art. A wide variety of cloning and in vitro amplification methods are suitable for constructing recombinant nucleic acids. Examples of these techniques and instructions sufficient to direct one of skill through numerous cloning activities can be found in Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol. 152, Academic Press, Inc., San Diego, CA (Berger); Sambrook et al., (1989) Molecular Cloning—A Laboratory Manual (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY (Sambrook); and Current Protocols in Molecular Biology, F.M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1994 Supplement) (Ausubel). Methods for producing recombinant immunoglobulins are also known in the art. See Cabilly, U.S. Patent No. 4,816,567; Queen et al. (1989) Proc. Natl. Acad. Sci. USA 86: 10029-10033. Furthermore, detailed protocols for expressing antibodies are also provided in Liu et al. (2004) Cancer Res. 64: 704-710, Poul et al. (2000) J. Mol. Biol. 301: 1149-1161, etc.

[0350] Generation of other antibody forms The known and / or identified sequences of the single chain antibodies provided herein (e.g., V H and / or V LThe sequences can be used to readily generate other antibody formats, including but not limited to multivalent antibodies, whole antibodies, scFv, (scFv')2, Fab, (Fab')2, chimeric antibodies, etc.

[0351] Preparation of homodimers For example, to create an (scFv')2 antibody, two anti-ALPP / ALPPL2 antibodies are connected via a linker (e.g., a carbon linker, a peptide, etc.) or, for example, via a disulfide bond between two cysteines. Thus, for example, to create a disulfide-linked scFv, a cysteine ​​residue can be introduced by site-directed mutagenesis at the carboxy terminus of an antibody described herein.

[0352] The scFv can be expressed from this construct, purified by IMAC, and analyzed by gel filtration. To generate the (scFv')2 dimer, the cysteines are reduced by incubation with 1 mM 3-mercaptoethanol, and half of the scFv is blocked by the addition of DTNB. The blocked and unblocked scFvs are incubated together to form (scFv')2, and the resulting material can be analyzed by gel filtration. The affinity of the resulting dimer can be determined using standard methods, for example, by BIAcore.

[0353] In one exemplary embodiment, (scFv')2 dimers are created by connecting scFv' fragments via a linker, e.g., a peptide linker. This can be achieved by a variety of means well known to those of skill in the art. For example, one approach is described in Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448 (see also WO 94 / 13804).

[0354] V as provided herein H and / or V LNote that by using the sequence, Fab and (Fab')2 dimers can also be easily prepared. Fab is a dimer that is connected by a disulfide bond to V H -C H F(ab)'2 is a light chain connected to an Fab, and can be readily produced using standard methods known to those of skill in the art. F(ab)'2 can be generated, for example, by dimerizing Fab, as described above for (scFv')2 dimers.

[0355] Chimeric antibodies Antibodies contemplated herein also include "chimeric" antibodies in which a portion of the heavy and / or light chain is identical to or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical to or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, and fragments of such antibodies, so long as they exhibit the desired biological activity (see, e.g., U.S. Pat. No. 4,816,567; Morrison et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855, etc.).

[0356] The original antibodies provided herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYG While antibodies such as M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF are fully human, chimeric antibodies are contemplated, particularly when such antibodies are to be used in species other than human (e.g., in veterinary applications). Chimeric antibodies are antibodies that contain portions from two different species (e.g., human and non-human portions). Typically, the antigen-combining region (or variable region) of a chimeric antibody is derived from one species source, and the constant region of the chimeric antibody (which confers biological effector function to the immunoglobulin) is derived from another source. Many methods of producing chimeric antibodies are known to those of skill in the art (see, e.g., U.S. Patent Nos. 5,502,167, 5,500,362, 5,491,088, 5,482,856, 5,472,693, 5,354,847, 5,292,867, 5,231,026, 5,204,244, 5,202,238, 5,169,939, 5,081,235, 5,075,431, 4,975,369, and PCT Publication WO 91 / 0996).

[0357] In general, the procedure used to generate chimeric antibodies consists of the following steps (although the order of some steps may be reversed): (a) identifying and cloning the correct gene segment encoding the antigen-binding portion of an antibody molecule; (b) cloning this gene segment (VDJ, variable, diversity, and joining region for the heavy chain, or VJ, variable, joining region, or simply V or variable region, or V) for the light chain. H and V L (b) cloning gene segments encoding the human constant region or desired portions thereof; (c) ligating the variable region to the constant region such that the complete chimeric antibody is encoded in a transcribable and translatable form; (d) ligating this construct into a vector containing selectable markers and gene regulatory regions, such as a promoter, enhancer, and poly(A) addition signal; (e) amplifying this construct in a host cell (e.g., a bacterium); (f) introducing the DNA into a eukaryotic cell, most often a mammalian lymphocyte (transfection); and culturing the host cell under conditions suitable for expression of the chimeric antibody.

[0358] Antibodies with a variety of distinct antigen-binding specificities have been addressed using these protocols to generate chimeric proteins (e.g., anti-TNP; Boulianne et al., (1984) Nature, 312:643) and anti-tumor antigens (see, e.g., Sahagan et al., (1986) J. Immunol., 137:1066). Similarly, several different effector functions have been achieved by linking new sequences to sequences encoding antigen-binding regions. Some of these include enzymes (Neuberger et al., (1984) Nature, 312:604), immunoglobulin constant regions from other species, and constant regions of other immunoglobulin chains (Sharon et al., (1984) Nature, 309:364; Tan et al., (1985) J. Immunol., 135:3565-3567).

[0359] In certain embodiments, the recombinant DNA vector is an anti-ALPP / ALPPL2 (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF) are used to transfect antibody-producing cell lines. The novel recombinant DNA vectors contain a "replacement gene" to replace all or part of a gene encoding an immunoglobulin constant region in a cell line (e.g., the replacement gene may encode all or part of the constant region of a human immunoglobulin, a specific immunoglobulin class, or an enzyme, toxin, biologically active peptide, growth factor, inhibitor, or linker peptide to facilitate conjugation to a drug, toxin, or other molecule, etc.), and a "targeting sequence" homologous to the immunoglobulin sequence in the cell that produces the antibody, allowing for targeted recombination.

[0360] In another embodiment, the recombinant DNA vector is used to transfect a cell line that produces an antibody with a desired effector function (e.g., a human immunoglobulin constant region), where the replacement gene contained in the recombinant vector can encode all or part of a region of an ALPPL2 / ALPP-specific antibody, and the targeting sequence contained in the recombinant vector allows for homologous recombination and targeted gene modification in the antibody-producing cells. In either embodiment, if only a portion of the variable or constant region is replaced, the resulting chimeric antibody can define the same antigen and / or have the same, albeit altered or improved, effector function, whereby the chimeric antibody may demonstrate greater antigen specificity, a greater affinity binding constant, increased effector function, or increased secretion and production by the cell line producing the transfected antibody, etc.

[0361] Regardless of the embodiment implemented, the process of selecting for integrated DNA (via a selectable marker), screening for chimeric antibody production, and cloning of the cells can be used to obtain clones of cells that produce chimeric antibodies.

[0362] Thus, a piece of DNA encoding a modification for a monoclonal antibody can be targeted directly to the site of an immunoglobulin gene expressed in a B cell or hybridoma cell line. DNA constructs for any specific modification can be made to alter the protein production of any monoclonal cell line or hybridoma. Expression levels of chimeric antibodies should be higher if the gene is in its natural chromosomal location rather than a random location. Detailed methods for preparing chimeric (humanized) antibodies can be found in U.S. Patent No. 5,482,856.

[0363] Intact human antibodies In another embodiment, the present invention provides intact, fully human anti-ALPP / ALPPL2 antibodies. Such antibodies can be readily generated in a manner similar to the production of chimeric, humanized antibodies. In this example, the VH and VL domains described herein are fully human and can be readily engineered into substantially complete antibodies (e.g., IgG, IgA, IgM, etc.).

[0364] For example, methods for converting scFvs to fully human substantially full-length immunoglobulins have been reported, inter alia, by Braren et al. (2007) Clin. Chem., 53(5):837-844. In one approach reported by Braren et al. (ibid.), human immunoglobulin constant regions are synthesized from cDNA derived from human peripheral blood mononuclear cells using standard reaction conditions. The genes for the human IgG1 and IgG4 heavy chain constant regions (IGHG1 and IGHG4) were amplified using PCR primers containing AscI and KpnI sites (γ1: GAT CGG TAC CGA TCG GCG CGC CCA AAT CTT GTG ACA AAA CT CAC (SEQ ID NO: 54); γ4: GAT CGG CGC GCC TTC CAC CAA GGG CCC ATC CGT CTT CCC CCT SEQ ID NO: 55)) and SfiI sites (γ1: GAT CGG CCC AGC CGG CCT CAT TTA CCC GGA GAC AGG GAG AGG CTC TTC (SEQ ID NO: 56); γ4: GAT CGG CCC AGC CGG CCT CAT TTA CCC AGA GAC AGG GA (SEQ ID NO: 57)). H 2-3 and γ4 C HThe 2-3 domain is amplified using primers containing AscI and KpnI sites (γ1: GAT CTC TAG ATC ATT TAC CCG GAG ACA GGG AGA GGC TCT TC (SEQ ID NO: 58), γ1: GAT CGG CGC GCC CAG CAA CAC CAA GGT GGA CA (SEQ ID NO: 59)) and XbaI sites (γ1: GAT CGG CGC GCC AGC CTC CAC CAA GGG CCC AT (SEQ ID NO: 60), γ1: GAT CTC TAG ATC ATT TAC CCA GAG ACA GGG Aγ).

[0365] For amplification of the gene for human IgE heavy chain constant region (IGHE), primers containing an AscI site (GAT CGG CGC GCC CAT CCG TCT TCC CCT TGA (SEQ ID NO: 61)), an SfiI site, and a 4x his tag (GAT CGG CCC AGC CGG CCT CAT TTA CCG GGA TTT ACA GAC AC (SEQ ID NO: 62)) can be used, and εC HFor the 2-4 domain, primers containing an AscI site (GAT CGG CGC GCC CAC CGT GAA GAT CTT AC (SEQ ID NO: 63)), an XbaI site, and a 4xhis tag (GAT CTC TAG ATC AAT GGT GGT GAT GTT TAC CGG GAT TTA CAG ACA CCG (SEQ ID NO: 64)) can be used. The signal sequence of the gene for rat kappa light chain is synthesized by PCR primers containing an NheI site (GTA CGC TAG CAA GAT GGA ATC ACA GAC CCA GGT CCT CAT GTC CCT GCT GCT CTG GAT TTC (SEQ ID NO: 65)) and a KpnI site (CAT GTC CCT GCT GCT CTG GAT TTC TGG TAC CTG TGG GGT GAG TCC TTA CAA CGC GTG TAC (SEQ ID NO: 66)). After introducing the leader sequence into a mammalian expression vector, such as pcDNA3.1-zeo (Invitrogen Life Technologies), individual Ig domains, Fc domains, and the entire heavy chains γ1, γ4, and ε can be inserted via the XbaI and AscI sites. H 2-3 or scFv-C H Transfer into the 2-4 format can be achieved by PCR introduction of an N-terminal BsiWI site and a C-terminal AscI site. The DNA can then be ligated into a vector containing a signal sequence and specific constant regions.

[0366] For expression of heterotetrameric IgG and IgE formats, the mammalian expression vector pBudCE4.1 (Invitrogen Life Technologies) can be used. The human light chain constant domain (IGKC) can be amplified using one PCR primer containing an XbaI site and another primer containing an SgfI site (GAT CTC TAG ACT AAC ACT CTC CCC TGT TGA AGC (SEQ ID NO: 67) and GAT CGC GAT CGC ACG AAC TGT GGC TGC ACC ATC TGT C (SEQ ID NO: 68)). Two human signal sequences, VH3-64 and VκI, can be synthesized by PCR using primers (AGA ATG CGG CCG CTA TGG AAT TGG GGC TGA GCT GGG TTT TCC TTG TTG C TAT ATT TAAA TGT GTC CAG TGT (SEQ ID NO: 69) and GAT CGT CGA CAT GGA CAT GAG GGT CCC CGC TCA GCT CCT GGG GCT CCT GCT ACT CTG CCT GCA GGG TGC CAG ATG T (SEQ ID NO: 70)) with NotI and internal SwaI or SalI sites, and an internal SbfI site for insertion of the variable region. After assembly of the leader sequence and constant region, the variable region can then be introduced via the SgfI and SbfI sites, or the AscI and SwaI sites, respectively. Finally, the entire light chain sequence including the leader sequence can be introduced into an expression vector, such as pBudCE4.1, via the XbaI and SalI sites, and the entire heavy chain sequence including the leader sequence can be introduced via the NotI and SfiI sites.

[0367] These approaches are illustrative and not limiting. Numerous other methods for converting scFv and other antibody fragments into full-length immunoglobulins are known to those of skill in the art.

[0368] Diabody In certain embodiments, the V H and V LDiabodies containing one or more of the V domains are contemplated. The term "diabody" typically refers to an antibody fragment having two antigen-binding sites. The fragments typically comprise fragments of the same polypeptide chain (V H -V L ) in the light chain variable domain (V L ) linked to a heavy chain variable domain (V H ). The use of a linker that is too short to allow pairing between the two domains on the same chain forces the domains to pair with complementary domains on another chain and create two antigen-binding sites. Diabodies are described in more detail in, for example, EP 404,097; WO 93 / 11161; and Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448.

[0369] unibody In certain embodiments, anti-ALPP / ALPPL2 antibodies can be constructed as unibodies using the sequence information provided herein. Unibodies are an antibody technology that generates stable, smaller antibody formats that are predicted to have a longer therapeutic window than certain small antibody formats. In certain embodiments, unibodies are generated from IgG4 antibodies by eliminating the antibody hinge region. Unlike full-sized IgG4 antibodies, half-molecule fragments are highly stable and are referred to as unibodies. By halving the IgG4 molecule, only one region on the unibody remains that can bind to the target. Methods for generating unibodies are described in detail in PCT Publication No. WO 2007 / 059782, which is incorporated herein by reference in its entirety (see also, e.g., Kolfschoten et al. (2007) Science 317:1554-1557).

[0370] Affibody In certain embodiments, the sequence information provided herein is used to construct affibody molecules that bind to ALPP / ALPPL2. Affibody molecules are a class of affinity proteins based on a 58-amino acid residue protein domain derived from one of the IgG-binding domains of Staphylococcus aureus protein A. This three-helix bundle domain is used as a scaffold for the construction of combinatorial phagemid libraries, from which affibody variants targeting desired molecules can be selected using phage display technology (see, e.g., Nord et al. (1997) Nat. Biotechnol. 15:772-777; Ronmark et al. (2002) Eur. J. Biochem. 269:2647-2655). Details of affibodies and methods for their production are known to those skilled in the art (see, e.g., U.S. Pat. No. 5,831,012, incorporated herein by reference in its entirety).

[0371] It will be appreciated that the above-described antibodies can be provided as whole, intact antibodies (e.g., IgG), antibody fragments, or single-chain antibodies using methods well known to those skilled in the art. In addition, although antibodies can be derived from essentially any mammalian species to reduce immunogenicity, it is desirable to use antibodies derived from the species in which the antibody and / or immunoconjugate will be used. In other words, for use in humans, it is desirable to use human antibodies, humanized antibodies, or chimeric human antibodies.

[0372] Measurement of antibody / polypeptide binding affinity As explained above, selection for increased binding activity can be achieved by selecting antibodies for a target antigen (e.g., ALPPL2, particularly M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRL ... The affinity of the antibody to the target protein (epitope bound by one or more of M25A, M25A, M25A, M25A, M25A, M25B ... d is determined from the kinetics of binding to target cells in, for example, BIAcore, a surface plasmon resonance-based biosensor. For this technique, antigens or cells (e.g., cells expressing ALPPL2) are tethered to a derivatized sensor chip that can detect mass changes. As antibodies pass over the sensor chip, they bind to the antigen resulting in a quantifiable increase in mass. Measurement of the binding rate as a function of antibody concentration can be used to determine the binding rate constant (k on After the binding phase, a buffer solution is passed over the chip, and the rate of dissociation of the antibody (K off ) is determined. on is typically 1.0×10 2 to 5.0 x 10 6 In the range of K off is 1.0 x 10 -1 to 1.0×10 -6 The equilibrium constant K d frequently, K off / k on Therefore, typically, 10 -5 From 10-12 The affinities measured in this manner correlate well with those measured in solution by fluorescence quenching titration.

[0373] Immunoconjugates containing antibodies that specifically bind to ALPP / ALPPL2 The prototypical anti-ALPP / ALPPL2 antibodies described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFY GDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF) specifically bind to ALPPL2-expressing cancer cells (e.g., cells of cancers such as, but not limited to, mesothelioma, testicular cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer). The antibodies can be used alone as a therapy (e.g., to inhibit the growth and / or proliferation of cancer cells expressing ALPPL2) or can be conjugated to effector-forming immunoconjugates that provide for the effective and specific delivery of effectors (e.g., cytotoxins, labels, radionuclides, ligands, antibodies, drugs, liposomes, nanoparticles, viral particles, cytokines, immunomodulatory molecules, etc.) to various cancer cells expressing ALPPL2 (e.g., isolated cells, cancer stem cells, metastatic cells, solid tumor cells, etc.).

[0374] Anti-ALPP / ALPPL2 immunoconjugates can be formed by conjugating an antibody described herein, or an antigen-binding portion thereof, to an effector (e.g., a detectable label, another therapeutic agent, etc.). Exemplary therapeutic agents include, but are not limited to, a cytotoxic or cytostatic agent (e.g., a chemotherapeutic agent), a toxin (e.g., a bacterial, fungal, plant, or animal organ enzymatically active toxin, or fragment thereof), and / or a radioisotope (i.e., a radioconjugate), a second antibody.

[0375] Exemplary Effectors Detectable Label-Imaging Composition In certain embodiments, anti-ALPP / ALPPL2 immunoconjugates can be used to direct a detectable label to tumor sites, thereby facilitating tumor detection and / or localization. They can be effective for detecting primary tumors or, in certain embodiments, secondary tumors produced by ALPPL2-expressing cancers (e.g., cells of cancers such as, but not limited to, mesothelioma, testicular cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and non-small cell lung cancer).

[0376] Thus, in certain embodiments, the effector comprises a detectable label. Suitable detectable labels include, but are not limited to, radiopaque labels, nanoparticles, PET labels, MRI labels, radiolabels, etc. Among the radionuclides and useful in various embodiments of the present invention, gamma emitters, positron emitters, X-ray emitters, and fluorescent emitters are suitable for localization, diagnosis, and / or staging, and / or treatment, while beta and alpha emitters, electron, and neutron capture agents such as boron and uranium may also be used therapeutically.

[0377] In various embodiments, detectable labels can be used in conjunction with external and / or internal detectors to provide a means for effectively localizing and / or visualizing ALPPL2-expressing cancer cells. Such detection / visualization can be useful in a variety of contexts, including, but not limited to, pre-operative and intra-operative settings. Accordingly, in certain embodiments, the present invention relates to methods for intraoperatively detecting ALPPL2-expressing cancers in a mammalian body. These methods typically involve administering to the mammal a composition comprising an anti-ALPPL2 antibody labeled with a detectable label as described herein in an amount sufficient for detection by a detector (e.g., a gamma-detecting probe), followed by allowing the active agent to be taken up by the target tissue, preferably after blood clearance of the label, and then subjecting the mammal to radioimmunodetection techniques in the relevant area of ​​the body, e.g., using a gamma-detecting probe.

[0378] In certain embodiments, antibodies conjugated to a label can be used in radioguided surgical techniques, in which relevant tissues in a subject's body can be detected and located intraoperatively with a detector, e.g., a gamma-detecting probe. Surgeons can use this probe intraoperatively to locate tissues that have taken up a compound labeled with a radioisotope, e.g., a low-energy gamma-photon emitter. In certain embodiments, such methods are particularly useful for localizing and removing secondary cancers produced by metastatic cells from a primary tumor.

[0379] The anti-ALPP / ALPPL2 antibodies described herein may be directly conjugated to a radiopaque moiety (e.g., an available cysteine) or may be conjugated to a "package" (e.g., a chelate, liposome, polymeric microbead, nanoparticle, etc.) that carries, contains, or includes a radiopaque material, for example, as described below.

[0380] In addition to radio-opaque labels, other labels are also suitable for use. Detectable labels suitable for use in immunoconjugates include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, or chemical means. Useful labels include magnetic beads (e.g., DYNABEADS™), fluorescent dyes (e.g., fluorescein isothiocyanate, Texas Red, rhodamine, green fluorescent protein, etc.), radioisotopes (e.g., 3 H, 125 I, 35 S, 14 C, or 32 P), enzymes (e.g., horseradish peroxidase, alkaline phosphatase, and others commonly used in ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads, nanoparticles, quantum dots, etc.

[0381] In certain embodiments, suitable radiolabels include, but are not limited to: 99 Tc, 99 Tc, 97 Ru, 95 Ru, 94 Tc, 90 Y, 90 Y, 89 Zr, 86 Y, 77 Br, 77 As, 76 Br, 75 Se, 72 As, 68 Ga, 68 Ga, 67 Ga, 67 Ga, 67 Cu, 67 Cu, 64 Cu, 62 Cu, 62 Cu, 59 Fe, 58 Co, 57 Co, 52 Mn, 52 Fe, 51 Cr, 47 Sc, 3 H, 35 S,33 P、 32 P、 225 Ac、 224 Ac、 223 Ra、 213 Bi、 212 Pb、 212 Bi、 211 At、 203 Pb、 203 Hg、 201 Tl、 199 Au、 198 Au、 198 Au、 197 Pt、 18 F、 189 Re、 188 Re、 188 Re,、 186 Re、 186 Re、 177 Lu、 177 Lu、 175 Yb、 172 Tm、 169 Yb、 169 Yb、 169 Er、 168 Tm、 167 Tm、 166 Ho、 166 Dy、 165 Tm、 165 Dy、 161 Tb、 15 O、 15 N、 159 Gd、 157 Gd、 153 Sm、 153 Pb、 151 Pm、 14 C、 149 Pm、 143 Pr、 142 Pr、 13 N、 133 I、 131 In、 131 I、 127 Te、 126 I、 125 Te、 125 I、 124 I、 123 I、 122 Te、 121 Te、 121 Sn、 11 C、 113 In、 111 In、111 In, 111 Ag, 111 Ag, 109 Pd, 109 Pd, 107 Hg, 105 Ru, 105 Rh, 105 Rh, and 103 Ru is included.

[0382] Means for detecting such labels are well known to those skilled in the art. Thus, for example, certain radiolabels can be detected using photographic film, scintillation detectors, PET imaging, MRI, etc. Fluorescent markers can be detected using a photodetector to detect emitted illumination. Enzyme labels are typically detected by providing a substrate to the enzyme and detecting the reaction product produced by the action of the enzyme on the substrate, and colorimetric labels are detected simply by visualizing the colored label.

[0383] Radiosensitizers In another embodiment, the effector may include a radiosensitizer that enhances the cytotoxic effects of ionizing radiation on cells (e.g., 60 Co or X-ray sources. Numerous radiosensitizers are known, including, but not limited to, benzoporphyrin derivative compounds (see, e.g., U.S. Pat. No. 5,945,439), 1,2,4-benzotriazine oxides (see, e.g., U.S. Pat. No. 5,849,738), compounds containing certain diamines (see, e.g., U.S. Pat. No. 5,700,825), BCNT (see, e.g., U.S. Pat. No. 5,872,107), radiosensitizing nitrobenzoic acid amide derivatives (see, e.g., U.S. Pat. No. 4,474,814), various heterocyclic derivatives (see, e.g., U.S. Pat. No. 5,064,849), platinum complexes (see, e.g., U.S. Pat. No. 4,921,963), and the like.

[0384] Alpha Emitter In certain embodiments, the effector may comprise an alpha emitter, i.e., a radioisotope that emits alpha particles. Alpha emitters have recently been shown to be effective in treating cancer (see, for example, McDevitt et al. (2001) Science 294:1537-1540; Ballangrud et al. (2001) Cancer Res. 61:2008-2014; Borchardt et al. (2003) Cancer Res. 63:5084-50). Suitable alpha emitters include, but are not limited to, Bi, 213 Bi, 211 At et al.

[0385] Chelate Many of the pharmaceuticals and / or radiolabels described herein can be provided as a chelate. The chelating molecule is typically a chelate molecule that is fused to an anti-ALPP / ALPPL2 antibody described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGD). M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF) are conjugated to a molecule (e.g., biotin, avidin, streptavidin, etc.) that specifically binds to the epitope tag attached to the antibody fragment (e.g., M25ALIA, M25ALF, M25wtIA, and / or M25wtLF).

[0386] Chelating groups are well known to those skilled in the art. In certain embodiments, the chelating group is derived from ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), cyclohexyl 1,2-diaminetetraacetic acid (CDTA), ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), N,N-bis(hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED), triethylenetetraminehexaacetic acid (TTHA), 1,4,7,10-tetraazacyclododecane-N,N'-,N'',N'''-tetraacetic acid (DOTA), hydroxyethyldiaminetriacetic acid (HEDTA), 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetra-acetic acid (TETA), substituted DTPA, substituted EDTA, and the like.

[0387] Examples of particularly preferred chelating agents include unsubstituted or substituted 2-iminothiolane and 2-iminothiacyclohexane, especially 2-imino-4-mercaptomethylthiolane.

[0388] One chelating agent, 1,4,7,10-tetraazacyclododecane-N,N,N'',N'''-tetraacetic acid (DOTA), is of particular interest due to its ability to chelate many diagnostically and therapeutically important metals, including radionuclides and radiolabels.

[0389] Conjugates of DOTA and proteins such as antibodies have been reported. For example, U.S. Patent No. 5,428,156 teaches a method for conjugating DOTA to antibodies and antibody fragments. To prepare such conjugates, one carboxylic acid group of DOTA is converted into an activated ester that can react with amine or sulfhydryl groups on antibodies or antibody fragments. Lewis et al. (1994) Bioconjugate Chem. 5:565-576 describes a similar method in which one carboxyl group of DOTA is converted into an activated ester, the activated DOTA is mixed with an antibody, and the antibody is bound to DOTA via the epsilon-amino group of a lysine residue on the antibody, thereby converting one carboxyl group of DOTA into an amide moiety.

[0390] In certain embodiments, the chelator can be attached directly or via a linker to the epitope tag or to a moiety that binds to the epitope tag. Conjugates of DOTA and biotin have been described (see, e.g., Su (1995) J. Nucl. Med., 36(5 Suppl):154, which discloses the linkage of DOTA to biotin via available amino side chain biotin derivatives such as DOTA-LC-biotin or DOTA-benzyl-4-(6-amino-caproamido)-biotin). WO 95 / 15335 to Yau et al. discloses a method for producing nitro-benzyl-DOTA compounds that can be conjugated to biotin. The method includes a cyclization reaction via temporary projection of the hydroxy group; tosylation of the amine; deprotection of the temporarily protected hydroxy group; tosylation of the deprotected hydroxy group; and intramolecular tosylate cyclization. Wu et al. (1992) Nucl. Med. Biol., 19(2): 239-244, 111 In and 90discloses the synthesis of a macrocyclic chelator for radiolabeling with Y. Wu et al. prepared a labeled DOTA-biotin conjugate to study the stability and biodistribution of the conjugate with avidin, a model protein for study. The conjugate was prepared using biotin hydrazide containing a free amino group to react with an activated DOTA derivative generated in situ.

[0391] Cytotoxic / cytostatic agents Anti-ALPP / ALPPL2 antibodies described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M25301 The cytotoxic agents (M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF) can be used to deliver a variety of cytotoxic and / or cytostatic agents, including therapeutic agents, radiation-emitting compounds, cytotoxic molecules of plant, fungal, or bacterial origin, biological proteins, and mixtures thereof. In certain embodiments, the cytotoxic agent can include an intracellularly active cytotoxic agent, such as a small organic molecule, a cytotoxic protein or peptide, a radiation emitter, e.g., the short-range, high-energy alpha emitters described above, and the like. Additional exemplary therapeutic agents include radioisotopes, chemotherapeutic agents, immunomodulatory agents, antiangiogenic agents, antiproliferative agents, proapoptotic agents, and cytolytic enzymes (e.g., RNAses). Agents can also include therapeutic nucleic acids, such as genes encoding immunomodulatory agents, antiangiogenic agents, antiproliferative agents, or proapoptotic agents. These drug descriptions are not mutually exclusive; thus, a therapeutic agent can be described using one or more of the above terms. For example, selected radioisotopes are also cytotoxins. In various embodiments, a therapeutic agent can be prepared as a pharmaceutically acceptable salt, acid, or derivative of any of the above.

[0392] In certain embodiments, the anti-ALPP / ALPPL2 antibody is conjugated to a therapeutic cytotoxic / cytostatic agent. In various embodiments, drugs used to construct ADCs include, but are not limited to, microtubule inhibitors and DNA damaging agents, polymerase inhibitors (e.g., polymerase II inhibitors, α-amanitin), and the like. In certain embodiments, the antibody is conjugated to the drug directly or via a linker, while in other embodiments, the antibody is conjugated to a drug carrier (e.g., a liposome containing the drug, a polymeric drug carrier, a nanoparticle drug carrier, a lipid drug carrier, a dendrimer drug carrier, etc.).

[0393] In certain embodiments, the drug comprises a tubulin inhibitor, including, but not limited to, auristatin, dolastatin-10, synthetic derivatives of dolastatin-10, which are synthetic versions of the natural product, and maytansine or maytansine derivatives.

[0394] In certain embodiments, the drug comprises an auristatin, hi certain embodiments, the auristatin is selected from the group consisting of auristatin E (AE), auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin D (MMAD) or monomethyl dolastatin 10, monomethyl auristatin F (MMAF) or N-methylvaline-valine-dolaisoleuin-dolaproine-phenylalanine, monomethyl auristatin E (MMAE) or N-methylvaline-valine-dolaisoleuin-dolaproine-norephedrine, 5-benzoylvaleric acid-AE ester (AEVB), vcMMAE, and vcMMAF.

[0395] In certain embodiments, the drug comprises an enediyne. Enediynes are a class of antitumor bacterial products characterized by either 9- and 10-membered rings or the presence of conjugated triple-double-triple bond ring systems. Exemplary enediynes include, but are not limited to, calicheamicin, esperamicin, and dynemicin. Calicheamicin is an enediyne antibiotic first isolated as a natural product from the soil organism Micromonospora echinospora ssp. calichensis (Zein et al., Science 27; 240(4856):1198-1201, 1988). It generates double-stranded DNA breaks in target cells and subsequently induces apoptosis (Zein et al., Science 27;240(4856):1198-1201, 1988; Nicolaou et al., Chem. Biol. Sep;1(1):57-66, 1994; Prokop et al., Oncogene 22:9107-9120, 2003). In certain embodiments, the drug comprises calicheamicin or a calicheamicin analog. Examples of calicheamicin and its analogs suitable for use in anti-ALPPL2 immunoconjugates are disclosed, for example, in U.S. Patent Nos. 4,671,958, 4,970,198, 5,053,394, 5,037,651, 5,079,233, 5,264,586, and 5,108,912, which are incorporated herein by reference in their entireties. In certain embodiments, these compounds contain a methyl trisulfide that can react with a suitable thiol to form a disulfide and simultaneously introduce a functional group, such as a hydrazide or other functional group useful for conjugating the calicheamicin to an anti-ALPPL2 antibody. Disulfide analogs of calicheamicin can also be used, such as those described in U.S. Patent Nos. 5,606,040 and 5,770,710, which are incorporated herein by reference in their entireties. In certain embodiments, the disulfide analog is N-acetyl-gamma-calicheamicin dimethylhydrazide.

[0396] In certain embodiments, the drug is geldanamycin. Geldanamycin is a benzoquinone ansamycin antibiotic that binds to Hsp90 (heat shock protein 90) and is used as an antitumor drug. Exemplary geldanamycins include, but are not limited to, 17-AAG (17-N-allylamino-17-demethoxygeldanamycin) and 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin).

[0397] In certain embodiments, the drug comprises maytansine. Maytansine or its derivative maytansinoids inhibit cell proliferation by inhibiting microtubule formation during mitosis through inhibition of tubulin polymerization (see, e.g., Remillard et al. (1975) Science 189:1002-1005). Exemplary maytansines include, but are not limited to, mertansine (DM1); and maytansine analogs such as DM3 or DM4, and ansamitocins.

[0398] In certain embodiments, the drug comprises a taxane. Taxanes are diterpenes that act as antitubulin or antimitotic agents. Exemplary taxanes include, but are not limited to, paclitaxel and docetaxel.

[0399] In certain embodiments, the drug comprises a DNA-interactive agent, including, but not limited to, a calicheamicin, a duocarmycin, a pyrrolobenzodiazepine (PBD), and the like.

[0400] In another exemplary, but non-limiting, embodiment, the drug comprises a duocarmycin. Duocarmycins are DNA damaging agents that can exert their mode of action at any stage in the cell cycle. Agents that are part of this class of duocarmycins typically have potency in the low picomolar range. Exemplary duocarmycins (e.g., duocarmycin analogs) that can be used as effectors in the chimeric constructs contemplated herein include, but are not limited to, duocarmycin A, duocarmycin B1, duocarmycin B2, duocarmycin C1, duocarmycin C2, duocarmycin D, duocarmycin SA, cyclopropylbenzoindole duocarmycin (CC-1065), centanamycin, rachelmycin, adozelesin, bizeresin, carzelesin, and the like.

[0401] In another exemplary, but non-limiting, embodiment, the drug comprises a pyrrolobenzodiazepine. In certain embodiments, the drug comprises two synthetic derivatives of pyrrolobenzodiazepines linked by a flexible polymethylene tether. Pyrrolobenzodiazepines (PBDs) and PBD dimers are described in U.S. Patent No. 7,528,126 B2, which is incorporated herein by reference for the pyrrolobenzodiazepines and PBD dimers described therein. In certain embodiments, the pyrrolobenzodiazepine is selected from the group consisting of anthramycin (and its dimer), mazethramycin (and its dimer), tomaymycin (and its dimer), prothracarcin (and its dimer), ticamycin (and its dimer), neothramycin A (and its dimer), neothramycin B (and its dimer), DC-81 (and its dimer), sibiromycin (and its dimer), polothramycin A (and its dimer), polothramycin B (and its dimer), sivanomycin (and its dimer), abveymycin (and its dimer), SG2000, and SG2285.

[0402] In certain embodiments, the drug comprises a polymerase inhibitor, including, but not limited to, α-amanitin and polymerase II inhibitors such as poly(ADP-ribose) polymerase (PARP) inhibitors. Exemplary PARP inhibitors include, but are not limited to, iniparib (BSI 201), talazoparib (BMN-673), olaparib (AZD-2281), olaparib, rucaparib (AG014699, PF-01367338), veliparib (ABT-888), CEP 9722, MK 4827, BGB-290, 3-aminobenzamide, and the like.

[0403] In certain embodiments, the drug comprises a vinca alkyloid. Vinca alkyloids are also antitubulin agents. Exemplary vinca alkyloids include, but are not limited to, vincristine, vinblastine, vindesine, and vinorelbine.

[0404] The above drugs are exemplary and not limiting. In various embodiments, other anti-cancer drugs can be utilized, including, but not limited to, anti-cancer antibodies (e.g., HERCEPTIN®), antimetabolites, alkylating agents, topoisomerase inhibitors, microtubule targeting agents, kinase inhibitors, protein synthesis inhibitors, somatostatin analogs, glucocorticoids, aromatose inhibitors, mTOR inhibitors, protein kinase B (PKB) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, cyclin-dependent kinase inhibitors, anti-TRAIL molecules, MEK inhibitors, etc. In certain embodiments, the anti-cancer compound is selected from the group consisting of, but not limited to, fluorouracil (5-FU), capecitabine / XELODA, 5-trifluoromethyl-2'-deoxyuridine, methotrexate sodium, raltitrexed / Tomudex, pemetrexed / Alimta®, cytosine arabinoside (cytarabine, Ara-C) / thioguanine, 6-mercaptopurine (mercaptopurine, 6-MP), azathioprine / Azasan, 6-thioguanine (6-TG) / Purinethol (TEVA), pentostatin / Nipent, fludarabine phosphate / Fludara®, cladribine (2-CdA, 2-chlorodeoxyadenosine) / Leustatin, floxuridine (5-fluoro-2) / FUDR (Hospira, Inc.), ribonucleotide reductase inhibitors (RNR), cyclophosphamide / Cytoxan (BMS), Neosal, ifosfamide / Mitoxana, thiotepa, BCNU-1,3-bis(2-chloroethyl)-1-nitrosourea, 1,-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, methyl CCNU, hexamethylmelamine, busulfan / Myleran, procarbazine HCl / Matulane, dacarbazine (DTIC), chlorambucil / Leukaran®, melphalan / Alkeran, cisplatin (cisplatinum, CDDP) / Platinol, carboplatin / Paraplatin, oxaliplatin / Eloxitan, bendamustine, carmustine, chloromethine,Dacarbazine (DTIC), fotemustine, lomustine, mannosulfan, nedaplatin, nimustine, prednimustine, ranimustine, satraplatin, semustine, streptozocin, temozolomide, treosulfan, triaziquone, triethylenemelamine, thioTEPA, triplatin tetranitrate, trofosfamide, uramustine, doxorubicin HCl / Doxil, daunorubicin citrate / DaunoXome®, mitoxantrone HCl / Novantrone, actinomycin D, etoposide / bepside, topotecan HCl / hycamtin, teniposide (VM-26), irinotecan HCl (CPT-11) / , camptosar®, camptothecin, belotecan, rubitecan, vincristine, vinblastine sulfate, vinorelbine tartrate, vindesine sulfate, paclitaxel / taxol, docetaxel / taxotere, nanoparticle paclitaxel, abraxane, ixabepilone, larotaxel, ortataxel, tesetaxel, vinflunine, and the like. In certain embodiments, the anti-cancer agent(s) are carboplatin (e.g., PARAPLATIN®), cisplatin (e.g., PLATINOL®, PLATINOL-AQ®), cyclophosphamide (e.g., CYTOXAN®, NEOSAR®), docetaxel (e.g., TAXOTERE®), doxorubicin (e.g., ADRIAMYCIN®), erlotinib (e.g., TARCEVA®), or cisplatin (e.g., cisplatin ... VA®), etoposide (e.g., VEPESID®), fluorouracil (e.g., 5-FU®), gemcitabine (e.g., GEMZAR®), imatinib mesylate (e.g., GLEEVEC®), irinotecan (e.g., CAMPTOSAR®), methotrexate (e.g., FOLEX®, MEXATE®, AMETHOPTERIN®), paclitaxel (e.g.,The treatment may include one or more drugs selected from the group consisting of TAXOL®, ABRAXANE®, sorafinib (e.g., NEXAVAR®), sunitinib (e.g., SUTENT®), topotecan (e.g., HYCAMTIN®), vinblastine (e.g., VELBAN®), vincristine (e.g., ONCOVIN®, VINCASAR PFS®). In certain embodiments, the anticancer agent comprises one or more drugs selected from the group consisting of retinoic acid, retinoic acid derivatives, doxirubicin, vinblastine, vincristine, cyclophosphamide, ifosfamide, cisplatin, 5-fluorouracil, camptothecin derivatives, interferon, tamoxifen, and taxol. In certain embodiments, the anticancer compound is selected from the group consisting of Abraxane, doxorubicin, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, toremifene, letrozole, trastuzumab, megestrol tamoxifen, paclitaxel, docetaxel, capecitabine, goserelin acetate, zoledronic acid, vinblastine, antisense molecules, siRNA, etc.

[0405] In certain embodiments, the cytotoxic / cytostatic agent comprises a protein or peptide toxin or fragment thereof. Enzymatically active toxins or fragments thereof are exemplified by, for example, diphtheria toxin A fragment, nonbinding active fragment of diphtheria toxin, exotoxin A (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, α-sarcin, certain Aleurites fordii proteins, certain dianthin proteins, Phytolaca americana proteins (PAP, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogillin, restrictocin, phenomycin, enomycin, and the trichothecenes.

[0406] In certain embodiments, cytotoxins may include, but are not limited to, Pseudomonas exotoxin, Diphtheria toxin, ricin, abrin, and derivatives thereof. Pseudomonas exotoxin A (PE) is a highly active monomeric protein (molecular weight 66 kD) secreted by Pseudomonas aeruginosa, which inhibits protein synthesis in eukaryotic cells through the inactivation of elongation factor 2 (EF-2) by catalyzing its ADP-ribosylation (catalyzing the transfer of the ADP-ribosyl moiety of oxidized NAD onto EF-2).

[0407] The toxin contains three structural domains that act in concert to cause cytotoxicity. Domain Ia (amino acids 1-252) mediates cell binding. Domain II (amino acids 253-364) is involved in translocation to the cytosol, and domain III (amino acids 400-613) mediates ADP-ribosylation of elongation factor 2, inactivating the protein and causing cell death. The function of domain Ib (amino acids 365-399) remains uncertain, but most of it, amino acids 365-380, can be deleted without loss of cytotoxicity. See Siegall et al. (1989) J. Biol. Chem. 264:14256-14261.

[0408] In certain embodiments, the antibody binds to a preferred molecule in which domain Ia (amino acids 1 to 252) has been deleted and amino acids 365 to 380 have been deleted from domain Ib. In certain embodiments, all of domain Ib and part of domain II (amino acids 350 to 394) can be deleted, particularly if the deleted sequence is replaced with a connecting peptide.

[0409] In addition, PE and other cytotoxic proteins can be further modified using site-directed mutagenesis or other techniques known in the art to alter the molecule for a particular desired use. For example, means for altering the PE molecule in a way that does not substantially affect the functional benefits provided by the PE molecules described herein can also be used, and such resulting molecules are intended to be encompassed within this specification.

[0410] Methods for cloning genes encoding PE fused to various ligands are well known to those skilled in the art (see, e.g., Siegall et al. (1989) FASEB J., 3:2647-2652; Chaudhary et al. (1987) Proc. Natl. Acad. Sci. USA, 84:4538-4542).

[0411] Like PE, diphtheria toxin (DT) kills cells by ADP-ribosylation elongation factor 2, thereby inhibiting protein synthesis. However, diphtheria toxin is divided into two chains, A and B, linked by a disulfide bridge. In contrast to PE, chain B of DT, located on the carboxyl terminus, is involved in receptor binding, while chain A, located on the amino terminus, contains enzymatic activity (Uchida et al., (1972) Science, 175:901-903; Uchida et al., (1973) J. Biol. Chem., 248:3838-3844).

[0412] In certain embodiments, the antibody-diphtheria toxin immunoconjugate has the native receptor-binding domain removed by truncation of the diphtheria toxin B chain. One exemplary modified diphtheria toxin is DT388, in which the carboxyl-terminal sequence beginning at residue 389 is removed (see, e.g., Chaudhary et al. (1991) Bioch. Biophys. Res. Comm., 180:545-551). Like the PE chimeric cytotoxin, the DT molecule can be chemically conjugated to an anti-ALPP antibody, but in certain preferred embodiments, the antibody is fused to the diphtheria toxin by recombinant means (see, e.g., Williams et al. (1990) J. Biol. Chem., 265:11885-11889).

[0413] immunomodulators In certain embodiments, an anti-ALPP / ALPPL2 antibody is conjugated to an immunomodulatory agent, which functions to localize the immunomodulatory agent at the cancer cell / tumor site. Many immunomodulatory agents capable of activating an immune response are known to those skilled in the art. In one exemplary, but non-limiting, embodiment, the immunomodulatory agent comprises an anti-CD3 antibody. Anti-CD3 monoclonal antibodies induce human T cell proliferation in vitro and activate specific and nonspecific cytolysis by human T cell clones and human peripheral blood lymphocytes. In vivo administration of anti-CD3 prevents tumor growth of UV-induced murine fibrosarcoma.

[0414] In certain embodiments, the immunomodulatory agent comprises an agent that blocks an immune checkpoint. Immune checkpoints refer to the numerous inhibitory pathways circuitized in the immune system that are important for maintaining self-tolerance and regulating the duration and amplification of physiological immune responses in peripheral tissues to minimize secondary tissue damage. It is now clear that tumors co-opt certain immune checkpoint pathways as a major mechanism of immune resistance, particularly against T cells specific for tumor antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be easily blocked by antibodies or modulated by recombinant forms of the ligand or receptor.

[0415] Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutic agents to achieve U.S. Food and Drug Administration (FDA) approval. Ipilimumab (Yervoy®), the first such drug to gain approval for the treatment of advanced melanoma, blocks the activity of a checkpoint protein known as CTLA4, which is expressed on the surface of activated immune cells called cytotoxic T lymphocytes. CTLA4 acts as a "switch" to inactivate these T cells, thereby reducing the intensity of the immune response. Ipilimumab binds to CTLA4 and prevents it from sending its inhibitory signal. Two other FDA-approved checkpoint inhibitors, nivolumab (Opdivo®) and pembrolizumab (Keytruda®), work in a similar pathway but target a different checkpoint protein on activated T cells known as PD-1. Nivolumab is approved to treat some patients with advanced melanoma or advanced lung cancer, and pembrolizumab is approved to treat some patients with advanced melanoma.

[0416] Thus, in certain embodiments, the immunomodulatory agent comprises an antibody directed against CTLA4 (e.g., ipilimumab) and / or an antibody directed against PD-L1 (e.g., nivolumab, pembrolizumab) and / or an antibody directed against PD-L2.

[0417] Other examples of immunomodulatory agents that can be conjugated to anti-ALPP / ALPPL2 antibodies include ganciclovir, etanercept, tacrolimus, sirolimus, voclosporin, cyclosporin, rapamycin, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, glucocorticoids and their analogs, cytokines, xanthines, stem cell growth factors, lymphotoxins, tumor necrosis factors (TNF), hematopoietic factors, interleukins (e.g., interleukin-1 (IL-1), IL-2, IL-3, IL-6, IL-10, IL-12, IL-18, and IL-21), colony-stimulating factors (e.g., granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage-colony stimulating factor (GM-CSF)), and the like. factor), interferons (e.g., interferon-alpha, interferon-beta, interferon-gamma), stem cell growth factor known as "S1 factor," erythropoietin, and thrombopoietin, or a combination thereof.

[0418] Useful immunomodulators also include antihormones that block hormone action on tumors, and immunosuppressants that suppress cytokine production, downregulate self-antigen expression, or mask MHC antigens. Representative antihormones include antiestrogens, including, for example, tamoxifen, raloxifene, aromatase-inhibiting 4(5)-imidazole, 4-hydroxytamoxifen, trioxifene, ketoxifene, LY 117018, onapnstone, and toremifene; and antiandrogens, such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and antiadrenal agents. Exemplary immunosuppressive agents include, but are not limited to, 2-amino-6-aryl-5-substituted pyrimidines, azathioprine, cyclophosphamide, bromocriptine, danazol, dapsone, glutaraldehyde, anti-idiotypic antibodies to MHC antigens and MHC fragments, cyclosporin A, steroids such as glucocorticosteroids, cytokine or cytokine receptor antagonists (e.g., anti-interferon antibodies, anti-IL-10 antibodies, anti-TNFα antibodies, anti-IL-2 antibodies), streptokinase, TGFβ, rapamycin, T cell receptors, T cell receptor fragments, and T cell receptor antibodies.

[0419] virus particles In certain embodiments, the effector comprises a viral particle (e.g., a filamentous phage, an adeno-associated virus (AAV), a lentivirus, etc.). The antibody may be conjugated to the viral particle and / or expressed on the surface of the viral particle (e.g., a filamentous phage). The viral particle may additionally comprise a nucleic acid to be delivered to a target cell (e.g., a cancer cell expressing ALPPL2). The use of viral particles to deliver nucleic acids to cells is described in detail in WO 99 / 55720, U.S. Patent Nos. 6,670,188, 6,642,051, and 6,669,936.

[0420] antibody In certain embodiments, the effector comprises another antibody (e.g., a second antibody). Binding of an antibody effector to an anti-ALPPL2 antibody described herein can provide a bispecific antibody. In certain embodiments, the antibody effector comprises an antibody that binds to a different epitope of ALPPL2 (from the epitope bound by the anti-ALPPL2 antibody) or a different target on cells that express ALPPL2. Thus, in certain embodiments, the effector comprises an antibody that binds to a marker expressed on the surface of cancer cells, such as mesothelioma cells, testicular cancer cells, endometrial cancer cells, and certain pancreatic cancer cells, ovarian cancer cells, and non-small cell lung cancer cells.

[0421] In certain embodiments, the effector antibody binds to a moiety other than a marker on cancer cells. For example, in certain embodiments, the effector may be an antibody that binds to CD3 (e.g., an anti-CD3 antibody). Anti-CD3 monoclonal antibodies induce cell proliferation of human T cells in vitro and activate specific and nonspecific cytolysis by human T cell clones and human peripheral blood lymphocytes. In vivo administration of anti-CD3 prevents tumor growth of UV-induced murine fibrosarcoma. Thus, anti-CD3 antibody effectors can be used to enhance immune responses against anti-ALPL2 target cells.

[0422] Other exemplary, but non-limiting, effector antibodies include antibodies directed against FcγRI (CD64), which is prominently expressed on monocytes and macrophages and is upregulated on neutrophils upon activation, antibodies directed against EpCAM (CD326), and the like.

[0423] It will be recognized that the above bispecific antibodies are exemplary and non-limiting, and that essentially any antibody can be conjugated to the anti-ALPP / ALPPL2 antibodies described herein, depending on the desired application.

[0424] B) Antibody binding to effector Those of skill in the art will be able to readily identify and characterize the anti-ALPP / ALPPL2 antibodies described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRIT It is understood that the targeting molecule (SGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF) and the effector molecule can be attached together in any order. Thus, when the antibody is a single-chain polypeptide, the effector molecule may be attached to either the amino or carboxy terminus of the targeting molecule. When the antibody comprises more than one amino acid chain, the effector molecule may be attached to either the amino or carboxy terminus of any peptide comprising the antibody. Alternatively, the antibody may be attached to an internal region of the effector molecule, or conversely, the effector molecule may be attached to an internal location of the antibody, so long as such attachment does not interfere with the respective activities of the molecules.

[0425] The antibody and effector can be linked by any of several means well known to those skilled in the art. Typically, the effector is conjugated to the antibody directly or through a linker (spacer). However, in certain embodiments, when the effector is or comprises a polypeptide, it is possible to recombinantly express a chimeric molecule as a single-chain fusion of the effector to a single-chain antibody or as a fusion of the effector to one chain of an antibody comprising more than one chain.

[0426] Conjugation of effector molecules to antibodies In certain embodiments, the anti-ALPP / ALPPL2 antibodies described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwt The polypeptides (e.g., LC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA and / or M25wtLF) can be chemically conjugated to an effector molecule (e.g., a cytotoxin, a label, a ligand, a drug, a liposome, etc.) Means for chemically conjugating molecules are well known to those of skill in the art.

[0427] The procedure for attaching an effector to an antibody varies depending on the chemical structure of the effector and / or the antibody. Polypeptides typically contain various functional groups, such as carboxylic acid (COOH) or free amine (-NH) groups, available for reaction with suitable functional groups on the effector molecule to attach the effector to the polypeptide.

[0428] Alternatively, the antibody and / or effector can be derivatized to expose or attach additional reactive functional groups. Derivatization can include attachment of any of several linker molecules, such as those available from Pierce Chemical Company (Rockford, Illinois).

[0429] As used herein, a "linker" is a molecule used to connect a targeting molecule to an effector molecule. The linker can form both a covalent bond to the targeting molecule and a covalent bond to the effector molecule. Suitable linkers are well known to those skilled in the art and include, but are not limited to, straight-chain or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. When the targeting molecule and the effector molecule are polypeptides, the linker can be connected to the constituent amino acids through their side chain groups (e.g., through a disulfide bond to cysteine). However, in a preferred embodiment, the linker is connected to the alpha-carbon amino or carboxyl group of the terminal amino acid.

[0430] Immunoconjugates can be prepared using a variety of bifunctional protein-binding agents, such as N-succinimidyl-3-(2-pyridyldithiol)propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyl adipimidate HCl), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bis-azido compounds (e.g., bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (e.g., bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., tolylene 2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al. (1987), Science 238, 1098. Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary, but non-limiting, chelating agent for conjugation of, for example, radionucleotides to antibodies (see, e.g., WO1994 / 011026 (PCT / US1993 / 010953)).

[0431] In certain embodiments, conjugation of an effector (e.g., a drug, liposome, etc.) or a linker attached to an effector to an antibody occurs at a solvent-exposed reactive amino acid, such as a lysine or cysteine, which can be derived from reduction of interchain disulfide bonds in the antibody. In certain embodiments, cysteine ​​conjugation can occur after reduction of the four interchain disulfide bonds.

[0432] In certain embodiments, site-specific conjugation can be performed, in which a known number of linker-drugs are consistently conjugated to defined sites in an antibody, generating highly homogeneous constructs. The drug-to-antibody ratio (DAR) can be precisely controlled to accommodate a variety of linker-drugs, generating, for example, either 2- or 4-DAR site-specific ADCs.

[0433] Several methods for achieving site-specific conjugation are known. For example, the amino acid cysteine ​​contains a reactive thiol group that plays an important role in the structure and function of many proteins. Conjugation of thio-reactive probes to proteins through cysteine ​​residues has long been a method for protein labeling and has also been applied to the generation of antibody-drug conjugates (ADCs). In certain exemplary, but non-limiting, embodiments, this method involves partial reduction of existing disulfide bonds (e.g., interchain disulfide bonds).

[0434] In certain embodiments, to maintain disulfide bonds, cysteine ​​residues can be artificially incorporated into proteins. The successful use of introduced cysteine ​​residues for site-specific conjugation depends on the ability to select appropriate sites such that the cysteine ​​substitution does not alter protein structure or function. To achieve this, a phage ELISA (PHESELECTOR) for the selection of reactive thiols was developed by introducing reactive cysteine ​​residues into an antibody-Fab (trastuzumab-Fab 4D5) at various sites, displaying the Fab on phage, and screening to identify reactive cysteines that do not interfere with antigen binding (see, e.g., Junutula et al. (2008), J. Immunol. Meth. 332, 41-52).

[0435] The PHESELECTOR approach has been shown to be efficient and specific, particularly compared to traditional cysteine ​​conjugation. For example, it has been shown that the optimal cysteine ​​sites discovered using the PHESELECTOR method with antibody fragments (e.g., Fabs) can also be applied to full-length antibodies, and data indicate that these sites also work well for site-specific conjugation to other mAbs (see, e.g., Boswell et al. (2011), Bioconjug. Chem. 22, 1994-2004; Boswell et al. (2012), Soc. Nuclear Med. 53, 1454-1461; Shen et al. (2012), Nat. Biotechnol. 30, 184-189).

[0436] Another exemplary, but non-limiting, strategy for site-specific conjugation centers on the insertion of amino acids bearing bioorthogonal reactive handles, such as the amino acid selenocysteine ​​and the unnatural amino acid acetylphenylalanine (pAcPhe). Two methods using these amino acids have been developed, both of which utilize stop codons. However, one method incorporates Sec by pairing the opal stop codon UGA with a selenocysteine ​​(Sec) insertion sequence, while the other incorporates acetylphenylalanine at the amber stop codon UAG using a tRNA / aminoacyl-tRNA synthetase pair. The selenocysteine ​​used by the first method is very similar to the amino acid cysteine ​​but contains a selenium atom instead of a sulfur atom. The selenolate group is a more reactive nucleophile than its thiolate counterpart, and therefore is suitable for conjugation with electrophilic compounds under conditions in which selenocysteine ​​is selectively activated. There are approximately 25 known selenium-containing proteins in mammals, including proteins such as glutathione peroxidase and thioreductase (Kryukov et al., 2003, Science, 300, 1439-1443). Under normal conditions, UGA encodes transcription termination; however, in the presence of a Sec insertion sequence (SECIS) located in the 3' UTR of a Sec-containing protein, termination is prevented by the formation of an mRNA secondary structure, and Sec is inserted at the UGA codon (Caban and Copeland, 2006, Cell Mol. Life Sci., 63, 73-81). Sec insertions can be artificially engineered into non-Sec-encoding genes by inserting a UGA codon and SECIS at the 3' end of the gene. This technique has been used in particular for Sec labeling of mAbs and subsequent site-specific conjugation (see, for example, Hofer et al. (2009), Biochem. 48, 12047-12057).

[0437] Another exemplary method for site-specific conjugation utilizes the unnatural amino acid p-acetylphenylalanine (pAcPhe). pAcPhe contains a keto group that can be selectively conjugated to alkoxy-amine-containing drugs through oxime ligation. To incorporate pAcPhe into an antibody, an amber stop codon is substituted into the antibody at the desired position. The antibody cDNA is then co-expressed with an amber suppressor tRNA and the appropriate pair of mutant tRNA synthetases. tRNA synthetase loads pAcPhe onto the amber tRNA, and thus pAcPhe is incorporated into the antibody at the amber site UAG (see, e.g., Liu et al. (2007), Nat. Meth. 4, 239-244; Wang et al. (2003), Proc. Natl. Acad. Sci. USA, 100, 56-61; Axup (2012), Proc. Natl. Acad. Sci. USA, 109, 16101-16116).

[0438] In addition to pAcPhe, other unnatural amino acids are available for use in site-specific conjugation using similar methods involving adapting tRNA / aminoacyl-tRNA synthetase pairs (see, e.g., Young (2002), J. Mol. Biol. 395, 361-374; Kiick et al. (2002), Proc. Natl. Acad. Sci. USA, 99, 19-24).

[0439] In various embodiments, the use of enzymes that catalyze bond formation can be utilized for use in site-specific conjugation. For example, the glycosyltransferase platform uses mutant glycosyltransferases to attach chemically active sugar moieties to glycosylation sites on antibodies. A molecule of choice can then be conjugated to the chemical handle on the sugar moiety. In another exemplary, but non-limiting, approach, transglutaminase is used to form a bond between an amine group on a linker / drug and an artificially incorporated glutamine residue on an antibody.

[0440] Glycosyltransferases are a large family of proteins involved in oligosaccharide synthesis, responsible for the transfer of sugar residues from activated sugar nucleotides to sugar acceptors or glycoproteins / lipids. The structures of several glycosyltransferases are known, revealing that sugar donor specificity is determined by a few amino acids within the catalytic pocket (Qasba et al. (2005) Trends Biochem. Sci. 30:53-62). Using this knowledge, residues within the pocket of glycosyltransferases have been mutated, e.g., B4Gal-T1, to broaden donor specificity and enable the transfer of the chemically reactive sugar residue 2-keto-Gal (see, e.g., Ramakrishnan et al. (2002) J. Biol. Chem. 277:20833-20839). This technique allows the ability to transfer chemically reactive sugars to any lipid or protein containing a glycosylation site. Human IgG antibodies contain an N-glycosylation site at the conserved Asn-297 in the Fc fragment. Glycans attached to this site are generally complex but can be degalactosylated to G, to which mutant glycosyltransferases can transfer C2-keto-Gal with high efficiency (see, e.g., Boeggeman et al. (2009), Bioconjug. Chem. 20, 1228-1236). The activated chemical handle of C2-keto-Gal can then be linked to biomolecules bearing orthogonal reactive groups. This approach has been successfully used for the site-specific conjugation of the anti-Her2 antibody, trastuzumab, with Alexa Fluor 488 aminooxyacetamide and is a viable technique for the generation of site-specific ADCs (ibid.).

[0441] The second platform utilizes transglutaminase to catalyze the formation of covalent bonds between free amine groups and glutamine side chains. Transglutaminase from Streptoverticillium mobaraense (mTG) is commercially available and has been widely used as a protein cross-linker (see, e.g., Yokoyama et al. (2004), ALPP. Microbiol. Biotechnol. 64, 447-454). mTG does not recognize any of the native glutamine residues in the Fc region of glycosylated antibodies, but rather recognizes the "glutamine tag" that can be artificially incorporated into antibodies (see, e.g., Jeger et al. (2010), Angew Chem. Int. Ed. Engl. 49, 9995-9997). As an example, the glutamine tag LLQG was engineered into various sites in the constant domain of an antibody targeting the epidermal growth factor receptor. mTG was then used to conjugate these sites with fluorophores or monomethyl dolastatin 10 (MMAD), and some sites were found to have excellent biophysical properties and high conjugation potential. mTG was also successfully used to conjugate glutamine tags to anti-Her2 and anti-M1S1 antibodies. The anti-M1S1-vc-MMAD conjugates showed strong in vitro and in vivo activity, suggesting that conjugation using this method does not alter antibody binding or affinity, demonstrating the utility of this approach for site-specific conjugation of ADCs (see, e.g., Strop et al. (2013), Chem. Biol. 20, 161-167).

[0442] In addition to glycosyltransferases and transglutaminase enzymes, other enzymes have been investigated for use in protein labeling (Sunbul and Yin (2009), Org. Biomol. Chem. 7, 3361-3371). One such enzyme, formylglycine-generating enzyme, recognizes the sequence CxPxR and oxidizes the cysteine ​​residue to form formylglycine, thus generating the protein with an aldehyde tag. The aldehyde group can then be conjugated to a molecule of choice, for example, through hydrozyno-Pictet-Spengler chemistry.

[0443] Many other techniques and linker molecules are known for attaching a variety of compounds, including radionuclide metal chelates, toxins, and drugs, to proteins such as antibodies (see, e.g., European Patent Application No. 188,256; U.S. Pat. Nos. 4,671,958; 4,659,839; 4,414,148; 4,699,784; 4,680,338; 4,569,789; and 4,589,071; and Borlinghaus et al. (1987), Cancer Res. 47, 4071-4075). In particular, the production of various immunotoxins is well known in the art and can be found, for example, in "Monoclonal Antibody-Toxin Conjugates: Aiming the Magic Bullet," Thorpe et al., Monoclonal Antibodies in Clinical Medicine, Academic Press, pp. 168-190 (1982); Waldmann (1991), Science, 252, 1657; U.S. Pat. Nos. 4,545,985 and 4,894,443.

[0444] In some situations, it is desirable to release the effector from the antibody when the immunoconjugate reaches its target site. Therefore, if the effector is to be released at the target site, an immunoconjugate containing a bond that is cleavable near the target site may be used. Cleavage of the bond to release the agent from the antibody can be induced by enzymatic activity or conditions to which the immunoconjugate is exposed within the target cell or near the target site. If the target site is a tumor, a linker that is cleavable under conditions present at the tumor site (e.g., when exposed to tumor-associated enzymes or acidic pH) may be used.

[0445] Several different cleavable linkers are known to those skilled in the art. See U.S. Patent Nos. 4,618,492, 4,542,225, and 4,625,014. Exemplary cleavable linkers include, but are not limited to, acid-labile linkers, protease-cleavable linkers, disulfide linkers, and the like. Acid-labile linkers are designed to be stable at pH levels encountered in blood but become unstable and degrade when they encounter the low pH environment of lysosomes. Protease-cleavable linkers are also designed to be stable in blood / plasma but rapidly release free drug within lysosomes in cancer cells upon cleavage by lysosomal enzymes. They take advantage of the high level of protease activity within lysosomes, such as occurs with dipeptide Val-Cit bonds that are rapidly hydrolyzed by cathepsins, and typically contain peptide sequences recognized and cleaved by these proteases. Disulfide linkers utilize high levels of intracellular reduced glutathione to release free drug within cells.

[0446] Thus, in various embodiments, the linker may be stable (non-cleavable) or hydrolyzable (cleavable), thereby allowing release after entry into the cell. The primary mechanisms by which drugs are cleaved from antibodies include hydrolysis (hydrazones, acetals, and cis-aconitic acid-like amides) in the acidic pH of the lysosome, peptide cleavage by lysosomal enzymes (cathepsins and other lysosomal enzymes), and disulfide reduction. As a result of these various mechanisms for cleavage, the mechanism of attachment of drugs to antibodies also varies widely, and any suitable linker can be used.

[0447] An example of a suitable conjugation technique relies on the conjugation of hydrazides and other nucleophiles to aldehydes generated by oxidation of carbohydrates naturally occurring on antibodies. Hydrazone-containing conjugates can be prepared with an introduced carbonyl group that provides the desired drug release properties. Conjugates can also be prepared with linkers that have a disulfide at one end, an alkyl chain in the middle, and a hydrazine derivative at the other end. Anthracyclines are an example of cytotoxins that can be conjugated to antibodies using this technique.

[0448] Linkers containing functional groups other than hydrazones have the potential to be cleaved in the acidic environment of the lysosome. For example, conjugates can be prepared from thiol-reactive linkers containing intracellularly cleavable moieties other than hydrazones, such as esters, amides, and acetals / ketals. Camptothecin is one cytotoxic agent that can be conjugated using these linkers. Ketals prepared from 5- to 7-membered cyclic ketones can also be used, with one oxygen atom attached to the cytotoxic agent and the other to the linker for antibody attachment. Anthracyclines are also an example of cytotoxins suitable for use with these linkers.

[0449] Another example of a class of pH-sensitive linkers is cis-aconitic acid, which has a carboxylic acid juxtaposed to an amide bond.Carboxylic acid accelerates amide hydrolysis in acidic lysosomes.Also, linkers with some other types of structures can be used to achieve similar types of hydrolysis rate acceleration.Maytansinoid is an example of a cytotoxin that can be conjugated with a linker that is linked at C-9.

[0450] Another potential method for releasing drug conjugates is enzymatic hydrolysis of peptides by lysosomal enzymes. In one example, a peptide is attached to para-aminobenzyl alcohol via an amide bond, followed by the generation of a carbamate or carbonate between the benzyl alcohol and the cytotoxic agent. Cleavage of the peptide causes the degradation or self-immolation of the aminobenzyl carbamate or carbonate. Exemplary cytotoxic agents using this strategy include anthracyclines, taxanes, mitomycin C, and auristatins. In one example, a phenol can also be released by degradation of the linker instead of the carbamate. In another variation, disulfide reduction is used to initiate the degradation of para-mercaptobenzyl carbamate or carbonate.

[0451] In certain embodiments, the cytotoxic agent conjugated to the antibody has little, if any, water solubility, which can limit drug loading into the conjugate due to aggregation of the conjugate. One approach to overcome this is to add a solubilizing group to the linker. Conjugates prepared with linkers consisting of PEG and dipeptides, including those with PEG diacid, thiolic acid, or maleimide acid attached to the antibody; dipeptide spacers; and amide bonds to the amine of anthracycline or duocarmycin analogs, may be used. Another example is a conjugate prepared with a PEG-containing linker disulfide-linked to the cytotoxic agent and amide-linked to the antibody. Approaches incorporating PEG groups can be beneficial in overcoming aggregation and drug loading limitations.

[0452] In certain embodiments, a compound of the formula: (CO-Alk 1 -Sp 1 -Ar-Sp 2 -Alk 2 -C(Z 1 =Q-Sp)

[0033] Examples of linkers include, but are not limited to, linkers having the formula: 1 and Alk 2 are independently a bond or a branched or unbranched (C1 to C 10 ) alkylene chain; Sp 1 is a bond, --S--, --O--, --CONH--, --NHCO--, --NR'--, --N(CH2CH2)2N-- or --X--Ar--Y--(CH2) n --Z, where X, Y and Z are independently a bond, --NR'--, --S-- or --O--, provided that when n=0, at least one of Y and Z must be a bond, and Ar' is optionally (C1-C5) alkyl, (C1-C4) alkoxy, (C1-C4) thioalkoxy, halogen, nitro, --COOR', --CONHR', --(CH2) n COOR', --S(CH2) n COOR', --O(CH2) n CONHR' or --S(CH2) n CONHR′, with the proviso that when Alk′ is a bond, Sp1 is a bond; n is an integer from 0 to 5; R′ is optionally —OH, (C1-C4)alkoxy, (C1-C4)thioalkoxy, halogen, nitro, (C1-C3)dialkylamino, or (C1-C3)trialkylammonium-A - A branched or unbranched (C1-C5) chain substituted with one or two groups of -is a pharmaceutically acceptable anion completing the salt; Ar is optionally (C1-C6) alkyl, (C1-C5) alkoxy, (C1-C4) thioalkoxy, halogen, nitro, --COOR', --CONHR', --O(CH2) where n and R' are as defined hereinabove. n COOR', --S(CH2) n COOR', --O(CH2) n CONHR' or --S(CH2) n CONHR' or 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 2,3-, 2,6- or 2,7-naphthylidene or

[0453] [ka]

[0454] wherein each naphthylidene or phenothiazine optionally contains (C1-C6) alkyl, (C1-C5) alkoxy, (C1-C4) thioalkoxy, halogen, nitro, --COOR', --CONHR', --O(CH2) n COOR', --S(CH2) n COOR' or --S(CH2) n CONHR′, and n and R′ are as defined above, with the proviso that when Ar is phenothiazine, Sp 1 is the bond connected only to nitrogen; Sp 2 is a bond, --S-- or --O--, provided that Alk 2 If is a bond, Sp 2 is a bond; Z 1 is optionally (C1-C5) alkyl, (C1-C5) alkoxy, (C1-C4) thioalkoxy, halogen, nitro, --COOR', --ONHR', --O(CH2), where n and R' are as defined above. n COOR', --S(CH2) nCOOR', --O(CH2) n CONHR' or --S(CH2) n CONHR′ is H, (C1-C5) alkyl, or phenyl substituted with one, two, or three groups; Sp is a straight or branched chain divalent or trivalent (C1-C 18 ) group, divalent or trivalent aryl or heteroaryl group, divalent or trivalent (C3-C 18 ) cycloalkyl or heterocycloalkyl groups, divalent or trivalent aryl- or heteroaryl-aryl (C1-C 18 ) group, a divalent or trivalent cycloalkyl- or heterocycloalkyl-alkyl (C1-C 18 ) group or a divalent or trivalent (C2-C 18 ) unsaturated alkyl group, wherein heteroaryl is preferably furyl, thienyl, N-methylpyrrolyl, pyridinyl, N-methylimidazolyl, oxazolyl, pyrimidinyl, quinolyl, isoquinolyl, N-methylcarbazoyl, aminocoumarinyl, or phenazinyl, and when Sp is a trivalent group, Sp may be further substituted by a lower (C1-C5) dialkylamino, lower (C1-C5) alkoxy, hydroxy, or lower (C1-C5) alkylthio group; and Q is =NHNCO--, =NHNCS--, =NHNCONH--, =NHNCSNH--, or =NHO--.

[0455] In certain embodiments, Alk 1 is branched or unbranched (C1 to C 10 ) an alkylene chain; Sp' is a bond, --S--, --O--, --CONH--, --NHCO--, or --NR', where R' is as defined hereinabove, provided that when Alk' is a bond, Sp 1 is a bond; Ar is optionally (C1-C6) alkyl, (C1-C5) alkoxy, (C1-C4) thioalkoxy, halogen, nitro, --COOR', --CONHR', --O(CH2), where n and R' are as defined hereinabove. n COOR', --S(CH2) nCOOR', --O(CH2) n CONHR' or --S(CH2) n or Ar is 1,2-, 1,3-, or 1,4-phenylene substituted with one, two, or three groups selected from the group consisting of (C1-C6) alkyl, (C1-C5) alkoxy, (C1-C4) thioalkoxy, halogen, nitro, --COOR', --CONHR', --O(CH2) n COOR', --S(CH2) n COOR', --O(CH2) n CONHR' or --S(CH2) n 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 2,3-, 2,6- or 2,7-naphthylidene substituted with one, two, three or four groups selected from the group CONHR′; Z 1 is optionally (C1-C5) alkyl, (C1-C4) alkoxy, (C1-C4) thioalkoxy, halogen, nitro, --COOR', --CONHR', --O(CH2) n COOR', --S(CH2) n COOR', --O(CH2) n CONHR' or --S(CH2) n (C1-C5) alkyl or phenyl substituted with one, two or three groups selected from the group consisting of CONHR'; Alk 2 and Sp 2 are both bonds; Sp and Q are as defined above.

[0456] U.S. Patent No. 5,773,001, incorporated herein by reference for the linkers and linking methods described herein, discloses linkers that can be used with nucleophiles, particularly hydrazides prepared from calicheamicin and related nucleophiles. These linkers are particularly useful when better activity is obtained when the linkage formed between the drug and the linker is hydrolyzable. These linkers contain two functional groups, including (1) a group for reaction with an antibody (e.g., a carboxylic acid) and (2) a carbonyl group (e.g., an aldehyde or ketone) for reaction with the drug. The carbonyl group can react with the hydrazide group on the drug to form a hydrazone linkage. This linkage is cleavable and hydrolyzable, allowing for release of the therapeutic agent from the conjugate after binding to target cells.

[0457] In certain embodiments, N-hydroxysuccinimide (OSu) esters or other relatively activated esters can be used to generate activated hydrolyzable linker-drug moieties. Examples of other suitable activated esters include, but are not limited to, NHS (N-hydroxysuccinimide), sulfo-NHS (sulfonated NHS), PFP (pentafluorophenyl), TFP (tetrafluorophenyl), and DNP (dinitrophenyl).

[0458] In certain embodiments, the linker is a hydrolyzable linker, such as maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (MC-vc-PAB-MMAE) or 4-(4-acetylphenoxy)butanoic acid (AcBut). In certain embodiments, the linker is a non-hydrolyzable linker, such as maleimidocaproyl (MC-MMAF). In certain exemplary, but non-limiting, embodiments, antibody-drug conjugates can be prepared using, for example, (3-acetylphenyl)acetic acid (AcPAc) or 4-mercapto-4-methyl-pentanoic acid (Amide) as linker molecules.

[0459] In certain embodiments, the linker may be a dipeptide linker, such as valine-citrulline (val-cit), phenylalanine-lysine (phe-lys) linker, or maleimidocaproic-valine-citrulline-p-aminobenzyloxycarbonyl (vc) linker; a tripeptide linker, such as GGG; a tetrapeptide linker, such as GGGG (SEQ ID NO: 71); or a pentapeptide linker, such as GGGGS (SEQ ID NO: 72). In certain embodiments, the linker is sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate (smcc). Sulfo-smcc conjugation occurs via the maleimide group, which reacts with sulfhydryls (thiols, --SH), while its sulfo-NHS ester is reactive toward primary amines (such as those found at lysines and the N-termini of proteins or peptides). Additionally, in certain embodiments, the linker may be maleimidocaproyl (mc).

[0460] The above linkers are exemplary and not limiting. In light of the many methods that have been reported for attaching various radiodiagnostic compounds, radiotherapeutic compounds, drugs, toxins, and other agents to antibodies, one skilled in the art can determine a suitable method for attaching a given agent to an antibody or other polypeptide.

[0461] Conjugated encapsulation systems. In various embodiments, the therapeutic agent is chemically conjugated to the antibody, e.g., as described above, while in other embodiments, the effector may comprise an encapsulation system, e.g., a viral capsid, liposome, or micelle, containing a therapeutic composition, e.g., a drug, a nucleic acid (e.g., antisense nucleic acid and RNAi or another nucleic acid to be delivered to a cell), or another therapeutic moiety that is preferably shielded from direct exposure to the circulatory system. Means for preparing liposomes bound to antibodies are well known to those skilled in the art (see, e.g., U.S. Pat. No. 4,957,735; Connor et al. (1985), Pharm. Ther., 28, 341-365, etc.).

[0462] Chelate conjugation. In certain embodiments, the effector comprises a chelate bound to an antibody or to an epitope tag. Because anti-ALPP / ALPPL2 antibodies have a corresponding epitope tag or antibody, simple contact of the antibody with the chelate results in binding of the antibody to the effector. A combination step may be performed before the moiety is used (targeting strategy), or the target tissue may be bound to the antibody before the chelate is delivered. Methods for generating chelates suitable for coupling to various targeting moieties are well known to those skilled in the art (e.g., U.S. Patent Nos. 6,190,923, 6,187,285, 6,183,721, 6,177,562, 6,159,445, 6,153,775, 6,149,890, 6,143,276). No. 6,143,274, No. 6,139,819, No. 6,132,764, No. 6,123,923, No. 6,123,921, No. 6,120,76 No. 8, No. 6,120,751, No. 6,117,412, No. 6,106,866, No. 6,096,290, No. 6,093,382, No. 6,090,80 No. 0, No. 6,090,408, No. 6,088,613, No. 6,077,499, No. 6,075,010, No. 6,071,494, No. 6,071,4 No. 90, No. 6,060,040, No. 6,056,939, No. 6,051,207, No. 6,048,979, No. 6,045,821, No. 6,045,7 (See Nos. 75, 6,030,840, 6,028,066, 6,022,966, 6,022,523, 6,022,522, 6,017,522, 6,015,897, 6,010,682, 6,010,681, 6,004,533 and 6,001,329).

[0463] Representative linkers useful for conjugation of radioisotopes include, but are not limited to, diethylenetriamine pentaacetate (DTPA)-isothiocyanate, succinimidyl 6-hydrazinium nicotinate hydrochloride (SHNH), and hexamethylpropylene amine oxime (HMPAO) (see, e.g., Bakker et al. (1990), J. Nucl. Med. 31, 1501-1509; Chattopadhyay et al. (2001), Nucl. Med. Biol. 28, 741-744; Dewanjee et al. (1994), J. Nucl. Med. 35, 1054-63; Krenning et al. (1989), Lancet 1, pp. 242-244; Sagiuchi et al. (2001), Ann. Nucl. Med. 15, pp. 267-270; U.S. Patent No. 6,024,938). Alternatively, in certain embodiments, antibodies can be derivatized so that radioisotopes can be directly attached thereto (see, e.g., Yoo et al. (1997), J. Nucl. Med. 38, pp. 294-300). Iodination methods are also known in the art, and representative protocols can be found, for example, in Krenning et al. (1989), Lancet 1, pp. 242-244, and Bakker et al. (1990), J. Nucl. Med. 31, pp. 1501-1509.

[0464] Generation of fusion proteins. If the antibody and / or effector are relatively short (e.g., less than about 50 amino acids), they can be synthesized using standard chemical peptide synthesis techniques. If both molecules are relatively short, the chimeric molecule can be synthesized as a single contiguous polypeptide. Alternatively, the targeting molecule and the effector molecule can be synthesized separately and then fused by condensation of the amino terminus of one molecule with the carboxyl terminus of the other, thereby forming a peptide bond. Alternatively, the targeting molecule and the effector molecule can each be condensed with one end of a peptide spacer molecule, thereby forming a contiguous fusion protein.

[0465] Solid-phase synthesis, in which the C-terminal amino acid of the sequence is attached to an insoluble support followed by sequential addition of the remaining amino acids in the sequence, is a preferred method for chemically synthesizing the polypeptides of the invention. The technique of solid-phase synthesis is described by Barany and Merrifield, Solid-Phase Peptide Synthesis, pp. 3-284, in The Peptides: Analysis, Synthesis, Biology., Vol. 2, Special Methods in Peptide Synthesis, Part A; Merrifield et al., J. Am. Chem. Soc., 85, pp. 2149-2156 (1963); and Stewart et al., Solid Phase Peptide Synthesis, 2nd ed., Pierce Chem. Co., Rockford, Ill. (1984).

[0466] In certain embodiments, the chimeric fusion proteins of the invention are synthesized using recombinant DNA methodology. Generally, this involves creating a DNA sequence encoding the fusion protein, placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein in a host, isolating the expressed protein, and optionally refolding the protein.

[0467] DNA encoding the fusion proteins of the invention can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences, or by direct chemical synthesis by methods such as the phosphotriester method of Narang et al. (1979), Meth. Enzymol. 68, 90-99; the phosphodiester method of Brown et al. (1979), Meth. Enzymol. 68, 109-151; the diethylphosphoramidite method of Beaucage et al. (1981), Tetra. Lett., 22, 1859-1862; and the solid-support method of U.S. Pat. No. 4,458,066.

[0468] Chemical synthesis produces single-stranded oligonucleotides, which can be converted into double-stranded DNA by hybridization with a complementary sequence or by polymerization with a DNA polymerase using the single strand as a template. Those skilled in the art will recognize that chemical synthesis of DNA is limited to sequences of about 100 bases, but longer sequences can be obtained by ligating shorter sequences.

[0469] Alternatively, in certain embodiments, sequences can be cloned and the appropriate sequences can be cleaved using appropriate restriction enzymes. The fragments can then be ligated to generate the desired DNA sequence.

[0470] In certain embodiments, DNA encoding the fusion proteins of the invention can be cloned using PCR cloning methods.

[0471] While the antibody and effector are, in certain embodiments, essentially directly linked together, one of skill in the art will understand that the molecules can be separated by a spacer, such as a peptide spacer consisting of one or more amino acids (e.g., (Gly4Ser)3, SEQ ID NO: 73). Generally, the spacer has no specific biological activity other than to connect the proteins or to preserve some minimum distance or other spatial relationship between them. However, the component amino acids of the spacer can be selected to affect certain properties of the molecule, such as folding, net charge, or hydrophobicity.

[0472] Nucleic acid sequences encoding fusion proteins can be expressed in a variety of host cells, including E. coli, other bacterial hosts, yeast, and various higher eukaryotic cells, such as COS, CHO, and HeLa cell lines and myeloma cell lines. The recombinant protein gene is operably linked to expression control sequences appropriate for each host.

[0473] The plasmids of the invention can be transferred to selected host cells by well-known methods, such as calcium chloride transformation of E. coli and calcium phosphate treatment or electroporation of mammalian cells. Cells transformed with the plasmids can be selected by resistance to antibiotics conferred by genes contained on the plasmids, such as the amp, gpt, neo, and hyg genes.

[0474] Once expressed, the recombinant fusion protein can be purified according to standard techniques in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis, and the like (see generally R. Scopes (1982), Protein Purification, Springer-Verlag, NY; Deutscher (1990), Methods in Enzymology, Vol. 182, Guide to Protein Purification, Academic Press, Inc., NY). Substantially pure compositions of at least about 90-95% homogeneity are preferred, with 98-99% or greater homogeneity being most preferred for pharmaceutical uses. Once the polypeptide has been purified, partially or to homogeneity as desired, it can then be used as a therapeutic.

[0475] Those skilled in the art will recognize that after chemical synthesis, biological expression, or purification, a fusion protein may have a conformation that is substantially different from the native conformations of the component polypeptides. In this case, it may be necessary to denature and reduce the polypeptide and then allow it to refold into the preferred conformation. Methods for reducing and denaturing proteins and inducing refolding are well known to those skilled in the art (see, e.g., Debinski et al. (1993), J. Biol. Chem., 268, 14065-14070; Kreitman and Pastan (1993), Bioconjug. Chem., 4, 581-585; and Buchner et al. (1992), Anal. Biochem., 205, 263-270).

[0476] Those skilled in the art will recognize that modifications can be made to fusion proteins without reducing the biological activity of the fusion protein. Some modifications may be made to facilitate the cloning, expression, or incorporation of a targeting molecule into the fusion protein. Such modifications are well known to those skilled in the art and include, for example, a methionine added to the amino terminus to provide a start site, or additional amino acids placed on either end to create conveniently located restriction enzyme sites or stop codons.

[0477] Pharmaceutical Composition Anti-ALPP / ALPPL2 antibodies described herein (e.g., M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M2530 The compounds of the present invention (e.g., 18IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF) and / or immunoconjugates thereof are useful for parenteral, topical, oral, or local (e.g., injected at the tumor site), aerosol, or transdermal administration for prophylactic, but primarily for therapeutic, treatment. The pharmaceutical compositions can be administered in various unit dosage forms depending on the method of administration. For example, unit dosage forms suitable for oral administration include powders, tablets, pills, capsules, and lozenges. It will be appreciated that the antibodies and / or immunoconjugates thereof described herein and pharmaceutical compositions comprising the antibodies and / or immunoconjugates thereof described herein are preferably protected from digestion when administered orally. This can be achieved by several means known to those skilled in the art, such as by complexing the protein with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the protein in a suitable resistant carrier, such as a liposome. Means for protecting proteins from digestion are well known in the art.

[0478] In various embodiments, compositions, e.g., pharmaceutical compositions, are provided that contain one or a combination of anti-ALPP / ALPPL2 antibodies or antigen-binding portions thereof, or immunoconjugates thereof, formulated together with a pharmaceutically acceptable carrier.

[0479] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal, or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound, i.e., antibody, immunoconjugate, may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

[0480] In certain embodiments, antibodies and / or immunoconjugates can be administered in "native" form or, if desired, in the form of salts, esters, amides, prodrugs, derivatives, etc., provided that the salts, esters, amides, prodrugs, or derivatives are pharmacologically suitable, i.e., effective in the present methods. Salts, esters, amides, prodrugs, and other derivatives of active agents are known to those skilled in the art of synthetic organic chemistry and can be prepared using standard techniques as described, for example, in March (1992), Advanced Organic Chemistry; Reactions, Mechanisms, and Structure, 4th Edition, Wiley-Interscience, NY, and as described above.

[0481] By way of example, pharmaceutically acceptable salts can be prepared for any of the antibodies and / or immunoconjugates described herein that have functionality capable of forming salts. A pharmaceutically acceptable salt is any salt that retains the activity of the parent compound and does not impart any deleterious or untoward effects to or in connection with the subject to which it is administered.

[0482] In various embodiments, pharmaceutically acceptable salts can be derived from organic or inorganic bases. Salts can be monovalent or polyvalent ions. The inorganic ions lithium, sodium, potassium, calcium, and magnesium are of particular interest. Organic salts can be made with amines, particularly ammonium salts, such as mono-, di-, and trialkylamines or ethanolamines. Salts can also be formed with caffeine, tromethamine, and similar molecules.

[0483] Methods for formulating pharmaceutically active agents as salts, esters, amides, prodrugs, and the like are well known to those skilled in the art. For example, salts can be prepared from the free base using conventional methods, typically involving reaction with a suitable acid. Generally, the base form of the drug is dissolved in a polar organic solvent, such as methanol or ethanol, and an acid is added thereto. The resulting salt precipitates or can be brought out of solution by adding a less polar solvent. Suitable acids for preparing acid addition salts include, but are not limited to, both organic acids, such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, and inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Acid addition salts can be reconverted to the free base by treatment with a suitable base. Certain particularly preferred acid addition salts of the active agents herein include halogen salts, such as may be prepared using hydrochloric acid or hydrobromic acid. Conversely, base salts of the active agents of the present invention are prepared in a similar manner using pharmaceutically acceptable bases, such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine, etc. Particularly preferred base salts include alkali metal salts, such as sodium and copper salts.

[0484] For the preparation of salt forms of basic drugs, the pKa of the counterion is preferably at least about 2 pH units lower than the pKa of the drug. Similarly, for the preparation of salt forms of acidic drugs, the pKa of the counterion is preferably at least about 2 pH units higher than the pKa of the drug. This means that the counterion will drive the pH of the solution to pH 0 so as to reach a salt steady state where the solubility of the salt dominates that of the free acid or base. max This allows for lower levels. The general rule of difference in pKa units of ionizable groups in the active pharmaceutical ingredient (API) and in the acid or base means that proton transfer is energetically favorable. If the pKa of the API and counterion are not significantly different, a solid complex may form in an aqueous environment but may quickly become disequilibrium (i.e., disintegrate into individual entities of drug and counterion).

[0485] Preferably, the counterion is a pharmaceutically acceptable counterion. Suitable anionic salt forms include, but are not limited to, acetate, benzoate, benzilate, bitartrate, bromide, carbonate, chloride, citrate, edetate, edisylate, estolate, fumarate, gluceptate, gluconate, hydrobromide, hydrochloride, iodide, lactate, lactobionate, malate, maleate, mandelate, mesylate, methyl bromide, methyl sulfate, mucate, napsylate, nitrate, pamoate (embonate), phosphate and diphosphate, salicylate and disalicylate, stearate, succinate, sulfate, tartrate, tosylate, triethiodide, valerate, and the like; suitable cationic salt forms include, but are not limited to, aluminum, benzathine, calcium, ethylenediamine, lysine, magnesium, meglumine, potassium, procaine, sodium, tromethamine, zinc, and the like.

[0486] Preparation of esters typically involves functionalization of hydroxyl and / or carboxyl groups present within the molecular structure of the antibody and / or immunoconjugate. In certain embodiments, the esters are typically acyl-substituted derivatives of free alcohol groups, i.e., moieties derived from carboxylic acids of the formula RCOOH, where R is alkyl, preferably lower alkyl. Esters can be reconverted to the free acids, if desired, using conventional hydrogenolysis or hydrolysis techniques.

[0487] Amides can also be prepared using techniques known to those skilled in the art or described in the pertinent literature. For example, amides may be prepared from esters, using suitable amine reactants, or they may be prepared from anhydrides or acid chlorides by reaction with ammonia or a lower alkyl amine.

[0488] Pharmaceutical compositions comprising the antibodies and / or immunoconjugates described herein can be administered alone or in combination therapy, i.e., in combination with other agents. For example, the combination therapy can include an antibody or immunoconjugate with at least one or more additional therapeutic agents, such as an anti-cancer agent described below. Pharmaceutical compositions can also be administered in conjunction with radiation therapy and / or surgery.

[0489] Compositions containing the antibodies and / or immunoconjugates described herein can be administered by a variety of methods known in the art. As one of skill in the art will appreciate, the route and / or mode of administration will vary depending on the desired results. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as controlled-release formulations, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art (see, e.g., Sustained and Controlled Release Drug Delivery Systems, edited by JR Robinson, Marcel Dekker, Inc., New York, 1978).

[0490] In certain embodiments, administration of an anti-ALPP / ALPPL2 antibody or immunoconjugate can be facilitated by coating the antibody or immunoconjugate composition or co-administering the antibody or immunoconjugate with a material that prevents its inactivation. For example, the compound can be administered to a subject in an appropriate carrier, such as a liposome or diluent. Pharmaceutically acceptable diluents include, but are not limited to, saline and aqueous buffer solutions. Liposomes include, but are not limited to, water-in-oil-in-water CGF emulsions and conventional liposomes (Strejan et al. (1984), J. Neuroimmunol, 7, 27).

[0491] Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.The use of such media and agents for pharmaceutically active substances is well known in the art.Except insofar as any conventional media or agent is incompatible with the active compound, its use in the pharmaceutical composition is contemplated.In addition, auxiliary active compounds may be incorporated into the composition.

[0492] In various embodiments, therapeutic compositions are typically sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as solutions, microemulsions, in lipids or liposomes, or other defined structures suitable for containing high drug concentrations. In certain embodiments, the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. It is often preferable to include isotonic agents, such as sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride, in the compositions. Prolonged absorption of injectable compositions can be achieved by including in the composition agents that delay absorption, such as monostearate salts and gelatin.

[0493] Sterile injectable solutions can be prepared by incorporating the required amount of active compound (e.g., antibody and / or immunoconjugate described herein) in an appropriate solvent, optionally with one or a combination of the ingredients listed above, followed by sterile microfiltration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and the required other ingredients listed above. In the case of sterile powders for the preparation of sterile injectable solutions, exemplary preparation methods include vacuum drying and freeze-drying (lyophilization), which produce a powder of the active ingredient and any additional desired ingredients from a previously sterile-filtered solution of these ingredients.

[0494] Dosage regimens are adjusted to provide the optimum desired response (e.g., therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. For example, in certain embodiments, the antibodies and / or immunoconjugates described herein may be administered by subcutaneous injection once or twice daily, or once or twice weekly, or once or twice monthly.

[0495] It is particularly advantageous to formulate parenteral compositions into unit dosage forms for ease of administration and uniformity of dosage. As used herein, unit dosage form refers to physically discrete units adapted as unitary dosages for the subjects to be treated. Each unit contains a predetermined amount of active compound calculated to produce the desired therapeutic effect, together with the required pharmaceutical carrier. The specifications for the unit dosage form are determined by and directly depend on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such active compounds for the treatment of individuals.

[0496] In certain embodiments, the formulation comprises a pharmaceutical antioxidant. Examples of pharmaceutically acceptable antioxidants include (1) water-soluble antioxidants, such as ascorbic acid, cysteine ​​hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, etc.; and (3) metal chelators, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.

[0497] For therapeutic compositions, formulations of antibodies and / or immunoconjugates described herein include formulations suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, and / or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any method known in the art of pharmacy. The amount of active ingredient that may be combined with a carrier material to produce a single dosage form will vary depending on the subject treated and the particular mode of administration. The amount of active ingredient that may be combined with a carrier material to produce a single dosage form will generally be that amount of the composition that produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.001 percent to about 90 percent of active ingredient, preferably from about 0.005 percent to about 70 percent, and most preferably from about 0.01 percent to about 30 percent.

[0498] Formulations of the antibodies and / or immunoconjugates described herein that are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams, or spray formulations containing carriers known in the art to be appropriate. Dosage forms for topical or transdermal administration of the antibodies and / or immunoconjugates described herein include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In certain embodiments, the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.

[0499] As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0500] Examples of suitable aqueous and non-aqueous carriers that may be used in pharmaceutical compositions comprising the antibodies and / or immunoconjugates described herein include, but are not limited to, water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate, etc. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0501] In various embodiments, these compositions may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Specific examples of adjuvants known in the art include, for example, inorganic adjuvants (e.g., aluminum salts, such as aluminum phosphate and aluminum hydroxide), organic adjuvants (e.g., squalene), oil-based adjuvants, and virosomes (e.g., virosomes containing membrane-bound hemagglutinin and neuraminidase from influenza virus).

[0502] Prevention of presence of microorganisms in a formulation may be ensured both by sterilization techniques and / or the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, etc. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, etc. in the compositions. Additionally, prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption, for example, aluminum monostearate and gelatin.

[0503] When the antibodies and / or immunoconjugates described herein are administered pharmaceutical to humans and animals, they can be given alone or in combination with a pharmaceutically acceptable carrier as a pharmaceutical composition containing, for example, 0.001 to 90% (more preferably 0.005 to 70%, e.g., 0.01 to 30%) of the active ingredient.

[0504] Regardless of the route of administration selected, the antibodies and / or immunoconjugates described herein, which may be used in suitable hydrated forms and / or pharmaceutical compositions, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.

[0505] The actual dosage level of the active ingredient (e.g., an antibody and / or immunoconjugate described herein) in the pharmaceutical composition of the present invention may be varied to obtain an amount of the active ingredient effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration without being toxic to the patient. The selected dosage level will depend on various pharmacokinetic factors, including the activity of the particular composition of the present invention or its ester, salt, or amide used, the route of administration, the time of administration, the rate of excretion of the particular compound used, the duration of treatment, other drugs, compounds, and / or materials used in combination with the particular composition used, the age, sex, weight, condition, general health, and previous medical history of the patient being treated, and factors well known in the pharmaceutical arts. A physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, a physician or veterinarian may start doses of the compound of the present invention used in the pharmaceutical composition at a level lower than required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. Generally, a suitable daily dose of the antibody and / or immunoconjugate described herein is that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such effective doses will generally depend on the factors described above. In certain embodiments, administration is intravenous, intramuscular, intraperitoneal, or subcutaneous, preferably administered proximal to the target site. If desired, an effective daily dose of a therapeutic composition may be administered as a single dose or as two, three, four, five, six, or more subdoses administered separately at appropriate intervals throughout the day, optionally in unit dosage form. While it is possible to administer the antibodies and / or immunoconjugates described herein alone, it is typically preferred to administer the compounds as a pharmaceutical formulation (composition).

[0506] In certain embodiments, therapeutic compositions can be administered with medical devices known in the art. For example, in exemplary embodiments, the antibodies and / or immunoconjugates described herein can be administered with a needleless hypodermic injection device, such as those disclosed in U.S. Patent Nos. 5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824, or 4,596,556. Examples of useful well-known implants and modules are described, for example, in U.S. Patent No. 4,487,603, which discloses an implantable microinfusion pump for dispersing drugs at a controlled rate, U.S. Patent No. 4,486,194, which discloses a therapeutic device for administering drugs through the skin, U.S. Patent No. 4,447,233, which discloses an infusion pump for delivering drugs at a precise infusion rate, U.S. Patent No. 4,447,224, which discloses a variable flow rate implantable infusion device for continuous drug delivery, U.S. Patent No. 4,439,196, which discloses an osmotic drug delivery system having multiple chamber compartments, and U.S. Patent No. 4,475,196, which discloses an osmotic drug delivery system. Many other such implants, delivery systems, and modules are known to those skilled in the art.

[0507] In certain embodiments, the anti-ALPP / ALPPL2 antibodies and / or immunoconjugates described herein can be formulated to ensure proper distribution in vivo. For example, the blood-brain barrier (BBB) ​​excludes many highly hydrophilic compounds. To ensure that the therapeutic compounds of the present invention cross the BBB (if desired), they can be formulated, for example, in liposomes. For methods of manufacturing liposomes, see, e.g., U.S. Patent Nos. 4,522,811, 5,374,548, and 5,399,331. Liposomes can contain one or more moieties that are selectively transported to specific cells or organs, thus improving targeted drug delivery (see, e.g., Ranade (1989), J. Clin. Pharmacol. 29, 685). Exemplary targeting moieties include, but are not limited to, folate or biotin (see, e.g., U.S. Pat. No. 5,416,016); mannosides (Umezawa et al. (1988), Biochem. Biophys. Res. Commun. 153, 1038); antibodies (Bloeman et al. (1995), FEBS Lett. 357, 140; Owais et al. (1995), Antimicrob. Agents Chemother. 39, 180); surfactant protein A receptor (Briscoe et al. (1995), Am. J. Physiol. 1233, 134).

[0508] kit. When radioactive or other effectors are used as diagnostic and / or therapeutic agents, it is often not possible to have a ready-to-use composition at the user's disposal due to the often poor shelf life of radiolabeled compounds and / or the short half-life of the radionuclides used. In such cases, the user can carry out the labeling reaction with the radionuclide in a hospital, doctor's office, or laboratory. For this or other purposes, the various reaction components can then be provided to the user in the form of a so-called "kit." The kit is preferably designed so that the operations required to carry out the desired reaction should be as simple as possible, so that the user can prepare the desired composition from the kit using the facilities at their disposal. Therefore, the present invention also relates to a kit for preparing the composition according to the present invention.

[0509] In certain embodiments, such kits comprise one or more antibodies or immunoconjugates described herein. The antibodies or immunoconjugates may be provided, if desired, with the addition of inert pharmaceutically acceptable carriers and / or compounding and / or adjuvants. In addition, the kits optionally contain a solution of a suitable radionuclide (or other active agent) salt or chelate, and (iii) instructions for use with recipes for administering and / or reacting the components present in the kit.

[0510] Alternatively, the kit supplied to the user may contain the components as defined above together with instructions for use, but the solution of a salt or chelate of a radionuclide as defined in subparagraph (ii) above, which solution has a limited shelf life, may be placed at the user's disposal separately.

[0511] The kit may optionally additionally contain a reducing agent and / or, if desired, a chelator and / or instructions for use of the composition and / or a formula for reacting the kit components to form the desired product. If desired, the kit components may be mixed, so long as they are compatible.

[0512] In certain embodiments, immunoconjugates can be produced by simply mixing the components in a neutral medium and allowing them to react, for which purpose the effector can be presented to the antibody, for example, in the form of a chelate.

[0513] When the kit components are used as components for pharmaceutical administration (e.g., as injection solutions), they are preferably sterile. If the components are provided in a dry state, the user should preferably use sterile physiological saline as the solvent. If desired, the components can be stabilized in a conventional manner with suitable stabilizers, such as ascorbic acid, gentisic acid, or salts of these acids, or they can contain other auxiliary agents, such as fillers, for example, glucose, lactose, mannitol, etc.

[0514] The instructional materials, if present, typically comprise written or printed materials, but are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by the present invention. Such media include, but are not limited to, electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.

[0515] Chimeric antigen receptor (CAR) constructs and therapies In certain embodiments, the antibodies described herein can be used in the creation of constructs / cells for CAR-T cell therapy, a cellular immunotherapy that involves the administration to a mammal (e.g., a cancer patient) of genetically engineered cells (e.g., T cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, etc.) that express a chimeric antigen receptor (CAR) and act on tumor cells (which interact with the CAR), resulting in apoptosis of the tumor cells.

[0516] Typically, genetically engineered cells are prepared by expressing CARs (carriers) containing antibody variable domains (VL and VH) combined with the CD3 chain (intracellular domain) on cells (e.g., T cells) using gene transfer techniques. CAR is a general term for chimeric proteins in which the light chain (VL) and heavy chain (VH) of the variable domains of a monoclonal antibody specific for a tumor antigen (e.g., the anti-ALPP / ALPPL2 antibody described herein) are linked in tandem, followed by a T cell receptor (TCR) chain at the C-terminus. Further details of CAR-T cell therapy are described, inter alia, by Nakazawa et al. (2013), Shinshu Med. J. 61(4), pp. 197-203.

[0517] In certain embodiments, the chimeric antigen receptor (CAR) comprises an extracellular and an intracellular domain. The extracellular domain is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018 In various embodiments, the target-specific binding element comprises an anti-ALPP / ALPPL2 antibody.

[0518] In various embodiments, the intracellular or otherwise cytoplasmic domain comprises one or more costimulatory signal regions, and in various embodiments, a zeta chain portion. A costimulatory signal region refers to a portion of a CAR that comprises the intracellular domain of a costimulatory molecule. In various embodiments, a costimulatory molecule is a cell surface molecule, other than an antigen receptor or its ligand, that is required for an efficient response of lymphocytes to antigens.

[0519] A spacer domain can be incorporated between the extracellular and transmembrane domains of a CAR, or between the cytoplasmic and transmembrane domains of a CAR. As used herein, the term "spacer domain" generally refers to any oligopeptide or polypeptide that functions to link a transmembrane domain to either the extracellular or cytoplasmic domain in a polypeptide chain. In various embodiments, a spacer domain can comprise up to 300 amino acids, or in various embodiments, from about 10 to about 100 amino acids, and in certain embodiments, from about 25 to about 50 amino acids.

[0520] CAR antigen binding portion In various embodiments, the chimeric antigen receptor construct is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M and / or M25ALIA, M25ALLF, M25wtIA and / or M25wtLF antibodies. In certain embodiments, the target-specific binding element is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, Comprises a binding domain from the M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA and / or M25wtLF antibodies.In certain embodiments, the target-specific binding element is M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHS RLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA and / or M25wtLF antibodies.

[0521] Transmembrane domain Regarding the transmembrane domain, the CAR can be designed to include a transmembrane domain fused to the extracellular domain of the CAR. In one embodiment, a transmembrane domain that is naturally associated with one of the domains of the CAR is used. In some cases, the transmembrane domain may be selected or modified by amino acid substitution to avoid binding of such domain to the transmembrane domain of the same or a different surface membrane protein, in order to minimize interaction with other members of the receptor complex.

[0522] In various embodiments, the transmembrane domain may be derived from a natural or synthetic source. If the source is natural, the domain may be derived from any membrane-bound or transmembrane protein. Illustrative, but non-limiting, examples of transmembrane regions of particular use in the CAR constructs contemplated herein may be derived from the alpha, beta, or zeta chains of the T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154. Alternatively, the transmembrane domain may be synthetic, in which case it may comprise primarily hydrophobic residues, such as leucine and valine. In certain embodiments, the amino acid triplet of phenylalanine, tryptophan, and valine is found at each end of a synthetic transmembrane domain. Optionally, a short oligopeptide or polypeptide linker, e.g., 2 to about 10 amino acids in length, can form the link between the transmembrane domain and the cytoplasmic signaling domain of the CAR. In certain embodiments, a glycine-serine duopolypeptide provides a particularly suitable linker.

[0523] In certain embodiments, the transmembrane domain of the CAR comprises a CD8 transmembrane domain. In one exemplary, but non-limiting, embodiment, the CD8 transmembrane domain comprises or consists of the amino acid sequence IleTrpAlaProLeuAlaGlyThrCysGlyValLeuLeuLeuSerLeuValIleThrLeuTyrCys (SEQ ID NO: 74). In certain exemplary, but non-limiting, embodiments, the CD8 transmembrane domain can be encoded by the nucleic acid sequence ATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTTGGTTATCACCCTTTACTGC (SEQ ID NO: 75).

[0524] In certain embodiments, the transmembrane domain of the CAR may comprise or consist of a CD8α hinge domain. In one exemplary, but non-limiting embodiment, the CD8α hinge domain comprises or consists of the amino acid sequence Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Glyl Ala Val Hhis Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr (SEQ ID NO: 76). In certain exemplary, but non-limiting, embodiments, the CD8α hinge domain can be encoded by the nucleic acid sequence ACCACGACGC CAGCGCCGCG ACCACCAACA CCGGCGCCCA CCATCGCGTC GCAGCCCCTG TCCCTGCGCC CAGAGGCGTG CCGGCCAGCG GCGGGGGGCG CAGTGCACAC GAGGGGGCTG GACTTCGCCT GTGAT (SEQ ID NO: 77).

[0525] Cytoplasmic domain The cytoplasmic domain or otherwise intracellular signaling domain of a CAR is responsible for activating at least one of the normal effector functions of an immune cell into which the CAR is inserted. The term "effector function" refers to a specialized function of a cell. For example, the effector function of a T cell can be cytolytic activity or helper activity, including cytokine secretion. Thus, the term "intracellular signaling domain" refers to a portion of a protein that transmits an effector function signal and causes the cell to perform a specialized function. Typically, the entire intracellular signaling domain can be used, but in many cases, it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such a truncated portion can be used in place of the intact chain, as long as it transmits the effector function signal. The term intracellular signaling domain is therefore meant to include any truncated portion of the intracellular signaling domain sufficient to transmit the effector function signal.

[0526] Illustrative, but non-limiting examples of intracellular signaling domains for use in CARs can include the cytoplasmic sequences of T cell receptors (TCRs) and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement, as well as any derivatives or variants of these sequences and any synthetic sequences that have the same function.

[0527] It is known that signals generated through the TCR alone are often insufficient for full activation of T cells and that secondary or costimulatory signals are also required. Thus, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signal sequences: those that initiate antigen-dependent primary activation through the TCR (primary cytoplasmic signal sequences) and those that act in an antigen-independent manner to provide secondary or costimulatory signals (secondary cytoplasmic signal sequences).

[0528] Primary cytoplasmic signal sequences regulate the primary activation of the TCR complex in either a stimulatory or inhibitory manner. Primary cytoplasmic signal sequences that act in a stimulatory manner may contain signal motifs known as immunoreceptor tyrosine-based activation motifs, or ITAMs.

[0529] Illustrative, but non-limiting, examples of ITAMs containing primary cytoplasmic signal sequences that are of particular use in the CARs contemplated herein include those derived from TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d. It is particularly preferred that the cytoplasmic signal molecule in the CAR of the invention comprises a cytoplasmic signal sequence derived from CD3 zeta.

[0530] In one exemplary, but non-limiting, embodiment, the cytoplasmic domain of a CAR may be designed to include a CD3 zeta signal domain by itself or may be combined with any other desired cytoplasmic domain useful in the context of a CAR. For example, the cytoplasmic domain of a CAR may include a CD3 zeta chain portion and a costimulatory signal region. A costimulatory signal region refers to a portion of a CAR that includes the intracellular domain of a costimulatory molecule. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for efficient lymphocyte response to antigens. Examples of such molecules include, but are not limited to, CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83. In one exemplary embodiment, the costimulatory signal element includes 4-1BB.

[0531] The cytoplasmic signal sequences within the cytoplasmic signal portion of the CAR can be linked to each other in a random order or in a specific order. Optionally, a short oligopeptide or polypeptide linker, e.g., 2 to about 10 amino acids in length, can form the linkage. In certain embodiments, a glycine-serine duopolypeptide provides a particularly suitable linker.

[0532] In one exemplary, but non-limiting embodiment, the cytoplasmic domain is designed to include the signaling domain of CD3 zeta and the signaling domain of CD28. In another embodiment, the cytoplasmic domain is designed to include the signaling domain of CD3 zeta and the signaling domain of 4-1BB. In yet another embodiment, the cytoplasmic domain is designed to include the signaling domain of CD3 zeta and the signaling domains of CD28 and 4-1BB.

[0533] In one embodiment, the cytoplasmic domain of the CAR of the invention is designed to comprise the signal domain of 4-1BB and the signal domain of CD3 zeta, wherein the signal domain of 4-1BB comprises or consists of the amino acid sequence Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly gly cys Glu Leu (SEQ ID NO: 78), and / or the signal domain of CD3 zeta comprises or consists of the amino acid sequence Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly ARg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys The amino acid sequence of the amino acid sequence of the present invention is Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg (SEQ ID NO: 79).

[0534] In one exemplary, but non-limiting embodiment, the signal domain of 4-1BB is encoded by a nucleic acid sequence comprising or consisting of the sequence AAACGGGGCA GAAAGAAACT CCTGTATATA TTCAAACAAC CATTTATGAG ACCAGTACAA ACTACTCAAG AGGAAGATGG CTGTAGCTGC CGATTTCCAG AAGAAGAAGA AGGAGGATGT GAACTG (SEQ ID NO: 80). In one exemplary, but non-limiting embodiment, the signal domain of CD3 zeta is encoded by a nucleic acid comprising or consisting of the sequence AGAGTGAAGT TCAGCAGGAG CGCAGACGCC CCCGCGTACA AGCAGGGCCA GAACCAGCTC TATAACGAGC TCAATCTAGG ACGAAGAGAG GAGTACGATG TTTTGGACAA GAGACGTGGC CGGGACCCTG AGATGGGGGG AAAGCCGAGA AGGAAGAACC CTCAGGAAGG CCTGTACAAT GAACTGCAGA AAGATAAGAT GGCGGAGGCC TACAGTGAGA TTGGGATGAA AGGCGAGCGC (SEQ ID NO: 81).

[0535] The above embodiments are illustrative and non-limiting. Using the teachings provided herein, many CARs directed against ALPPP and / or ALPPL2 are available to those skilled in the art.

[0536] vector In various embodiments, a DNA construct is provided that comprises the sequence of a CAR described herein. In certain embodiments, the CAR is selected from the group consisting of antibodies M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018L The CAR of the present invention comprises an antigen-binding portion that specifically binds to ALPP bound by F, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF, and / or to ALPPL2, and / or to a domain of ALPP and / or ALPPL2, wherein the nucleic acid sequence of the antigen-binding portion is operably linked to the nucleic acid sequence of the intracellular domain. Exemplary intracellular domains that can be used in the CAR of the present invention include, but are not limited to, intracellular domains such as CD3 zeta, CD28, 4-1BB, etc. In some cases, the CAR may include any combination of CD3 zeta, CD28, 4-1BB, etc.

[0537] In one embodiment, a CAR of the invention comprises an anti-ALPP / ALPPL2 scFv (e.g., M25AD, M25ADX, M25, etc.), human CD8 hinge and transmembrane domains, and human 4-1BB and CD3 zeta signal domains.

[0538] Nucleic acid sequences encoding the desired molecules can be obtained using recombinant methods known in the art, for example, by screening libraries from cells which express the gene, by deriving the gene from a vector known to contain the same, or by isolating it directly from cells and tissues containing the same, using standard techniques. Alternatively, the gene of interest can be produced synthetically rather than cloned.

[0539] In certain embodiments, a vector is provided that is inserted with the nucleic acid sequence encoding the CAR described herein.Retrovirus-derived vectors, such as lentivirus-derived vectors, are suitable tools for achieving long-term gene transfer, because they allow the long-term stable integration of transgenes and their propagation in daughter cells.Lentivirus vectors have an additional advantage over oncoretrovirus-derived vectors, such as murine leukemia virus-derived vectors, in that they can transduce non-proliferating cells, such as hepatocytes.They also have the additional advantage of low immunogenicity.

[0540] Briefly summarized, expression of a natural or synthetic nucleic acid encoding a CAR can be achieved by operably linking a nucleic acid encoding a CAR polypeptide or a portion thereof to a promoter and incorporating the construct into an expression vector. The vector may be suitable for replication and integration in eukaryotes. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulating the expression of the desired nucleic acid sequence.

[0541] The expression constructs described herein can also be used for nucleic acid immunization and gene therapy using standard gene delivery protocols. Methods for gene delivery are known in the art (see, for example, U.S. Patent Nos. 5,399,346, 5,580,859, and 5,589,466)....

Claims

1. An isolated antibody or fragment thereof that specifically binds to ALPP and / or ALPPL2 expressed in the human placenta, but does not bind to ALPL and ALPI expressed outside the placenta.

2. An antibody that specifically binds to a cell expressing ALPPL2 and / or ALPP, comprising: M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25GRITSGFYGDwtLC 2. The antibody of claim 1, which specifically binds to an epitope bound by one or more antibodies selected from the group consisting of: M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

3. 3. The antibody of claim 1 or 2, which preferentially binds to the cell surface form of ALPPL2 compared to the released / solution form of ALPPL2.

4. 4. The antibody of any one of claims 1 to 3, which binds to a cell expressing ALPPL2 with an affinity of better than about 5 nM, or better than about 3 nM, or with an affinity of about 2 nM or better.

5. 4. The antibody of claim 1, which in IgG1 form binds to cells expressing ALPPL2 with an affinity of better than about 50 pM, or with an affinity of better than about 40 pM, or with an affinity of better than about 30 pM, or with an apparent affinity of about 28 pM.

6. The antibody according to any one of claims 2 to 5, wherein the cells expressing ALPP and / or ALPPL2 are cancer cells.

7. 7. The antibody of any one of claims 2 to 6, wherein the cell expressing or overexpressing is a cell of a cancer selected from the group consisting of mesothelioma, testicular cancer, endometrial cancer, and a subset of ovarian, pancreatic, and non-small cell lung cancer.

8. The antibody of claim 7, which binds to cells of a cell line selected from the group consisting of M28, VAMT-1, CAPAN-1, and H1651 cells.

9. at least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein the heavy chain variable region is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADLFEG, M25AD ... The antibody according to any one of claims 1 to 8, comprising VH CDR1, and / or VH CDR2, and / or VH CDR3 of an antibody selected from the group consisting of 25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

10. at least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein the light chain variable region is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADLFEG, M25ADLFDS, M25ADLFEG ... The antibody according to any one of claims 1 to 8, comprising the VL CDR1, and / or the VL CDR2, and / or the VL CDR3 of an antibody selected from the group consisting of 25ADYHSRLF, M25GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

11. At least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein the heavy chain variable region is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25 The antibody of any one of claims 1 to 8, which is a heavy chain variable region of an antibody selected from the group consisting of GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

12. At least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein the light chain variable region is selected from the group consisting of M25ADLF, M25ADLFEG, M25ADLFDS, M25FYIA, M25FYIAEG, M25FYIADS, M25, M25EG, M25DS, M25AELF, M25AELFEG, M25AELFDS, M25ADL99P, M25ADL99G, M25ADS95R, M25ADD28G, M25ADS91G, M25ADY93H, M25ADYHSRLF, M25 The antibody of any one of claims 1 to 8, which is a light chain variable region of an antibody selected from the group consisting of GRITSGFYGDwtLC, M25FSITSGFYGDwtLC, M253018IA, M253018LF, M25AD, M25ADX, ALPPL2rd3_1, ALPPL2rd3_2, M25AGIA, M25AGLF, M25ASIA, M25ASLF, M25ASwt, M25AVIA, M25AVLF, M25ALIA, M25ALLF, M25wtIA, and / or M25wtLF.

13. comprising the heavy chain variable region (VH) of the M25ADLF antibody and the light chain variable region (VL) of the M25ADLF antibody; or comprising the heavy chain variable region (VH) of the M25ADLFEG antibody and the light chain variable region (VL) of the M25ADLFEG antibody; or comprising the heavy chain variable region (VH) of the M25ADLFDS antibody and the light chain variable region (VL) of the M25ADLFDS antibody; or comprising the heavy chain variable region (VH) of the M25FYIA antibody and the light chain variable region (VL) of the M25FYIA antibody; or comprising the heavy chain variable region (VH) of the M25FYIAEG antibody and the light chain variable region (VL) of the M25FYIAEG antibody; or comprising the heavy chain variable region (VH) of the M25FYIADS antibody and the light chain variable region (VL) of the M25FYIADS antibody; or comprising the heavy chain variable region (VH) of the M25 antibody and the light chain variable region (VL) of the M25 antibody; or comprising the heavy chain variable region (VH) of the M25EG antibody and the light chain variable region (VL) of the M25EG antibody; or comprising the heavy chain variable region (VH) of the M25DS antibody and the light chain variable region (VL) of the M25DS antibody; or comprising the heavy chain variable region (VH) of the M25AELF antibody and the light chain variable region (VL) of the M25AELF antibody; or comprising the heavy chain variable region (VH) of the M25AELFEG antibody and the light chain variable region (VL) of the M25AELFEG antibody; or comprising the heavy chain variable region (VH) of the M25AELFDS antibody and the light chain variable region (VL) of the M25AELFDS antibody; or comprising the heavy chain variable region (VH) of the M25ADL99P antibody and the light chain variable region (VL) of the M25ADL99P antibody; or comprising the heavy chain variable region (VH) of the M25ADL99G antibody and the light chain variable region (VL) of the M25ADL99G antibody; or comprising the heavy chain variable region (VH) of the M25ADS95R antibody and the light chain variable region (VL) of the M25ADS95R antibody; or comprising the heavy chain variable region (VH) of the M25ADD28G antibody and the light chain variable region (VL) of the M25ADD28G antibody; or comprising the heavy chain variable region (VH) of the M25ADS91G antibody and the light chain variable region (VL) of the M25ADS91G antibody; or comprising the heavy chain variable region (VH) of the M25ADY93H antibody and the light chain variable region (VL) of the M25ADY93H antibody; or comprising the heavy chain variable region (VH) of the M25ADYHSRLF antibody and the light chain variable region (VL) of the M25ADYHSRLF antibody; or comprising the heavy chain variable region (VH) of the M25GRITSGFYGDwtLC antibody and the light chain variable region (VL) of the M25GRITSGFYGDwtLC antibody; or comprising the heavy chain variable region (VH) of the M25FSITSGFYGDwtLC antibody and the light chain variable region (VL) of the M25FSITSGFYGDwtLC antibody; or comprising the heavy chain variable region (VH) of the M253018IA antibody and the light chain variable region (VL) of the M253018IA antibody; or comprising the heavy chain variable region (VH) of the M253018LF antibody and the light chain variable region (VL) of the M253018LF antibody; or comprising the heavy chain variable region (VH) of the M25AD antibody and the light chain variable region (VL) of the M25AD antibody; or comprising the heavy chain variable region (VH) of the M25ADX antibody and the light chain variable region (VL) of the M25ADX antibody; or comprising the heavy chain variable region (VH) of the ALPPL2rd3_1 antibody and the light chain variable region (VL) of the ALPPL2rd3_1 antibody; or comprising the heavy chain variable region (VH) of the ALPPL2rd3_2 antibody and the light chain variable region (VL) of the ALPPL2rd3_2 antibody; or comprising the heavy chain variable region (VH) of the M25AGIA antibody and the light chain variable region (VL) of the M25AGIA antibody; or comprising the heavy chain variable region (VH) of the M25AGLF antibody and the light chain variable region (VL) of the M25AGLF antibody; or comprising the heavy chain variable region (VH) of the M25ASIA antibody and the light chain variable region (VL) of the M25ASIA antibody; or comprising the heavy chain variable region (VH) of the M25ASLF antibody and the light chain variable region (VL) of the M25ASLF antibody; or comprising the heavy chain variable region (VH) of the M25ASwt antibody and the light chain variable region (VL) of the M25ASwt antibody; or comprising the heavy chain variable region (VH) of the M25AVIA antibody and the light chain variable region (VL) of the M25AVIA antibody; or comprising the heavy chain variable region (VH) of the M25AVLF antibody and the light chain variable region (VL) of the M25AVLF antibody; or comprising the heavy chain variable region (VH) of the M25ALIA antibody and the light chain variable region (VL) of the M25ALIA antibody; or comprising the heavy chain variable region (VH) of the M25ALLF antibody and the light chain variable region (VL) of the M25ALLF antibody; or comprising the heavy chain variable region (VH) of the M25wtIA antibody and the light chain variable region (VL) of the M25wtIA antibody; or The antibody according to any one of claims 1 to 8, comprising the heavy chain variable region (VH) of the M25wtLF antibody and the light chain variable region (VL) of the M25wtLF antibody.

14. 14. The antibody of any one of claims 1 to 13, which is a substantially intact immunoglobulin.

15. The antibody of claim 14, comprising IgA, IgE or IgG.

16. The antibody of claim 14, comprising an IgG.

17. 15. The antibody of claim 14, comprising IgG1.

18. The antibody according to any one of claims 1 to 13, which is an antibody fragment that specifically binds to cells expressing ALPP and / or ALPPL2.

19. Fv, Fab, (Fab') 2 , (Fab') 3 19. The antibody of claim 18, which is an antibody fragment selected from the group consisting of IgGΔCH2, and a minibody.

20. The antibody of any one of claims 1 to 13, which is a single chain antibody.

21. The antibody of claim 20 which is a human scFv.

22. The heavy chain variable region has the amino acid sequence 4 Ser) 3 The antibody of claim 21, wherein the light chain variable region is connected to the light chain variable region by a linker comprising or consisting of: (SEQ ID NO: 82).

23. 23. An immunoconjugate comprising the antibody of any one of claims 1 to 22 conjugated to an effector selected from the group consisting of a second antibody, a detectable label, a cytotoxic or cytostatic agent, a liposome containing a drug, a radionuclide, a drug, a prodrug, an immunomodulatory agent, a viral particle, a cytokine, a second antibody, and a chelate.

24. The immunoconjugate of claim 23, wherein the antibody is conjugated to a cytotoxic and / or cytostatic agent.

25. The antibody, directly or through a linker, said drug; a lipid or liposome containing the drug; A polymeric drug carrier comprising the drug; and Nanoparticle drug carriers comprising the drug 24. The immunoconjugate of claim 23, wherein the immunoconjugate is linked to one or more of the following:

26. 26. The immunoconjugate of claim 24 or 25, wherein the drug is an anticancer drug.

27. 26. The immunoconjugate of claim 24 or 25, wherein the drug is selected from the group consisting of microtubule inhibitors, DNA damaging agents, and polymerase inhibitors.

28. The immunoconjugate of claim 27, wherein the drug comprises a tubulin inhibitor.

29. 29. The immunoconjugate of claim 28, wherein the drug comprises a drug selected from the group consisting of auristatin, dolastatin-10, a synthetic derivative of the natural product dolastatin-10, and maytansine or a maytansine derivative.

30. 29. The immunoconjugate of claim 28, wherein the drug comprises a drug selected from the group consisting of monomethylauristatin F (MMAF), auristatin E (AE), monomethylauristatin E (MMAE), vcMMAE, and vcMMAF.

31. 29. The immunoconjugate of claim 28, wherein the drug comprises a maytansine selected from the group consisting of mertansine (DM1), DM3, and DM4.

32. 28. The immunoconjugate of claim 27, wherein the drug comprises a DNA damaging agent.

33. 33. The immunoconjugate of claim 32, wherein the drug comprises a drug selected from the group consisting of a calicheamicin, a duocarmycin, and a pyrrolobenzodiazepine.

34. The immunoconjugate of claim 33 , wherein the drug comprises a calicheamicin or a calicheamicin analog.

35. 34. The immunoconjugate of claim 33, wherein the drug comprises a duocarmycin.

36. 36. The immunoconjugate of claim 35, wherein the drug comprises a duocarmycin selected from the group consisting of duocarmycin A, duocarmycin B1, duocarmycin B2, duocarmycin C1, duocarmycin C2, duocarmycin D, duocarmycin SA, cyclopropylbenzoindole duocarmycin (CC-1065), centanamycin, rachelmycin, adozelesin, bizeresin, and carzelesin.

37. 34. The immunoconjugate of claim 33, wherein the drug comprises a pyrrolobenzodiazepine or a pyrrolobenzodiazepine dimer.

38. 38. The immunoconjugate of claim 37, wherein the drug comprises a drug selected from the group consisting of anthramycin (and its dimer), mazethramycin (and its dimer), tomaymycin (and its dimer), prothracalcin (and its dimer), ticamycin (and its dimer), neothramycin A (and its dimer), neothramycin B (and its dimer), DC-81 (and its dimer), sibiromycin (and its dimer), polothramycin A (and its dimer), polothramycin B (and its dimer), sivanomycin (and its dimer), abveymycin (and its dimer), SG2000, and SG2285.

39. 26. The immunoconjugate of claim 24 or 25, wherein the drug is selected from the group consisting of an auristatin, a dolastatin, a colchicine, a combretastatin, and an mTOR / PI3K inhibitor.

40. The drug is selected from the group consisting of fluorouracil (5-FU), capecitabine, 5-trifluoromethyl-2'-deoxyuridine, methotrexate sodium, raltitrexed, pemetrexed, cytosine arabinoside, 6-mercaptopurine, azathioprine, 6-thioguanine (6-TG), pentostatin, fludarabine phosphate, cladribine, floxuridine (5-fluoro-2), ribonucleotide reductase inhibitors (RNR), cyclophosphamide, neosal, ifosfamide, thiotepa, 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, methyl (CCNU), hexamethylmelamine, busulfan, procarbazine HCL, dacarbazine (DTIC), chlorambucil, melphalan, cisplatin, carboplatin, oxaliplatin, bendamustine, carmustine, chloromethine, dacarbazine (DTIC), fotemustine, lomustine, mannosulfan, ne Daplatin, nimustine, prednimustine, ranimustine, satraplatin, semustine, streptozocin, temozolomide, treosulfan, triaziquone, triethylenemelamine, thioTEPA, triplatin tetranitrate, trophosphamide, uramustine, doxorubicin, daunorubicin citrate, mitoxantrone, actinomycin D, etoposide, topotecan HCL, teniposide (VM-26), irinotecan HCL (CPT-11), camptothecin, benzamidine, Lotecan, Rubitecan, Vincristine, Vinblastine sulfate, Vinorelbine tartrate, Vindesine sulfate, Paclitaxel, Docetaxel, Nanoparticle Paclitaxel, Abraxane, Ixabepilone, Larotaxel, Ortataxel, Tesetaxel, Vinflunine, Retinoic acid, Retinoic acid derivatives, Doxyrubicin, Vinblastine, Vincristine, Cyclophosphamide, Ifosfamide, Cisplatin, 5-Fluorouracil, Camptothecin derivatives, Interferon 26. The immunoconjugate of claim 24 or 25, wherein the anticancer compound is selected from the group consisting of tamoxifen, tamoxifen, and taxol, or is selected from the group of anticancer compounds consisting of abraxane, doxorubicin, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, toremifene, letrozole, trastuzumab, megestrol tamoxifen, paclitaxel, docetaxel, capecitabine, goserelin acetate, and zoledronic acid.

41. The immunoconjugate of claim 23, wherein the antibody is conjugated to a cytotoxin.

42. 42. The immunoconjugate of claim 41, wherein the antibody is conjugated to a cytotoxin selected from the group consisting of diphtheria toxin, Pseudomonas exotoxin, ricin, abrin, saporin, and thymidine kinase.

43. The immunoconjugate of claim 23, wherein the antibody is conjugated to an immunomodulatory agent.

44. The immunoconjugate of claim 43, wherein the immunomodulatory agent comprises a second antibody.

45. The immunoconjugate of claim 44, wherein the second antibody comprises an anti-CD3 antibody.

46. The immunoconjugate of claim 43, wherein the immunomodulatory agent blocks an immune checkpoint.

47. The immunoconjugate of claim 46, wherein the immunomodulatory agent comprises an antibody selected from the group consisting of an anti-CTLA4 antibody, an anti-PDL1 antibody, an anti-PDL2 antibody, an anti-ICOS antibody, and an anti-BTLA antibody.

48. 48. The immunoconjugate of claim 47, wherein the antibody is an antibody comprising the VH and VL domains of an antibody selected from the group consisting of ipilimumab, nivolumab, and pembrolizumab.

49. 48. The immunoconjugate of claim 47, wherein the antibody is an antibody selected from the group consisting of ipilimumab, nivolumab, and pembrolizumab.

50. The antibody is 99 Tc 99 Tc 97 Ru 95 Ru 94 Tc 90 Y 90 Y 89 Zr 86 Y 77 Br 77 As 76 Br 75 Se 72 As 68 Ga 68 Ga 67 Ga 67 Ga 67 Cu 67 Cu 64 Cu 62 Cu 62 Cu 59 Fe 58 Co 57 Co 52 Mn 52 Fe 51 Cr 47 Sc 3 H 35 S 33 P 32 P 225 Ac 224 Ac 223 Ra 213 Bi 212 Pb 212 Bi 211 At 203 Pb 203 Hg 201 Tl 199 Au 198 Au 198 Au 197 Pt 18 F 189 Re 188 Re 188 Re 186 Re 186 Re 177 Lu 177 Lu 175 Yb 172 Tm 169 Yb 169 Yb 169 Er 168 Tm 167 Tm, 166 Ho, 166 Dy, 165 Tm, 165 Dy, 161 Tb, 15 O. 15 N, 159 Gd, 157 Gd, 153 Sm, 153 Pb, 151 Pm, 14 C. 149 Pm, 143 Pr, 142 Pr, 13 N, 133 I, 131 In, 131 I, 127 Te, 126 I, 125 Te, 125 I, 124 I, 123 I, 122 Te, 121 Te, 121 Sn, 11 C. 113 In, 111 In, 111 In, 111 Ag, 111 Ag, 109 Pd, 109 Pd, 107 Hg, 105 Ru, 105 Rh, 105 Rh, and 103 24. The immunoconjugate of claim 23, wherein the immunoconjugate is bound to a chelate comprising an isotope selected from the group consisting of Ru.

51. 24. The immunoconjugate of claim 23, wherein the antibody is complexed to an anti-cancer drug or bound to a lipid or liposome containing an anti-cancer drug.

52. The immunoconjugate of claim 23, wherein the antibody is conjugated to a detectable label.

53. a pharma- ceutically acceptable carrier and an antibody according to any one of claims 1 to 22; and / or A pharma- ceutically acceptable carrier and an immunoconjugate according to any one of claims 23 to 52.

13. A pharmaceutical formulation comprising:

54. 54. The pharmaceutical formulation of claim 53, which is a unit dosage formulation.

55. 55. The pharmaceutical preparation of claim 53 or 54, formulated for administration via a route selected from the group consisting of oral administration, nasal administration, rectal administration, intraperitoneal injection, intravascular injection, subcutaneous injection, transdermal administration, and intramuscular injection.

56. A method for reducing tumor initiating cells in a cell population, comprising contacting a cell population comprising tumor initiating cells expressing ALPPL2 and cells other than tumor initiating cells with an anti-ALPPL2 immunoconjugate described in any one of claims 23 to 51, wherein an effector comprising the immunoconjugate has cytostatic and / or cytotoxic and / or immunomodulatory activity, thereby reducing the frequency of tumor initiating cells in the tumor cell population.

57. 57. The method of claim 56, wherein the contacting step is performed in vivo.

58. 57. The method of claim 56, wherein the contacting step is performed in vitro.

59. 1. A method for inhibiting the growth and / or proliferation of cells expressing ALPPL2, comprising: Contacting the cells with an antibody according to any one of claims 1 to 22; and / or 52. A method comprising contacting said cells with an anti-ALPPL2 immunoconjugate according to any one of claims 23 to 51, wherein an effector comprising said immunoconjugate has cytostatic and / or cytotoxic and / or immunomodulatory activity.

60. 60. The method of claim 59, wherein the cell is a cancer cell.

61. 61. The method of claim 60, wherein the cancer cells are selected from the group consisting of mesothelioma, testicular cancer, endometrial cancer, and a subset of ovarian cancer, pancreatic cancer, and non-small cell lung cancer.

62. 62. The method of claim 60 or 61, wherein the cell is a metastatic cell.

63. The method of any one of claims 60 to 62, wherein the cell is a solid tumor cell.

64. 64. The method of any one of claims 59 to 63, wherein the effector comprises a radionuclide and / or a cytostatic agent.

65. The effector is selected from the group consisting of: cytotoxic and / or cytostatic agents; lipids or liposomes containing cytotoxic and / or cytostatic agents; A polymeric drug carrier comprising a cytotoxic and / or cytostatic agent; and Nanoparticle drug carriers containing cytotoxic and / or cytostatic agents - Patent Application 20070223333 65. The method of claim 64, comprising one or more of the following:

66. 66. The method of claim 65, wherein the drug is an anti-cancer drug.

67. 67. The method of claim 66, wherein the drug is selected from the group consisting of an auristatin, a dolastatin, a colchicine, a combretastatin, and an mTOR / PI3K inhibitor.

68. 67. The method of claim 66, wherein the drug is monomethylauristatin F.

69. The drug is selected from the group consisting of fluorouracil (5-FU), capecitabine, 5-trifluoromethyl-2'-deoxyuridine, methotrexate sodium, raltitrexed, pemetrexed, cytosine arabinoside, 6-mercaptopurine, azathioprine, 6-thioguanine (6-TG), pentostatin, fludarabine phosphate, cladribine, floxuridine (5-fluoro-2), ribonucleotide reductase inhibitors (RNR), cyclophosphamide, neosal, ifosfamide, thiotepa, 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, methyl (CCNU), hexamethylmelamine, busulfan, procarbazine HCL, dacarbazine (DTIC), chlorambucil, melphalan, cisplatin, carboplatin, oxaliplatin, bendamustine, carmustine, chloromethine, dacarbazine (DTIC), fotemustine, lomustine, mannosulfa , nedaplatin, nimustine, prednimustine, ranimustine, satraplatin, semustine, streptozocin, temozolomide, treosulfan, triaziquone, triethylenemelamine, thioTEPA, triplatin tetranitrate, trophosphamide, uramustine, doxorubicin, daunorubicin citrate, mitoxantrone, actinomycin D, etoposide, topotecan HCL, teniposide (VM-26), irinotecan HCL (CPT-11), camptosine, Tothecin, belotecan, rubitecan, vincristine, vinblastine sulfate, vinorelbine tartrate, vindesine sulfate, paclitaxel, docetaxel, nanoparticle paclitaxel, abraxane, ixabepilone, larotaxel, ortataxel, tesetaxel, vinflunine, retinoic acid, retinoic acid derivatives, doxorubicin, vinblastine, vincristine, cyclophosphamide, ifosfamide, cisplatin, 5-fluorouracil, camptothecin derivatives 67. The method of claim 66, wherein the anticancer compound is selected from the group consisting of ribavirin, interferon, tamoxifen, and taxol, or is selected from the group of anticancer compounds consisting of abraxane, doxorubicin, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, toremifene, letrozole, trastuzumab, megestrol tamoxifen, paclitaxel, docetaxel, capecitabine, goserelin acetate, and zoledronic acid.

70. the drug is directly conjugated to the antibody; or the drug is contained in a lipid or liposome bound to the antibody; or 70. The method of any one of claims 65 to 69, wherein the drug is contained in a polymeric and / or nanoparticle carrier bound to the antibody.

71. The method of any one of claims 59 to 63, wherein the effector comprises a cytotoxin.

72. 60. The method of claim 59, wherein the effector comprises a radionuclide.

73. The method of any one of claims 59 to 72, wherein the immunoconjugate or antibody is administered in a pharmaceutical composition comprising a pharma- ceutically acceptable carrier.

74. 74. The method of any one of claims 59 to 73, wherein said administering comprises administering to a human or a non-human mammal.

75. The administration, administering parenterally; and / or Administering to the tumor or surgical site The method of any one of claims 59 to 74, comprising:

76. The method of any one of claims 59 to 75, wherein the antibody and / or immunoconjugate is administered as an adjunct therapy to surgery and / or radiation therapy.

77. The method of any one of claims 59 to 76, wherein the antibody and / or immunoconjugate is administered in combination with another anti-cancer drug and / or hormone.

78. A method for detecting cancer cells of a cancer that expresses ALPPL2, comprising: contacting the cancer cells with an immunoconjugate comprising the antibody of any one of claims 1 to 22 linked to a detectable label; and detecting the presence and / or location of said detectable label, the presence and / or location being indicative of the location and / or presence of cancer cells. A method comprising:

79. 79. The method of claim 78, wherein the label comprises a label selected from the group consisting of a radioactive label, a radiopaque label, an MRI label, a PET label, and a SPECT label.

80. 80. The method of claim 78 or 79, wherein the cancer cells are selected from the group consisting of mesothelioma, testicular cancer, endometrial cancer, and a subset of ovarian cancer, pancreatic cancer, and non-small cell lung cancer.

81. 81. The method of any one of claims 78 to 80, wherein said contacting step comprises administering said immunoconjugate to a non-human mammal or to a human.

82. 82. The method of any one of claims 78 to 81, wherein said detecting step comprises detecting said label in vivo.

83. 83. The method of claim 82, wherein said detecting step comprises using a detection method selected from the group consisting of X-ray, PET, SPECT, MRI, and CAT.

84. 82. The method of any one of claims 78 to 81, wherein the detecting step comprises detecting the label ex vivo in a biopsy or a biopsy-derived sample.

85. A nucleic acid encoding the antibody or antibody fragment of any one of claims 1 to 22.

86. 86. An expression vector comprising the nucleic acid of claim 85.

87. 87. A cell comprising the expression vector of claim 86.

88. A chimeric antigen receptor (CAR) comprising the antibody of any one of claims 1 to 22.

89. the antibody; transmembrane domain; at least one costimulatory signaling region; and CD3 zeta signaling domain 89. The chimeric antigen receptor of Claim 88, comprising:

90. 90. The chimeric antigen receptor of claim 89, wherein the costimulatory signaling region comprises the intracellular domain of a costimulatory molecule selected from the group consisting of CD27, CD2S, 4-IBB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds CD83, and any combination thereof.

91. The chimeric antigen receptor of Claim 89, wherein the costimulatory signaling region comprises 4-1BB.

92. 92. The chimeric antigen receptor of any one of claims 89 to 91, wherein the transmembrane domain comprises a CD8 hinge domain or a fragment thereof.

93. 93. An isolated nucleic acid sequence encoding the chimeric antigen receptor (CAR) of any one of claims 88 to 92.

94. 93. A cell comprising a nucleic acid sequence encoding the chimeric antigen receptor (CAR) of any one of claims 88 to 92.

95. 95. The cell of claim 94, selected from the group consisting of T cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), and regulatory T cells.

96. 96. The cell of claim 94 or 95, wherein when the antigen-binding domain binds to a cell expressing ALPP and / or ALPPL2, the cell exhibits an anti-cancer immune response.

97. A pharmaceutical composition for treating cancer in a mammal comprising the genetically engineered cells (CAR-T cells) of any one of claims 94 to 96 and a pharma- ceutical acceptable carrier.

98. and an antitumor effective amount of cells, the antitumor effective amount of cells being about 10 per kg of body weight of a mammal in need of such cells. 4 ~Maximum of about 10 7 98. The pharmaceutical composition of claim 97, which is a range of cells.

99. 93. A vector comprising a nucleic acid sequence encoding the chimeric antigen receptor (CAR) of any one of claims 88 to 92.

100. 1. A method of stimulating a T cell mediated immune response against a target cell population or tissue in a mammal, said target cell population and / or tissue expressing ALPP and / or ALPPL2, or a region of ALPP and / or ALPPL2 bound by antibodies M25AD, M25ADX and / or M25, 93. A method comprising administering to a mammal an effective amount of cells genetically modified to express the chimeric antigen receptor (CAR) of any one of claims 88-92.

101. 93. A method of conferring anti-tumor immunity in a mammal against tumors expressing ALPP and / or ALPPL2, and / or regions of ALPP and / or ALPPL2 bound by antibodies M25AD, M25ADX and / or M25, comprising administering to the mammal an effective amount of cells genetically modified to express a chimeric antigen receptor (CAR) according to any one of claims 88 to 92, thereby conferring anti-tumor immunity in the mammal.

102. 1. A method of treating a mammal having a cancer comprising cells expressing ALPP and / or ALPPL2, or a region of ALPP and / or ALPPL2 bound by antibodies M25AD, M25ADX and / or M25, comprising:

93. A method comprising administering to a mammal an effective amount of cells genetically modified to express the chimeric antigen receptor (CAR) of any one of claims 88-92.

103. 100. A method of generating a persistent population of genetically engineered T cells in a mammal diagnosed with cancer, comprising administering to the mammal T cells genetically modified to express a chimeric antigen receptor (CAR) of any one of claims 88-99, wherein the persistent population of genetically engineered T cells persists in the human for at least one month following administration.

104. The method of claim 103, wherein the persistent population of engineered T cells comprises memory T cells.

105. 105. The method of claim 103 or 104, wherein the persistent population of engineered T cells persists in the human for at least 3 months, or at least 4 months, or at least 5 months, or at least 6 months, or at least 7 months, or at least 8 months, or at least 9 months, or at least 10 months, or at least 11 months, or at least 12 months, or at least 2 years, or at least 3 years after administration.

106. The method of any one of claims 100 to 102, wherein the cell is a T cell.

107. The method of any one of claims 100 to 102, wherein the cell is an autologous T cell.

108. The method of any one of claims 100 to 102, wherein the cell is an allogeneic T cell.

109. 100. A method of expanding a population of genetically engineered T cells in a mammal diagnosed with cancer, comprising administering to the mammal T cells genetically modified to express a chimeric antigen receptor (CAR) of any one of claims 88-92, wherein the administered genetically engineered T cells produce a population of progeny T cells in a human.

110. The method of any one of claims 100 to 109, wherein the mammal is a human.

111. The method of any one of claims 100 to 109, wherein the mammal is a non-human mammal.

112. 112. The method of any one of claims 100 to 111, wherein the cancer comprises cells of a cancer selected from the group consisting of mesothelioma, testicular cancer, endometrial cancer, and ovarian cancer, pancreatic cancer, and non-small cell lung cancer, which express ALPP and / or ALPPL2.

113. 113. The method of any one of claims 100 to 112, wherein the administered cells are T cells.

114. 114. The method of any one of claims 100-113, wherein the administered cells are autologous T cells.

115. 93. A method of treating cancer comprising contacting a genetically engineered T cell (CAR-T cell) of any one of claims 88 to 92 with a mammalian cancer cell to induce apoptosis of the cancer cell.